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Summary 
Alginate hydrogel made from alginate and crosslinking divalent ions is a natural 
biomaterial that is biocompatible, has low toxicity, is relatively cheap and has mild 
gelation chemistry. It is a porous material that allows diffusion of small molecules. 
Alginate hydrogel is a polymeric network that contains 95-99% water and it does in 
many ways resemble the natural extracellular matrix (ECM) that surrounds cells in 
the body. It is also hydrophilic, which reduces friction in body fluids and minimizes 
protein adsorption and it is easily stored and sterilized. 
Alginate is produced by both algae and bacteria, and it is initially synthesized as 
mannuronan (M) with 100% M-residues. Guluronic acid residues (G) are introduced 
in a post-polymerization step by enzymes called mannuronan C-5 epimerases that 
catalyze conversion of M into G without breaking the glycosidic bond. Seven different 
mannuronan C-5 epimerases have been sequenced, cloned and produced 
recombinantly, and these enzymes introduce MG-blocks, G- blocks or both in the 
alginate chains. With the use of these mannuronan C-5 epimerases it is now possible 
to engineer alginate with desired and known structure. It is also possible to covalently 
modify alginates with coupling of cell specific adhesion molecules to the carboxylic 
group in the monomers. An example is the RGD peptide (arginine-glycine-aspartic 
acid) that is commonly found in collagen and fibronectin in the ECM. The RGD 
peptide is the smallest sequence that integrin receptors can recognize and bind to. 
Central nervous system (CNS) damage is still one of the major causes of both death 
and disability, despite intense research efforts to achieve neurogenesis and restore 
functional synaptic connection of CNS neurons. None of he current therapy 
strategies promote regeneration or regrowth of neural cells or axons. In vitro and in 
vivo   studies has shown that CNS axons can regenerate when located in a 
permissive environment and it is known that on-going neurogenesis occurs in certain 
areas of the adult brain, such as the olfactory bulb. Olfactory ensheathing cells 
(OECs) are found in the olfactory mucosa and olfactory bulb and secrete 
neurotrophins, provide necessary ECM molecules and substrates for axon elongation 
and myelination. They do not activate and induce inhibitory molecules or hypertrophy 
in astrocytes, and are therefore believed to be a promising candidate for cell-
mediated repair of the CNS. 
The major aims of this study was to investigate whether encapsulation of OECs in 
different types of alginate matrices would improve cell viability over time and induce 
change of cell morphology, as a future goal is to transplant OECs into the CNS. 
Viability of OECs up to 14 days in 1.8% UP-LVG capsules have been reported by 
Kristin Karstensen (Karstensen, 2010), and similar results were achieved in  an 
experiment in this project. Indications of cell concentration dependency on viability 
were observed in this experiment, with higher viability in capsules with low cell 
concentration (1.5 mil cells/mL alginate, 3.0 and 5.0 mil/mL).  
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It was decided to conduct an encapsulation of high and low OEC concentration (4.0 
mil/mL and 1.0 mil/mL) in 1.0% UP-LVG Ca2+/Ba2+ alginate, with the aim of 
examining whether reduced alginate concentration would improve cell viability. The 
results were promising, with a live cell percentage of 50% in the low cell 
concentration batch after 51 days. The high cell concentration batch was discarded 
after 22 days with estimated 30% live cells. This result strengthened the hypothesis 
that lower cell concentration enhanced cell viability, and confirmed that lower alginate 
concentration improved cell viability notably. These indications were supported by the 
results of a second encapsulation with similar settings.  
High and low concentrations (1.5 mil/mL and 5.0 mil/mL) of OECs were encapsulated 
in 1.0% epimerized Ca2+ alginate with and without 0.2 % RGD peptide graft. The 
experiment did not show an effect of the RGD peptide on cell viability or morphology. 
The viability of the cells was extended with one week and viable cells could be 
observed for 22 days, but in this experiment increased viability as a result of lower 
cell concentration was less pronounced. This experiment was therefore inconclusive 
in terms of improved viability connected to cell concentration, but indicated that a 
lower alginate concentration had a beneficial impact on cell viability.  
Star shaped channels were observed inside all capsules in this experiment, and a 
large fraction of dead cells were found to be located inside these channels. This 
experiment was later repeated with another source of epimerized alginate grafted 
with ≈ 0.4% RGD peptide with comparable results in terms of cell viability and 
morphology. 
Two encapsulations of low cell concentration in 1.0% UP-LVG Ca2+/Ba2+ alginate 
mixed with three different concentrations of gelatin (0.5%, 1.0% and 2.0%) were 
carried out, with the aim of observing capsule stability and cell viability. In first 
experiment the capsule stability appeared to be inversely proportional with gelatin 
concentration. This was not confirmed when the experiment was repeated, as the 
batch with the middle gelatin concentration was perceived as most stable.  The cell 
viability was overall high for both encapsulations.  
Finally, four batches of 1.5 mil/mL OECs were encapsulated in 0.9% UP-LVG 
Ca2+/Ba2+ alginate gel with one type of ECM molecule mixed with the alginate per 
batch to yield a concentration of 1.0 mg/mL. Sulphated MG alginate was mixed with 
0.9% UP-LVG Ca2+/Ba2+ alginate to a final concentration of 1.0 mg/mL, and included 
in the experiment. The experiment was terminated at day 28, with varying cell 
viabilities in the different batches. Common for all was overall lower cell viability 
compared with the viability observed for cells with similar concentration encapsulated 
in pure 1.0% UP-LVG, but the capsules proved to be relatively stable.  
In conclusion, reducing the alginate concentration from 1.8% to 1.0% had notable 
positive effect on cell viability. High cell concentration in the alginate capsules also 
proved to have a negative impact on cell viability, but this effect was most evident in 
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the UP-LVG alginate gels. The negative effect on cell viability related to high cell 
concentration was not as profound in the epimerized alginate gels. 
RGD peptide grafted onto alginate did not show any unambiguous effect on cell 
viability and no effect on cell morphology, regardless of 0.2 % peptide graft or ≈ 0.4% 
peptide graft. The gelatin-1.0% UP-LVG alginate mixes also failed to induce 
morphology change in the OECs, and neither did any of the ECM molecule-1.0% UP-
LVG alginate mixes or the sulphated alginate-1.0% UP-LVG alginate mix. The cells 
encapsulated in gelatin-alginate mix capsules displayed an overall high viability, 
while the cells encapsulated in ECM molecule- alginate mix and sulphated alginate- 
alginate mix displayed lower viability than cells encapsulated in pure UP-LVG 
alginate.  
All capsule varieties displayed generally good stability in culture, with the exception 
of the gelatin-alginate mix capsules that progressively dissolved in culture. 
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Sammendrag (Norwegian) 
Alginat hydrogel laget av alginat og kryssbindende divalente ioner er et naturlig 
biomaterial, som er biokompatibelt, billig, har mild gelingskjemi og lav toksisitet. Det 
er et porøst materiale som tillater diffusjon av små molekyler. Alginat hydrogel består 
av et polymerisk nettverk som inneholder 95-99% vann og minner på mange måter 
om ekstracellulært matriks (ECM) som omslutter cellene i kroppen. Det er også 
hydrofilt, hvilket reduserer friksjon i kroppsvæsker og minimerer proteinadsorpsjon. 
Alginatløsninger er enkle å lagre og sterilisere.  
Alginat blir produsert av både alger og bakterier, og det blir først syntetisert som 
mannuronan (M) med 100% M innhold. Guluronsyremonomerer (G) blir introdusert i 
et post-polymeriseringsteg av enzymer kalt mannuronan C-5 epimeraser som 
katalyserer omgjøringen av M til G uten å bryte det glykosidiske båndet mellom 
monomerene. Syv forskjellige mannuronan C-5 epimeraser har blitt sekvensert, 
klonet og produsert rekombinant i Escheriichia coli, og disse enzymene introduserer 
MG-blokker, G-blokker eller begge i alginatkjedene. Ved hjelp av disse mannuronan 
C-5 epimerasene er det nå mulig å skreddersy alginat med ønsket og kjent 
sammensetning. Det er også mulig å modifisere alginat ved å kovalent binde 
cellespesifikke adhesjonsmolekyler til karboksylgruppene på alginatkjedene. Et 
eksempel er RGD peptidet (arginin-glysin-aspartat) som vanligvis blir funnet i 
kollagen og fibronektin i ECM. RGD peptidet er den korteste peptidsekvensen et 
integrin kan kjenne igjen å binde seg til. 
Skader i sentralnervesystemet (CNS) er fremdeles en av de vanligste årsakene til 
både død og funksjonshemning, til tross for intens forskning på å oppnå nevrogenese 
og reparasjon av synapser for å gjenopprette synaptisk kobling av CNS nevroner. 
Ingen av dagens terapistrategier promoterer regenerasjon og gjenvekst av nevrale 
celler/aksoner. In vivo og in vitrostudier har vist at CNS aksoner kan regenereres når 
de er lokalisert i et miljø som tillater det og det finnes områder i den voksne hjernen 
hvor nerveregenerering skjer, og et eksempel er luktelappen (olfactory bulb).  
Olfactory ensheathing celler (OECs) finnes i luktelappen og de sekrerer nevrotrofiske 
stoffer, produserer nødvendige ECM molekyler og substrater for aksonforlengelse og 
myelinisering. Cellene aktiverer ikke inhibitoriske molekyler, eller hypertrofi i 
astrocytter og er derfor en lovende kandidat til cellemediert reparasjon av CNS.  
Hovedmålene med dette prosjektet var å undersøke om innkapsling av OECs i 
forskjellige typer alginatmatriser ville øke cellenes viabilitet over tid og indusere 
morfologiendringer i cellene, siden et fremtidig mål er å transplanterer OECs inn i 
CNS. Levende OECs i 1.8% Ca2+ UP-LVG alginatkapsler i opp til 14 dager har blitt 
rapportert av Kristin Karstensen i hennes masterprosjekt (Karstensen, 2010), og 
lignende resultater ble oppnådd i et forsøk i dette prosjektet. Indikasjoner på 
cellekonsentrasjonsavhengig levedyktighet ble observert i dette forsøket, med 
høyere levedyktighet i kapsler med lav cellekonsentrasjon (1.5 millioner celler/mL 
alginat,  3.0 mill/mL og 5.0 mill/mL). 
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Det ble besluttet å gjennomføre innkapslinger av høy og lav OEC konsentrasjon (4.0 
mill/mL og 1.0 mill/mL)  i 1.0% UP-LVG Ca2+/Ba2+ alginat, for å undersøke om lavere 
alginatkonsentrasjon ville ha innvirkning på celleviabiliteten. Resultatene var lovende, 
med en prosentandel på 50% levende celler i prøven med lavest cellekonsentrasjon 
etter 51 dager. Den tilhørende prøven med høy cellekonsentrasjon ble forkastet etter 
22 dager med anslagsvis 30% levende celler. Dette resultatet styrket hypotesen om 
at lavere cellekonsentrasjonen forbedret celleviabilitet, og bekreftet at lavere 
alginatkonsentrasjon forbedret celleviabilitet betydelig. Det andre forsøkets resultater 
støttet disse indikasjonene.  
1.5 mill/mL og 5.0 mill/mL konsentrasjoner av OECs ble innkapslet i 1.0% epimerisert 
Ca2+ alginat med og uten 0.2% RGD peptid koblet på. Eksperimentet viste ingen 
effekt av RGD peptid, på verken celleviabilitet eller morfologi. Levedyktigheten til 
cellene ble utvidet med en uke og levende celler kunne observeres i 22 dager. I dette 
eksperimentet var effekten av lavere cellekonsentrasjon mindre uttalt, men indikerte 
ytterligere at en lavere alginatkonsentrasjon hadde en gunstig effekt på cellenes 
levedyktighet. 
Stjerneformede kanaler ble observert i alle kapsler i dette eksperimentet, og en stor 
andel av døde celler var lokalisert inne i disse kanalene. Dette eksperimentet ble 
senere gjentatt med epimerisert alginat med ≈ 0.4% RGD peptid koblet på fra en 
annen kilde, med sammenlignbare resultater med tanke på viabilitet og morfologi. 
To innkapslinger med 1.5 mill/mL cellekonsentrasjon i 1.0% UP-LVG Ca2+/Ba2+ 
alginat blandet med tre ulike konsentrasjoner av gelatin (0.5%, 1.0% og 2.0%) ble 
gjennomført, med sikte på å observere kapselstabilitet og celleviabilitet. I det første 
eksperimentet syntes kapselenstabiliteten å være omvendt proporsjonal med gelatin 
konsentrasjon. Dette ble ikke bekreftet da forsøket ble gjentatt, da prøven med 1.0% 
gelatinkonsentrasjonen ble oppfattet som mest stabil. Cellen levedyktighet var 
generelt høy for begge innkapslingene.  
Til slutt ble fire prøver med 1.5 mil/mL OECs innkapslet i 0.9% UP-LVG Ca2+/Ba2+ 
alginat blandet med en type ECM molekyl, med konsentrasjon på 1.0 mg/mL. 
Sulfatert MG alginat ble blandet med 0.9% UP-LVG Ca2+/Ba2+ alginat med 
konsentrasjon på 1.0 mg sulfatert alginat per mL UP-LVG alginat, og inkludert i 
forsøket. Forsøket ble avsluttet på dag 28, med varierende celleviabilitiet i de ulike 
prøvene. Felles for alle prøvene var en generell lavere celleviabilitet sammenlignet 
med levedyktigheten observert for celler med tilsvarende konsentrasjon innkapslet i 
ren 1.0% UP-LVG Ca2+/Ba2+alginat, men kapslene viste seg å være relativt stabile 
gjennom hele forsøket. 
Det ble funnet at å redusere alginatkonsentrasjon fra 1.8% til 1.0% hadde merkbar 
positiv effekt på cellelevedyktighet i kapslene. Høy cellekonsentrasjon i 
alginatkapsler viste seg å ha en negativ innvirkning på celleviabilitet, men denne 
effekten var mest tydelig i kapsler av UP-LVG alginatgel. Den negative effekten på 
celleviabilitet relatert til høy cellekonsentrasjon var ikke så tydelig i kapsler av 
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epimerisert Ca2+ alginat gel. 
RGD-peptid koblet på alginat viste ingen entydig effekt på celleviabilitet og ingen 
effekt på cellemorfologi, uavhengig av 0.2% peptidkobling eller ≈ . peptidkobling. 
Gelatin-1.0% UP-LVG alginatblandingene mislyktes også på å indusere 
morfologiendring i OECs. Heller ikke noen av ECM molekyl-1.0% UP-LVG 
alginatblandingene eller sulfatert alginat-1.0% UP-LVG alginatblanding påvirket 
morfologien til cellene. Cellene innkapslet i kapsler  av gelatin-alginatblanding vises 
en generelt høy levedyktighet, mens cellene innkapslet i ECM molekyl-0.9% UP-LVG 
alginatblanding og sulfatert alginat-0.9% UP-LVG alginatblanding viste lavere 
levedyktighet enn celler innkapslet i ren UP-LVG alginat. 
Alle kapselvarianter viste generelt god stabilitet i kulturen, med unntak av gelatin-
alginat blandingkapsler som gradvis ble oppløst i kultur over tid. 
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1. Theory 
1.1. Alginate 
Alginate was discovered by Stanford in 1881 (Draget, 2002) and is produced in 
marine brown algae (Phaeophyta) (Draget, 2005) and some bacteria, such as 
Azotobacter vinelandii (Gorin, 1966) and several Psudomonas species (Painter T.J., 
1983).  In brown algae alginate accounts for 40% of the dry weight and its main 
purpose is to provide the seaweed with strength and flexibility. The composition and 
structure of alginate can vary, both in the same plant and between species. The 
supply of alginate is considered to be unlimited and about 30000 metric tons are 
produced from brown algae annually(Draget, 2002). 
Alginate consists of two monomers, β-D-mannuronic (M) and its C5 epimer α-L-
guluronic (G) acid bound by 14 glycosidic linkages in randomly arranged linear 
structures of alternating MG blocks, homopolymeric M-blocks or G-blocks, all of 
varying length. The chemical structure of alginate and is shown in figure 1.1 together 
with block composition (Smidsrød, 1974). 
 
Figure 1.1: Alginate chemical structure. (a) Illustration of the Haworth formulas of the 
two monomers. M = β- D-mannuronic acid and G = α- L-guluronic acid. (b) Block 
composition in alginates (excerpt directly reproduced from(Mørch, 2008)). 
The sequential structure in alginate is determined by measurements of diads and 
triads frequencies. There are four diad frequencies; FGG, FGM, FMG and FMM and eight 
possible triad frequencies; FGGG, FGGM, FMGG, FMGM, FMMM, FMMG FGMM and FGMG. 
These can be measured by NMR techniques. From these measurements the 
average consecutive length of both G (F(G<1) = FG - FMGM/ FMGG) and M (F(M<1) = FM – 
FGMG/ FMMG)  blocks can be calculated (Smidsrod and Skjak-Braek, 1990). 
The ring conformations of the different alginate chains are shown in figure 1.2.  
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Figure 1.2: The ring conformation of the different alginate chains (Excerpt directly 
reproduced from(Mørch, 2008)) 
1.1.1. Alginate in solution  
It has previously been thought that chain stiffness of alginate in solution has varied 
with block composition, but recent work has shown that chain stiffness is similar for 
G-blocks, M-blocks and MG-blocks (Vold et al., 2006). 
The intrinsic viscosity of alginate depends on molecular weight, composition and 
sequence of M and G as well as the ionic strength of the solution (Draget et al., 
2006).The viscosity of a solution of alginate will depend on the alginate concentration 
and its molecular weight. Alginate is a random coil molecule, and the viscosity of an 
alginate solution will therefore also depend on the ionic strength of the solution. A 
chain with fixed charges will expand in a solution with low ionic strength due to 
internal repulsion of charges within the molecule, and this will increase the viscosity. 
In a solution with high ionic strength the counter ions will shield the charges and 
cause the alginate molecule to contract, hence lowering the viscosity (Smidsrød O., 
1995). 
1.1.2. Mannuronan C-5 epimerases 
Alginate from both algae and bacteria is initially synthesized as mannuronan with 
100% M-residues. G-residues are introduced in a post-polymerization step by 
enzymes called C-5 epimerases that catalyse conversion of mannuronic acid 
residues into guluronic residues without breaking the glycosidic bond. 
Seven different mannuronan C-5 epimerases from Azotobacter vinelandii have been 
sequenced, cloned and produced recombinantly in Escherichia coli. Some create G-
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blocks (AlgE2, AlgE5 and AlgE6), while AlgE4 create MG-blocks (Campa et al., 
2004) AlgE1 and AlgE3 are bifunctional epimerases and produce both G and MG-
blocks (Steigedal et al., 2008) Lyase activity has been observed in AlgE7 (Svanem et 
al., 2001). 
For AlgE4 from A. vinelandii the MG-blocks generated are on average 10 residues 
epimerized for each enzyme-substrate encounter and the enzyme has been shown 
to work progressively. The G-block forming enzymes create different patterns that 
vary in terms of both G-block length and relative amount of alternating structures 
(Campa et al., 2004). With knowledge of the sequences generated and the ability to 
recombinantly produce the enzymes, it is now possible to engineer alginate with 
desired and known structure (Morch et al., 2007, Morch et al., 2008)Bifunctional 
epimerases are also discovered and researchers have also constructed new 
epimerases from known parent enzymes by interchanging modules between different 
epimerases. This possibility enlarges the spectra of engineered alginate (Bjerkan et 
al., 2004). 
1.1.3. Alginate gel 
The ratio of G and M monomers together with their exact sequence affect the 
properties of alginate gel. When divalent ions such as Ca2+, Sr2+, and Ba2+ are added 
to a solution of alginate, a gel will be formed. It has been shown that alginate with 
large fractions of M and MG-blocks create soft and compact gels, while alginate 
containing a lot of G-blocks generates gels with an open and stiff network with higher 
porosity (Martinsen et al., 1989a, Draget, 2006a) It has also been shown that MG-
blocks are participating in junction formation, forming MG-MG junctions and MG-GG 
junctions (Donati et al., 2005). 
Calcium will bind to four G-monomers in a G-block forming a cavity in the chain, ideal 
for binding divalent ions. This binding causes two chains to bind to each other in an 
“eggbox” fashion, i.e. with the ion resembling an egg in a box as shown in figure 1.3. 
The ion will bind to four G residues, two in each chain as shown in figure 1.3. It 
follows that an abundant amount of G-blocks makes a stiffer and more stable gel as it 
enables more binding sites between the chains. It has also been suggested that the 
chains bind to each other laterally, further enhancing the stability of the gel (Stokke, 
2000, Draget, 2006b) The “eggbox” model does only apply to Ca2+ ions, as Sr2+and 
Ba2+ ions are larger and will bind to G-blocks in a different fashion (personal 
communication, Dr. Ing. Berit L. Strand, 10.04.2012). 
The binding of ions to the G-blocks is highly selective and the order of affinity from 
highest to lowest is: 
Ba2+>Sr2+>Ca2+>>Mg2+ 
Barium has been shown to bind to both G and MG-blocks, while strontium only bind 
G-blocks (Morch et al., 2006) and barium is often added to gelling solution to stabilize 
gels because of its strong affinity with G-blocks. The gels tend to swell and dissolve 
4 
 
under physiological conditions when only calcium ions are used as a gelling ion. This 
is due to the networks sensitivity towards chelating agents such as lactate, citrate 
and phosphate and exchange of Ca2+ ions with non-gelling ions such as Na+ and 
Mg+. Swelling leads to higher porosity and less elasticity due to fewer junctions 
(Flory, 1953). The use of barium should be limited, due to barium’s potential 
cytotoxicity. A Ca2+: Ba2+ relationship of 50:1 has been shown to stabilize gels 
sufficiently (Morch et al., 2006) (Morch et al., 2007). Another strategy to avoid 
swelling is to use alginate with a high G-block content, as it introduces more junctions 
(Martinsen et al., 1989a) (Thu et al., 1996). 
The gel strength of alginate gels has been shown to be proportional with the square 
of alginate concentration (Strand et al., 2002a) and the gel stiffness has been shown 
to increase proportionally with increased alginate concentration (Kong et al., 2003). 
 
Figure 1.3: Schematic depiction of the interaction between calcium ions and the G-
blocks of alginate. The divalent positive ion will be captured between two strands of 
G-blocks, and resembles an egg in an egg box (Braccini and Perez, 2001). 
Gel formation is autocooperative. This is explained by the fact that the first binding of 
divalent ion to G-blocks is entropically unfavourable, while the subsequent bindings 
are not (zipper mechanism) (Moe, 1995). The minimum amount of G monomers 
adjacent to another required to form a gel is shown to vary between 8 and 20 
residues, depending of the affinity for the ion (Kohn and Larsen, 1972, Stokke, 1993). 
Ions for which the G-blocks has high affinity, requires shorter G-block lengths (Stokke 
et al., 1993). 
Syneresis is the phenomenon of gel shrinking , which causes release of water, hence 
the reduction of gel volume. It has been proposed that MG blocks are particularly 
involved in the syneresis mechanisms (Morch et al., 2008). This may be due to their 
ability to be compressed due to additional crosslinking with calcium in addition to the 
crosslinks formed by the G-blocks (Donati et al., 2005). Syneresis is mainly affected 
by the composition of alginate (Strand et al., 2003). 
1.1.4. Alginate as a biomaterial 
According to Lee and Mooney, a biomaterial is defined: “as a material intended to 
interface with biological systems to evaluate, treat, augment or replace any tissue, 
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organ or function of the body”. The evolution of biomaterials has gone from wood, to 
ceramics and is now focused on nature-derived materials that are inherently 
biocompatible and in some cases able to interact with cells (Lee and Mooney, 2012). 
Alginate hydrogel made from alginate and divalent ions is a natural biomaterial, 
which is biocompatible, has low toxicity, is relatively cheap and has mild gelation 
chemistry. It is a porous material with pores in the nanometer scale, which allows 
smaller molecules to diffuse through it. Alginate hydrogel is a polymeric network that 
contains 95-99% water and it does in many ways resemble the natural extracellular 
matrix that surrounds cells in the body (Partap et al., 2007). It is also hydrophilic, 
which reduces friction in body fluids and minimizes protein adsorption (de Vos et al., 
2002) (Li, 1998) (Uludag et al., 2000) and is also easily stored and sterilized (Rowley 
et al., 1999). 
These properties allow alginate to be used as a scaffold in tissue engineering where 
the aim is to replace lost or damaged tissue or organs with man-made tissue. 
Hydrogels such as alginate are able to deliver cells to a desired site and provide 
space, structure and control over engineered tissue (Lee and Mooney, 2012). 
Alginate can be utilized as an immobilizing matrix for cells, or as a scaffold for cells 
meant to migrate out of the matrix. In the latter case the gel has to be modified in 
order to obtain large enough pores for the cells to navigate through or be constructed 
to degrade in vivo   (Augst et al., 2006). In the hydrogel, linear hydrophilic alginate 
chains crosslinked by divalent cations such as calcium or barium ions creates a 
scaffold that provides encapsulated cells or compounds with structural support and 
protects them from the surrounding environment (Freeman et al., 2008). 
1.2. Alginate derivatives 
Many alginate derivatives with biomedical applications have been constructed and 
different substituents have also been successfully attached to the monomers (Augst 
et al., 2006). These modifications allow control over solubility, pH sensitivity and 
affinity for specific proteins (Freeman et al., 2008) and interaction with cells. 
Examples of such substituents are the RGD peptide, YIGSR peptide (Augst et al., 
2006) and sulphate groups (Freeman et al., 2008). 
1.2.1 
Covalently modified alginate 
Alginate does not interact with mammalian cells and due to their hydrophilic nature 
they do not promote protein adsorption, therefore interaction cannot be mediated 
through serum proteins. Cellular anchorage is a prerequisite to survival for many cell 
types and cannot be met by pure alginate matrix. It is thus often necessary to culture 
aggregated cells to promote survival in pure alginate matrix.  The interaction between 
cells and their environment is mediated through transmembrane receptors that binds 
adhesion ligands on the outside of the cell membrane and conveys signals to the 
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cell’s interior. These are signals that govern migration, apoptosis, differentiation and 
proliferation. 
It is possible to covalently modify alginates with cell specific adhesion molecules, 
most easily to the carboxylic group in the monomers (Rowley et al., 1999). 
Alginate covalently linked to RGD peptide 
The RGD peptide (arginine-glycine-aspartic acid) is commonly found in collagen and 
fibronectin in the extracellular matrix. It is the smallest sequence that integrin 
receptors can recognize and bind to. The modification is usually carried out by 
aqueous carbodiimide chemistry, where stable covalent amide bonds between the 
peptide and the alginate polymer are formed (Rowley et al., 1999). It is though that a 
minimum concentration of RGD peptide is required to elicit cell adhesion and cell 
proliferation, and this minimum concentration is presumed to be cell specific (Augst 
et al., 2006). 
Carbodiimides are compounds with the chemical formula ‘RN=C=NR’ and act as 
zero-length crosslinking agents that couples carboxyl groups to primary amines. The 
reaction forms an unstable amin-reactive o-acylisourea intermediate, which is 
stabilised by N-hydroxysulfosuccinimide sodium salt (s-NHS). The salt reacts with o-
acylisourea and forms an amine- reactive ester that binds to peptide. RGD peptide 
has two carboxyl groups and one nucleophilic group and the presence of several 
functional groups increases the probability of side reactions. Some common by-
products include N-acylourea and amides (Braccini and Perez, 2001). The RGD 
peptide is shown in figure 1.4. 
It has been shown that mouse skeletal myoblasts adhere, proliferate and express a 
differentiated phenotype on RGD coupled alginate in 2D culture (Rowley et al., 1999). 
Recent work in our lab done by Kristin Karstensen(Karstensen, 2010) has 
demonstrated that OECs attach to RGD peptides and change morphology due to this 
attachment in 2D culture. 
 
Figure 1.4: The RGD peptide (Hersel et al., 2003). 
Sulfation of alginate 
Sulphated polysaccharides can either be manufactured chemically or are found in 
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nature. The most commonly known sulphated polyaccaride is heparin, which 
prevents blood clotting and acts as an anticoagulant (Pawar and Edgar, 2012). 
Heparin is also known to bind growth factors, such as fibroblast growth factor-1 
(FGF-1), which is believed to modulate olfactory axon growth. This feature is also 
associated with the heparin-like molecule heparin sulphate proteoglycans (HSPGs), 
which are located on cell membranes and in the extracellular matrix. The HSPGs are 
known to activate FGF by presenting it to the high affinity signal transducer receptors 
on cell surfaces and it has been shown that FGF-1 is localised to sites of axonal 
growth and synaptic neuropil in the olfactory pathway. FGF-2 is believed to have a 
more global effect in both brain and spinal cord and is expressed in both glia and 
neurons (Key et al., 1996). 
It is possible to synthesise sulphated alginate as reported by Yumin et al who used 
chlorosulfonic acid in formamide as shown in figure 1.5. The sulphate groups will 
bind to the OH groups on the uronic acids and it is believed that they will mainly bind 
to C2 and C3 in the mannurounic acid and guluronic acids, as these peaks will shift 
downwards during characterisation by 13 C NMR. This indicates that the sulphate 
groups are added to either one or both hydroxyl positions (Pawar and Edgar, 2012). 
 
Figure 1.5: Sulfation of alginate by ClSO3H in formamide (Pawar and Edgar, 2012). 
In the study by Yumin et al it was also found that the sulphated alginate displayed 
anticoagulant activities comparable to heparin by the intrinsic coagulation pathway 
(Pawar and Edgar, 2012).Recently, sulphation of alginate has been carried out in our 
lab, showing that the mannuronic acid binds two sulphate groups and that the 
guluronic acid binds one, giving an average of 1.5 sulphate groups per monomer 
yielding a total sulphtion of 150% per monomer (Personal communication from 
Øystein Arlov, 15.04.2012).  It is known that heparin has >70% sulfation while 
heparin sulphate has <50% sulfation (Bruce Alberts, 2002), and compared to these 
values the sulphated alginate has a relatively high content of sulphate groups. 
1.3. Encapsulation 
When foreign cells are transplanted to an organism, the immune system will 
inevitably reject the implanted cells and try to destroy them in order to protect the 
organism. Immunosuppression has been one alternative to circumvent this obstacle, 
but it has many side effects such as increased cancer prevalence, frequent infections 
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and general toxicity. Other options are therefore highly requested. Immunoisolation 
obtained by encapsulation of cells in alginate microbeads (100-1000 µm in diameter) 
is one alternative.  The alginate microbead forms a selective membrane around the 
implanted cells that allows small molecules such as nutrients, oxygen, electrolytes 
and biotherapeutic agents to pass through it, but shields the foreign cells from the 
immune system (Morch et al., 2008). Alginate microcapsules have been shown to 
protect both allo-grafts and xeno-grafts against destruction in mice (Omer et al., 
2005). Desired properties in alginate gels utilized in encapsulation are; high 
mechanical and chemical stability, controllable swelling properties, low content of 
toxic, pyrogenic and immunogenic contaminants, defined pore size and a narrow 
pore size distribution (Orive et al., 2004). 
The encapsulation process is both simple and versatile as it is a one-step procedure 
that does not require extensive training in biopolymer chemistry. An aqueous solution 
of alginate is mixed with cells and dripped into a gelling bath containing divalent ions 
such as Ca2+, Ba2+ or Sr2+. The divalent ions will diffuse into the droplet and create 
hydrogel spheres where the cells are trapped inside a three-dimensional network of 
ionic cross-linked polymers. Beads with a diameter of  <200 µm can be manufactured 
with a bead generator as shown in figure 1.6, and a narrow size distribution is easily 
obtained. 
 
Figure 1.6: Encapsulation of cells using an electrostatic bead generator shown 
schematically (directly reproduced from (Mørch, 2008)). 
The sizes of the beads depend on several factors, such as the viscosity of the 
alginate, needle size, flow rate and the voltage magnitude. The electrostatic bead 
generator creates an electrostatic potential between the tip of the needle and the 
gelling batch, usually between 1-20 kV. This potential causes the droplet to be pulled 
from the needle and into the batch, and allows control over the bead size by 
regulating the voltage (Strand et al., 2001). 
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The permeability of alginate capsules is determined by the gels porosity. Small 
molecules have been shown to diffuse almost unhindered through alginate, while 
glycol and ethanol exhibits a diffusion rate close to 90% of that in water (Tanaka et 
al., 1984) (Oyaas et al., 1995). Proteins up to 3,5 105 Da will diffuse through alginate 
gel with some difficulty, and even larger proteins will be able to escape the capsules 
with a rate depending on molecular weight, shape and pH in the solution (Tanaka et 
al., 1984) (Martinsen et al., 1989a). Gels with high G content will have large pores 
and an open and rigid network, due to the high number of junctions between the G-
blocks, compared to gels with lesser G content (Morch et al., 2008). 
The size of capsules is another parameter that affects cell survival and capsule 
properties. Smaller capsules have a larger surface to volume ratio that enhances 
exchange of nutrients, cell products/waste and oxygen (Morch et al., 2007). In 
capsules with a diameter 250µm of with islets of Langerhan’s encapsulated, 
differences in oxygen tension throughout the capsule has been reported, as well as 
anoxia in the center of the capsule (Colton, 1995). 
On the other hand, smaller capsules may provide less immunoisolation than larger 
capsules (Rokstad et al., 2001), and in addition they are more vulnerable to osmotic 
stress and swelling (Strand et al., 2002a). 
1.4. Olfactory Ensheathing Cells and CNS repair 
1.4.1. Damage in the Central nervous system (CNS) 
CNS damage is still one of the major causes of both death and disability, despite 
intense research efforts to achieve neurogenesis and restore functional synaptic 
connection of CNS neurons. This process was believed to be impossible due to the 
non-permissive physical and chemical environment created after trauma in the CNS 
but this belief was disproved in the early 1980s, when researchers showed that 
axotomised CNS neurons regrew their axons in the presence of peripheral nerve 
grafts (David and Aguayo, 1985). Since then a tremendous effort has been put into 
creating a permissive environment and promote neuroregeneration in CNS, but the 
task has proven to be very difficult as the processes connected to both degeneration 
and regeneration of neurons are very complex (Sandvig, 2011). 
1.4.2. Cell Transplant mediated repair 
Current therapy after traumatic brain injury and spinal cord injury is limited to 
preventing inflammation, prevent secondary cell death and increase plasticity in 
spared circuits. None of these strategies promote regeneration or regrowth of neural 
cells/axons. In vitro and in vivo   studies has shown that CNS axons can regenerate 
when located in a permissive environment (David and Aguayo, 1985) and it is known 
that on-going neurogenesis occurs in certain areas of the adult brain. Extensive 
research is performed with the aim to create such permissive environments at lesion 
sites, and many different strategies have been tested. The most promising 
techniques are transplantation of biomatrices and cell mediated transplant therapy 
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(McCreedy and Sakiyama-Elbert, 2012), where cells are implanted into CNS and 
deliver active molecules involved in repair of neurological damages (Li, 1998). 
Relevant cell types include embryonic stem cell (ESCs), neural stem/progenitor cells 
(NSPCs) and oligodendrocyte precursor cells (OPCs). Another promising candidate 
are olfactory ensheathing cells (OECs), which enwrap olfactory axons in the olfactory 
bulb, one of the areas in the brain where neurogenesis occurs throughout life 
(Barnett and Chang, 2004). Systemic delivery of therapeutic agents to the CNS is 
often hampered by the blood-brain barrier, and the cell candidates for cell-mediated 
transplant therapy are often short lived and labile. An alternative to systemic delivery 
is to encapsulate cells that produce therapeutic agents in alginate microcapsules and 
directly engraft the capsules into the brain or spinal cord, as the capsules provides 
the cells with a protective microenvironment (Li, 1998). 
1.4.3. Olfactory ensheathing cells 
Olfactory ensheathing cells (OECs) are found in the olfactory mucosa and olfactory 
bulb. They were first discovered by Golgi (1875) and Blanes (1889), and soon after 
proved to be a distinct glial cell type. OECs express GFAP and S100β, a trait 
normally associated with astrocytes (Higginson and Barnett, 2011).OECs display a 
certain plasticity regarding to their phenotype and two main types are recognized, the 
astrocyte-like and the non-myelin forming Schwann-cell like morphology. The 
astrocyte-like form is distinguished by the fact that it has more cytoplasm around its 
nucleus, is flat and stellate-shaped and it can display a larger concentration of 
expressed filamentous GFAP (Higginson and Barnett, 2011). 
The Schwann-like OECs expresses the p75NTR receptor and is spindle-shaped. It is 
suggested that the two morphologies are associated with different cell migratory 
patterns and that OECs have the ability to spontaneously interchange between the 
two. It is also suggested that the Schwann-like cells are superior in supporting neurite 
outgrowth compared to the astrocyte-like OECs (Higginson and Barnett, 2011). 
OECs enwraps developing and regenerating axons of olfactory receptor neurons 
(ORNs) from the olfactory mucosa through the cribriform plate, and into the olfactory 
bulb glomeruli, where ORNs synapse with second order neurons (Lindsay et al., 
2010), as shown in figure 1.7. Before 1980 it was thought that neurogenesis ceased 
to happen in the CNS after development, but recent research proved that there are 
areas in the brain where neurogenesis happens (Lindsay et al., 2010).the primary 
olfactory system being one of them (Lindsay et al., 2010).It is suggested that this 
property is due to the fact that olfactory receptor neurons can frequently be exposed 
to damaging toxins and subsequently need to be replaced, as the olfactory bulb also 
is characterized by ORN regeneration (Lindsay et al., 2010). 
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Figure 1.7: The ORNs trajectory from the olfactory bulb to the nasal cavity. OECs are 
wrapped around the ORNs and are shown as blue cells in this figure (directly 
reproduced from (Sandvig, 2011)). 
OECs secrete neurotrophins, provide necessary ECM molecules and substrates for 
axon elongation and myelination. In contrast to Schwann cells they do not activate 
and induce inhibitory molecules, including chondroitin sulphate proteoglycans and 
hypertrophy in astrocytes, and are therefore believed to be a better candidate for cell-
mediated repair of the CNS. Schwann cells have also been shown to promote axon 
regeneration, but unlike OECs they are not able to promote growth that goes beyond 
the local graft area and into CNS (Barnett and Chang, 2004). 
As mentioned above there are different morphologies of OECs, and the relationship 
between the two principal morphologies (Schwann- and astrocyte-like) is not known. 
One hypothesis is that the astrocyte-like cell is an immature form of the Schwann-like 
cell, similar to real Schwann-cells that also have an immature and non-active flat 
stellar-shaped precursor. Another theory states that the two morphologies are mature 
forms of OECs with different tasks, and this theory is perhaps supported by the fact 
that the cells are found to have different antigenic profiles in the olfactory system 
based on their location, indicating that they perform different tasks. Both theories are 
depicted in figure 1.8 (Barnett and Chang, 2004). 
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Figure 1.8: The two theories concerning OECs morphologies and origin as well as 
relationship to each other. The protein expression associated with the different 
morphologies is also mentioned in the figure (Directly reproduced from (Barnett and 
Chang, 2004)). 
To obtain successful restitution of functional synapses and regrowth of neurons it is 
necessary for glia cells, neurons and ECM to communicate with each other. It is 
perhaps utopian to expect all this from a single cell type, and a realistic approach 
may include transplantation of several different cell types combined with suppression 
of inhibitory factors (Barnett and Chang, 2004). 
1.5. 3D culture 
Culturing cells in 3D cultures is thought to be more physiologically relevant than 2D 
cultures as most cells in vivo   reside in 3D environments (Augst et al., 2006). 
Mesenchymal stem cells encapsulated in RGD peptide grafted alginate have been 
shown to change differentiation pathway in response to the rigidity of three-
dimensional microenvironments. Stiff gels (11-30 kPa) induced osteogenesis, and 
softer gels (2.5–5 kPa) induced an adipogenic lineage. In contrast to cells grown on 
2D cultures of variable stiffness, no morphological change was observed in cells 
grown in 3D capsules with variable stiffness, as the cells appeared to be more or less 
spherical. Small protrusions were detected, but their numbers were not correlatable 
with the stiffness of the 3D matrix. The fate of the stem cell seemed to be related to 
the number of adherence bonds between the gel and cells, not the morphological 
changes. The cells were shown to alter the receptors used to adhere to RGD peptide 
in the 3D microenvironment compared to 2D culture (Huebsch et al., 2010). 
In another experiment done by Fischbach et al carcinoma cells were encapsulated in 
alginate grafted with RGD peptide with a RGD density that correlated with the density 
found in tumors in vivo  . In this study it was revealed that 3D microenvironmental 
cues affected cell signaling and tumor vascularization. 3D integrin engagement was 
shown to be critical regulators of IL-8 secretion in carcinoma cells. This is knowledge 
that can be utilized in cancer research (Huebsch et al., 2010). 
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1.6. Molecules in the extracellular matrix (ECM) 
The composition of the ECM can vary and enables an enormous diversity in the 
tailoring of biomaterials, from calcified structures in bone to the transparent structure 
of the cornea. Despite these differences, the molecular classes that are the 
components of ECM are for the most part the same and they differ only in their 
organization and relative amounts (Bruce Alberts, 2002). 
The ECM in the brain has several important tasks such as providing structural 
support, regulate synaptic functions and neuronal plasticity. Both neuronal and glial 
cells produce its constituents and the main components are hyaluronic acid, 
proteoglycans, lectican-link proteins and phosphacan.  The most prominent feature of 
the brain ECM is the perineural nets that are assembled around cell bodies and 
axons during the postnatal maturation of ECM (Zimmermann and Dours-
Zimmermann, 2008). These loose flexible nets consist of hyaluronic acid polymer 
that protrudes from the cells and binds to the end of a lectican proteoglycan. This 
binding is stabilised by link proteins collectively called hyaluronic acid and 
proteoglycan binding link proteins (HAPLs). The other end of lectican is bound to an 
arm of a tenascin oligomere that can bind three or six lecticans (dependent of the 
type of tenascin) and thus creates bridges between different lectican-link protein-
hyaluronic acid complexes. Tenascins are large multimeric glycoproteins that bind to 
many constituents in the ECM, among them lecticans, integrins, cell surface HSPGs 
and cell adhesion immunoglobulines. It has been observed that the migration of 
neurons into the outer layers of the olfactory bulb in adult knockout mice deficient of 
tenascin R (Tn-R) is impaired, thus, it has been hypothesized that Tn-R has a role as 
a positive cue for neuronal migration (Zimmermann and Dours-Zimmermann, 2008). 
1.6.1. Integrins 
Integrins are some of the most widely studied members of cell receptors, and are 
found in all nucleated cells of multicellular organisms. They are essential for cell-cell 
interaction and cell-matrix adhesion, and contribute to development, homeostasis 
and immune responses. Integrins do also play a part in autoimmune diseases and 
cancer. These proteins are both mechanic links as well as being involved with 
bidirectional signalling over the cell membrane (Lowell and Mayadas, 2012). 
Integrins are αβ heterodimeric transmembrane proteins. The α subunit has four 
subclasses in mammals, while the β unit has three subunits with two represented in 
vertebrates. The combination of different α and β subunits determines the function of 
the integrin. Group 1 of α subunits (α3, α6 and α7) combined with B1 subunits will act 
as laminin receptors, while group 2 α subunits (αIIb, αv, α5 and α8) combined with 
B1 or B3 will form receptors for the RGD peptide (Arg-Gly-Asp motif), as an example.  
The β subunits in vertebrates are organized in two groups; A (β1, β2 and β7) and B 
(β3, β4 and β5), with β1 subunit most widely expressed throughout the body (Lowell 
and Mayadas, 2012). The β subunit is rich in Cys residues, which enables many 
intrachain disulphide bonds. The α unit contains many binding sites for Ca2+ ions, 
which has to be bound for the integrin to become activated. As can be seen in figure 
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1.9 the integrin has a short cytoplasmic extension with one transmembrane helix and 
a large ECM domain with ligand binding site. The most prominent ligands include the 
RGD motif in collagen, laminin and heparan sulphate proteoglycans (HSPGs) (Albert 
L. Lehninger, 2008). 
 
Figure 1.9: Overview of the organization of the transmembrane integrin dimer (Directly 
reproduced from(Albert L. Lehninger, 2008)). 
The expression of integrins on the cell membrane are controlled by gene 
transcription which in turn can be regulated by signals relayed by the integrins 
themselves and the process is known as “inside-out” signalling. The regulation is 
dynamic, which allow the cell to control their adherence to other cells as well as ECM 
and this is especially important during migration.  It can activate the integrins by 
making them change their conformation from closed to open, as well as order 
accumulation of integrins at specific locations in the cell membrane. When an integrin 
is activated by a ligand situated in ECM it leads to an assembly of many cytoplasmic 
proteins and this links the integrin to actin filament and microtubule cytoskeletal 
network. The activated integrin can reorganize the cytoskeleton and modulate ECM, 
as well as transmitting intracellular signals, which is known as “outside-in” signaling 
(Lowell and Mayadas, 2012) 
Integrins play an important part in the central nerve system (CNS). It is known to 
guide migration of nerve precursor cells and stabilize neural synapses. Knockout 
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mice deficient of β1 integrins will for display relatively normal neural migration, but 
have a completely disorganized cortex, due to lack of contact between cortex 
structures and the meningeal basement membrane. This deficit will also affect the 
peripheral nervous system (PNS), and leads to severe perturbations of the system 
caused by defective migration through the embryonic ECM (Lowell and Mayadas, 
2012). 
1.6.2. Hyaluronic acid 
Hyaluronic acid is produced by the enzyme hyaluronic acid synthase (HAS) located 
on the inner cell membrane of astrocytes (foundation, 1989) and the linear polymer 
protrudes out from the cell and into ECM. It consists of repetitive disaccharides; 
glucoronic acid and N-acetylglucosamide.  Three different isotopes of the HAS 
enzyme are found in mammals and in the brain HAS2 and HAS3 predominates. 
Hyaluronic acid binds proteoglycans of the lectican family and is the main constituent 
of the ECM in the brain (Zimmermann and Dours-Zimmermann, 2008). 
1.6.3. Proteoglycans 
Proteoglycans are variable N- and O- linked oligosaccharides that contain at least 
one long glucosaminoglycan polysaccharide (GAG) covalently bound to a core 
protein. The main proteoglycans found in the brain are of either lectican or 
hyalectican family, which both bind to hyaluronic acid, tenascin and link proteins 
(HAPLs). The GAG sequence in the proteoglycan determines the class and the 
different classes in the brain are heparan/heparin-, dermatan- or chondroitin- 
sulphate proteoglycan (Zimmermann and Dours-Zimmermann, 2008). 
1.6.4. Collagen 
Collagen is the most abundant protein in ECM and is known to interact with cells via 
several receptors, such as glycoproteins, heparan sulphate proteoglycans and most 
prominently, integrins, as well as discoidin domain receptors in the tyrosine kinase 
family.  It is known to be involved with cell adhesion and migration, differentiation and 
wound healing, aside from being the main contributor to biomechanical properties of 
tissue (Leitinger and Hohenester, 2007). 
Collagen consists of three different polypeptide α-chains, intertwined in a triple helix 
conformation. Each of the α-chains comprises about 1000 different amino acids and 
the triple helix is 300 nm long and has a diameter of 1,4 nm. Collagen is made 
intracellularly and starts out as pro-collagen with additional non-helical residues 
located at the terminal ends. These residues are primarily involved with transport and 
aggregation and are cleaved off when the triple helix is finished, with the exception of 
9-26 amino acids called telopeptides. Collagen contains large amounts of two 
unusual amino acids; 4-hydroxyproline and ε-hydroxylysine, both manufactured by 
post-translational modifications done by special enzyme systems. The ε-
hydroxylysine can also be glycosylated by other enzyme systems and the degree of 
glycosylation varies between the different types of collagen. 33% is glycine, 22% is 
proline and hydroxyproline and the remaining 45% is some 17 different amino acids 
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with a relatively high share of basic and acidic amino acids.  Some observations 
indicate that the carbohydrates participate in intra- and inter-molecular covalent 
crosslinking, but their exact function is still not known. Both hydroxylation and 
glycosylation are restricted to growing chains, and the helix stability is dependent on 
the content of hydroxyproline content. 
Up until now 19 different types of collagen has been discovered. Type I is mainly 
found in bone and skin, and is used to produce gelatin industrially.  Type II is 
primarily found in cartilage and type III is also found in skin (the ratio decreases with 
age) (Babel, 1996). All of these three collagens are water-soluble until they are 
crosslinked and turned first into microfibrils of 2-8 collagen molecules and these are 
further turned into fibrils by enzyme-catalysed steps outside the cell membrane.  The 
structure of collagen I is shown in figure 1.10, with proline in the X-position and 
hydroxyproline in the Y-position (Friess, 1998). 
 
Figure 1.10: Overview of the collagen structures where (a) is the chemical structure of 
collagen I, (b) shows the primary amino acid sequence and (c) is a schematic 
presentation of the quaternary staggered sequence (Friess, 1998). 
 
Gelatin 
Gelatin is formed from collagen by gentle conversion of highly cross-linked and 
water-insoluble raw material into water-soluble gelatin. The collagen is obtained from 
by-products from slaughtered calves, cattle and pigs. The skin from animals is often 
treated with acids, and bone is treated with alkaline suspensions. The main goal of 
these procedures is to hydrolyze residual fat and crosslinks, and extract non-
collagenous proteins, nucleic acids and carbohydrates. After such treatment, the raw 
materials are washed to remove excess acid/base and the gelatin is extracted. 
Historically, the same result was obtained with boiling of raw materials, and this way 
of converting collagen to gelatin is experienced by all of us when cooking meat to 
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make it tenderer. The partial thermal hydrolysis is schematically shown in figure 
1.11.(Babel, 1996). 
 
Figure 1.11: Partial thermal hydrolysis of collagen into gelatin (directly reproduced 
from (Babel, 1996)). 
Gelatin has a molecular weight ranging from 10000 to several million daltons and 
contains amino acids that possess side chains with amino-carboxyl and hydroxyl 
groups. These groups allow altering of chemical and physical properties of the 
gelatin. Gelatin is able to interconvert between sol and gel thermo-reversibly. If an 
aqueous solution with higher gelatin concentration than 0.5% is allowed to cool below 
35-40°C it will form a gel. This process is reversible by heating the solution again. It 
is thought that the gelling occurs due to association of dissolved α-chains via 
hydrophobic structural elements that form ordered helical structures. Further on, 
crystal formation of two or three such helical structures occurs. The structure is 
stabilized by hydrogen bonds within and between the helices, as well as the addition 
of water molecules that form hydrogen bonds with the hydrophilic OH-groups of the 
corresponding amino acids. The viscosity of the gel is dependent of concentration of 
gelatin in the solution as well as pH, temperature and additives present. The viscosity 
increases with higher gelatin concentration and decreases with increasing 
temperatures (Babel, 1996). 
1.6.5. Fibronectin 
Fibronectin is associated with cell migration and organization of ECM. It is a non-
collagen glycoprotein with many domains that binds both other matrix molecules and 
cell receptors. It consists of two large subunits that form a dimer, joined by two 
disulphide bindings near the C-termini. Each subunit is folded into series of functional 
domains with flexible polypeptide regions separating them. Fibronectin can be 
solubilized in body fluid as single chains, but can also be assembled into insoluble 
fibrils. The fibrils are only formed when the fibronectin is anchored to a structure in 
ECM and attached to an appropriate cell receptor, causing the protein to stretch and 
HEATING COOLING 
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thereby reveal binding sites where other fibronectin molecules can cross-link with 
additional disulphide bonds. This feature ensures that fibrils are only formed at 
appropriate locations in the organism as shown in figure 1.12 (Bruce Alberts, 2002). 
 
Figure 1.12: Fibronectin anchored to collagen in the ECM and an integrin receptor in 
the cell membrane (Education, 2011). 
The different domains in fibronectin bind to heparin, collagen and cell receptors. The 
type III fibronectin domain contains the RGD peptide (Arg-Gly-Asp) that bind to 
integrins, and occurs 15 times in each subunit allowing fibronectin to bind cells 
strongly (Bruce Alberts, 2002). 
Fibronectin is found in the embryonal nervous system and is expressed in a specific 
spatial and temporal manner important for both neuronal migration and outgrowth 
during development.  It is also associated with remodelling of injured brain tissue 
where it promotes nerve generation and activates astrocytes (A. Alovskaya, 2007). 
1.6.6. Laminin 
Laminin is a large heteromeric glycoprotein consisting of three polypedtide chains; α, 
β, and γ and is shaped like a cross. To date there are found five α-chains, four β-
chains and three γ-chains and when these are combined they make up 16 different 
types of laminins in mammals. Laminins are the main constituents of the basal 
membrane, also known as the basal lamina, and their main task is to anchor the cells 
to the membrane. Its receptors include eight different integrins, dystroglycan and 
other non-integrin molecules. The integrin receptors bind to specific sequences of the 
α-chain. The structure of laminin is shown in figure 1.13 (Shay et al., 2008). 
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Figure 1.13: A schematic overview of the protein laminin (Sitterley, 2008). 
Laminin-1 has been observed to play a role in olfactory development in earlier 
studies and is expressed in vivo   by OECs. In vitro it stimulates ORN migration and 
promotes axon extension. During glomerular development in mice the OECs express 
laminin-1 in all regions of the olfactory pathway. It has also been observed that 
laminin-1 is expressed before HSPGs and Tenascin-R during development (Shay et 
al., 2008). 
Several domains and peptide sequences in the laminin protein are shown to promote 
axon growth in vitro. Some examples are P1543 peptide, YIGSR peptide, IKVAV 
peptide and p20 peptide. When NB2a neuroblastoma cells from mouse were cultured 
on discs with three different concentrations of YIGSR peptide conjugated onto 
alginate, it was shown that the adhesion of cells did not follow the increase of YIGSR 
concentration proportionally. Comparing to the control of native alginate, an increase 
of peptide concentration from 0.5 mg/g alginate to 1 mg/g alginate prompted an 
increase of cell adhesion from 9,5% to 44%.  When comparing 1mg/g peptide 
concentration to 2mg/g peptide concentration, the cell adhesion percentage only 
increases from 44% to 63%. It was deduced that the minimum critical ligand density 
was represented somewhere between the two lowest concentrations. A disc coated 
with regular laminin produced a cell adhesion percentage of 63%, comparable to the 
disc with the highest YIGSR concentration (Dhoot et al., 2004). 
When laminin was coated onto the alginate dish it displayed much lower ability to 
promote axonal growth, compared to when coated onto a tissue culture dish and 
treated with differentiation media. This suggests that the active sites that promotes 
axonal growth is either masked by alginate or that the alginate poses steric hindrance 
to axonal growth. The peptide density also seemed to have an impact on the length 
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of the axons, as the highest concentrations displayed the longest axons (Dhoot et al., 
2004). 
Laminin has a great affinity for Ca2+ions, which may cause the gel to dissolve over 
time. It is also a large protein that may occlude diffusion of substances out of alginate 
microbeads (Dhoot et al., 2004). 
It has been shown that extracellular matrix, via the b1 integrin component of laminin 
receptors, is important in myelination (Barnett and Chang, 2004). 
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2. Materials and methods 
2.1. Alginate characteristics 
The characteristics of the different alginate types that were used in this project are 
listed in table 2.1 and the alginates are more closely described below. 
Ultra Pure Low Viscosity Guluronic acid  (UP-LVG) sodium alginate 
UP-LVG alginates are ultra purified and contains at least 60% G monomers. It can be 
modified in several ways, and is approved for use in pharmaceutical, biomedical, 
biotechnology and tissue engineering applications. The term ultra pure implies that 
the endotoxin levels in the alginate are <100EU/g (Systems, 2012).The UP-LVG 
alginate used in this project originated from batch FP 603-04 and was purchased 
from NovaMatrix. 
Peptide grafted alginate I 
Mannuronan (batch 512-215-01 TP) was isolated from an epimerase negative mutant 
of Pseudomonas fluorescens and modified by coupling GRGDSP peptide (RGD 
peptide) onto the C5 carboxylic group on mannuronic acid monomers using 
carbodiimide chemistry, yielding 0.2% grafted RGD peptide. 
The grafted alginate was epimerized by the mannuronan from C-5 epimerases AlgE4 
and AlgE6 from Azotobacter vinelandii produced in Hansenulia polymorpha and 
Escherichia coli, respectively. AlgE4 created MG-blocks and AlgE6 created G-blocks. 
A similar mannuronan without peptide was also modified with these epimerases and 
used as a non-peptide coupled reference. The composition of both alginates can be 
found in table 2.1. The alginates were dissolved in 0,3 M mannitol and stored in a 
refrigerator, and sterile filtered before utilized in this project.  Kristin Karstensen made 
this alginate during her master thesis (Karstensen, 2010). 
 
Alginate mixed with gelatin 
Alginate was mixed with gelatin in three concentrations (0.5%, 1.0% and 2.0%) to 
establish whether gelatin could resemble the extracellular matrix (ECM) molecule 
collagen in capsules, and determine if it induced any changes in cell morphology 
and/or viability. 
Freeze dried UP-LVG alginate (batch FP 603-04) was dissolved in sterile water to 
1.0% concentration by stirring with a magnet. Gelatin (Gelatin type A, Gelita®, 
Pigskin gelatin, 260 Bloom, 628305, provided by Ingvild Haug) was also dissolved in 
sterile water heated to approx. 40°C and stirred by a magnet until it dissolved. The 
gelatin was kept at 40°C to avoid gelation until mixed with alginate. 
Both dissolved gelatin and dissolved alginate was mixed with stock solution 
containing 200 mM NaCl and 0,6 M mannitol, before the gelatin and alginate were 
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mixed together to yield three different concentrations of gelatin in three batches; 
0.5% gelatin, 1.0% gelatin and 2.0% gelatin. All three batches had a final 
concentration of 1.0% UP-LVG alginate, 60 mM NaCl and 0,18 M mannitol, and pH 
was adjusted to 7,2-7,4 before sterile filtering and storage in sterile test tubes. 
Alginate mixed with ECM molecules 
Alginate was mixed with four different ECM molecules; collagen, hyaluronic acid, 
fibronectin and laminin. Olfactory ensheathing cells (OECs) were encapsulated in 
these mixtures with the goal of observing any morphological changes and/or viability 
changes, as well as to monitor the capsules’ shape and stability throughout the 
experiment.  
2 mg collagen (powdered collagen from rat tail, purchased from SigmaAldrich, 
product no: C7661) was solved in 0.5 mL 0,01M HCl and stirred by magnet until the 
collagen had dissolved (approx. 2 hours). The solution was sterile filtered and stored 
in a sterile tube in a refrigerator until mixed with alginate. 
2 mg hyaluronic acid (lyophilized hyaluronic acid sodium salt from bovine vitreous 
humor, purchased from SigmaAldrich, product no: 53728 FLUKA) was dissolved in 
0.5 mL sterile water by magnet stirring. The solution was sterile filtered and stored in 
a sterile tube in a refrigerator until mixed with alginate. 
1 mg fibronectin (lyophilized bovine plasma fibronectin, purchased from Invitrogen, 
cat.no: 33010.018) was solved in 0.25 mL sterile water by magnet stirring. The 
solution was sterile filtered and stored in a sterile tube in a refrigerator until mixed 
with alginate. 
0,024 g HEPES (hydroxyethyl piperazineethanesulfonic acid) buffer was added to 4 
mL 1,2% UP-LVG alginate solution to a concentration of 25 mM HEPES and 1,2% 
alginate. The pH was adjusted to pH: 7,2-7,4 with 1 M NaOH. 
0.25 mL of each protein solution described above was mixed with 0,75 mL alginate 
solution, yielding three different batches of 1 mL ECM molecule-alginate mix. 
1 mg laminin (natural mouse laminin, purchased from Invitrogen, cat.no: 23017-15) in 
1 mL 50mM Tris-HCl buffer (pH: 7,4) with 0,15 M NaCl were stored in a sterile test 
tube until mixed with UP-LVG alginate to yield 0.9% concentration of alginate and 
1mg/mL laminin. The laminin-alginate mix was sterile filtered before use. 
All ECM-molecule-alginate mixes had a final ECM-molecule concentration of 1mg 
protein per mL 0,9% alginate. 
Sulphated alginate  
Sulphated alginate produced by Øystein Arlov was included in this experiment 
because it was hypothesized that the sulphated alginate would resemble the 
sulphated ECM protein heparin, and to a lesser degree HSPGs. The alginate had an 
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estimated sulphation percentage of 1-2,5% per monomer and consisted of MG-
blocks. 4 mg of the freeze-dried alginate was dissolved in 0.25 mL sterile water and 
sterile filtered before it was stored in a sterile test tube until mixed with 1,2% alginate. 
0.25 mL of sulphated alginate was mixed with 0,75 mL UP-LVG alginate buffered 
with 25mM HEPES and pH adjusted to pH: 7,2-7,4 with 1M NaOH. The final 
concentration of sulphated alginate was 1 mg per mL 0.9% UP-LVG alginate. 
Peptide grafted alginate II 
Ultrapure polymannuronan from NovaMatrix (Ref. H3:512-216-01TP, FM =1) was 
coupled with GRGDYP-peptide by carbodiimide chemistry, yielding approximately 
0.1-0.4% grafted RGD peptide. The RGD peptide graft percentage is probably nearer 
0.4%, as measured by 1H NMR spectroscopy (personal communication,  Birgitte 
McDonagh, 10.05.12) 
High molecular mass mannuronan from epimerase-negative mutant of P.fluorescens 
was produced by SINTEF (batch: 206-011-01-TP, FM =1). 
Polymannuronan from this latter source was used as a non-peptide coupled 
reference.   
The epimerase AlgE4 from H. polymorpha was used to introduce alternating MG-
blocks to while the epimerase AlgE6 from E. coli was used to insert G-blocks in both 
alginates described above. The samples were filtrated by active coal and dialysis 
was performed in sterile water until the conductivity was below 2microµ Siemens. 
The pH was adjusted to 7.0 and the samples were freeze-dried. This work was 
performed by Birgitte McDonagh.  
 
Table 2.1: The characteristics of the different alginate types that were used in this 
project. 
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UP-LVG* 0,670 0,330 0.550 0,120 0.21 0,050 0,090 0.500 12.0 
Alg Epi RGD I** 0.550 0.450 0.200 0,350 0,10 0.400 0,340 0,160 5,0 
Alg Epi I ** 0.520 0.480 0,160 0,360 0,13 0,040 0,340 0,120 4,0 
Alg Epi RGD II*** 0,340 0,660 0,059 0.280 0,39 0,023 0.280 0,032 3,0 
Alg Epi II*** 0.500 0.500 0,110 0,390 0,11 0,038 0.500 0,079 4,0 
Sulphated alginate**** 0.47 0.530 - 1.000 - - 1.000 - 1.0 
* Given by Wenche Strand 
** Given by Kristin Karstensen 
*** Given by Birgitte McDonagh 
**** Given by Øystein Arlov 
2.2. Cell purification and culture 
Experimental: OECs were purified from the olfactory bulb of neonatal rats (n=5-6) at 
P7 or P8 by enzymatic digestion in L-15 (Leibovitz) medium (Sigma), incubation in 
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O4 (IgM at 1:4) and anti-galactocerebroside (IgG3 at 1:2) primary antibodies followed 
by goat anti-mouse IgM phycoerythrin and goat anti-mouse IgG3 fluorescein 
secondary antibodies (1:100, Southern Biotech, Cambridge, UK) and FACS (Becton 
Dickenson, Oxfordshire, UK) sorting, selecting for O4-positive and 
galactocerebroside-negative cells. The above work was performed by Ioanna 
Sandvig, PhD, Department of Circulation and Medical Imaging, NTNU. 
Primary cells were plated on PLL-coated cell culture flasks (BD Biosciences) and fed 
with OEC media made with DMEM-Glutamax (GIBCO) supplemented with 250 
µL/mL gentamicin (GIBCO), 41.6% SATO media, 5.5% FBS (Autogen Bioclear), 
2.7% FGF (Peprotech), 0.27% Heregulin (Fischer Scientific), and 0.05% Forskolin 
(Sigma). The cell were maintained at 37°C with 7% CO2 and passaged at confluence. 
Cells were harvested by trypsinisation, placed in cryotubes at approx. 1.5-1.8 million 
cells/mL of freezing media (made with 5 mL FBS, 4 mL DMEM and 1 mL DMSO 
(Fischer Chemicals)) and stored at 80°C for a couple of days, before being 
transferred into a liquid nitrogen freezer. Frozen cells were rapidly thawed in a water 
bath at 37°C, suspended in 4 mL FBS 10% (made with 22,5 mL DMEM, 2,5 mL FBS 
and 125µL L-glutamine (Gibco)), and centrifuged at 310 G. After centrifugation, the 
supernatant was removed and the cells resuspended in OEC media before 
encapsulation or culture. 
The above work was performed in collaboration with Ioanna Sandvig, PhD, 
Department of Circulation and Medical Imaging, NTNU. 
2.3. Gelling solution 
Experimental: Two gelling solutions were utilized during this project, with and without 
barium ions. The gelling solution containing Ba2+ ions produce more stable gels as 
the high G alginate has stronger affinity to Ba2+ ions than calcium ions (Smidsrod and 
Skjak-Braek, 1990). On the downside, Ba2+ ions are cytotoxic and it is not preferable 
if the capsules are to be transplanted in vivo   (Morch et al., 2006).The capsules 
made with gelling solution containing Ba2+ also proved difficult to dissolve with citrate 
with the aim of performing RNA extraction from the cells trapped inside the capsules. 
Also, the epimerized alginate utilized in this project is engineered to be gelled with 
only Ca2+ as gelling ion.  
It was therefore decided to make capsules with gelling solution with only calcium 
ions, to avoid toxicity and enable the capsules to be dissolved by citrate. 
Gelling solution with barium ions 
CaCl2  (50 mM), BaCl2 (1 M), HEPES buffer (10mM) and mannitol (0,15 M) were 
dissolved in 2000 mL sterile water by stirring with a magnet. The pH was adjusted to 
7,2-7,4 with 10M/5M NaOH in sterile water. The solution was filter sterilized by 
vacuum filter into a sterile plastic bottle and kept in RT until used. 
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Gelling solution without barium ions 
CaCl2 (50 mM), HEPES buffer (10mM) and mannitol (0,15M) were dissolved in 2000 
mL sterile water by stirring with a magnet The pH was adjusted to 7,2-7,4 with 
10M/5M NaOH in sterile water. The solution was filter sterilized by vacuum filter into 
a sterile plastic bottle, and kept in RT until used. 
2.4. Encapsulation of OECs  
Experimental: Twelve encapsulations of OECs in different types of alginates were 
performed during the project, and they are summarized in table 2.2 below. The basic 
protocol for encapsulation is described in the following paragraph, with deviations 
from protocol stated beneath. 
Table 2.2: Overview of the different alginates and cell concentrations used in the 
project. Deviations from protocol are indicated with x in the last column, and are 
described below. 
Experiment Type of alginate 
Cell 
concentration  
Deviations 
from main 
protocol 
A 
A1: 1.8% UP-LVG  A1a: 1.5 mil/mL 
A1b: 3.0 mil/mL 
A1c: 5.0 mil/mL 
  
B 
B1: 1.0% Alg LG Epi RGD I  
B2: 1.0 % Alg LG Epi I  
B1a: 1.5 mil/mL 
B1b: 5.0 mil/mL 
B2a: 1.5 mil/mL 
B2b: 5.0 mil/mL 
  
X 
C 
C1: 1.0 % UP-LVG C1a: 1.0 mil/mL 
C1b: 4.0 mil/mL 
  
D 
D1: 1.0 % UP-LVG D1a: 1.5 mil/mL 
D1b: 5.0 mil/mL  
  
E 
E1: 1.0 % UP-LVG with 0.5% gelatin 
E2: 1.0 % UP-LVG with 1.0% gelatin 
E3: 1.0% UP-LVG with 2.0% gelatin 
E1: 1.5 mil/mL 
E2:  1.5 mil/mL 
E3: 1.5 mil/mL 
 
X 
F 
F1: 1.0 % UP-LVG with 0.5% gelatin 
F2: 1.0 % UP-LVG with 1.0% gelatin 
F3: 1.0 % UP-LVG with 2.0% gelatin 
F1: 1.5 mil/mL 
F2: 1.5 mil/mL 
F3: 1.5 mil/mL 
 
X 
G 
G1: 0.9 % UP-LVG with laminin (1mg/mL) 
G2: 0.9 % UP-LVG with fibronectin (1mg/mL) 
G3: 0.9  % UP-LVG with hyaluronic acid (1mg/mL) 
G4: 0.9 % UP-LVG with collagen (1mg/mL) 
G5: 0.9  % UP-LVG with sulphated alginate (1mg/mL) 
G1: 1.5 mil/mL 
G2: 1.5 mil/mL 
G3: 1.5 mil/mL 
G4: 1.5 mil/mL 
G5: 1.5 mil/mL 
 
 
x 
H 
H1: 1.0 % Alg LG Epi RGD II 
H2: 1.0 % Alg LG Epi II 
H3: 1.0 % UP-LVG 
H1: 1.5 mil/mL 
H2: 1.5 mil/mL 
H3: 1.5 mil/mL 
 X 
X 
X 
 
Cryotubes containing 1.5 million olfactory ensheathing cells purified from neonatal rat 
olfactory bulbs in 1 mL freezing media, were taken out of -80°C liquid nitrogen 
freezer and melted in a water bath of 37°C. Each cryotube content was transferred to 
4 mL 10% FBS and centrifuged down at 310 G. The supernatant was removed and 
the cells were resuspended in 4 mL OEC-media before counted using Countess 
automated cell counter (Invitrogen).  
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After another centrifugation with the same settings the cells were resuspended with 
0,1 mL OEC growth media. 
0,1 mL cell suspension and 0,9 mL alginate were mixed in a 3 mL syringe and 
attached to an infusion pump. The syringe was connected to a needle through a 
plastic tube and the cell-alginate mix was dripped into a gelling bath by an 
electrostatic bead generator. 
The electrostatic bead generator was adjusted to the following settings: 
Voltage: 7.0 kV 
Distance between needle and gelling bath: 2.5 cm 
Flow: 8 mL/hour 
Needle size: 0.35 mm (one needle) 
Each batch of capsules was allowed to gel in the gelling bath for approximately 7 
minutes. Gelling solutions with Ba2+ was used in almost all experiments, exceptions 
are mentioned below. The capsules were filtered out of the gelling bath and washed 
three times with 10 mL Hanks Buffered Salt Solution (HBSS).  The capsules were 
suspended in approximately 1 mL of HBSS and 9 mL of OEC growth media was 
added, giving a total volume of 10 mL of capsule suspension. The capsule 
suspension were transferred to 75 cm2 culture flasks and cultured in 37°C with 7 % 
CO2. The media was changed every other week or more often, and media was 
withdrawn for use in assays such as alamarBlue®, Live/dead, protein gel 
electrophoresis and actin/nucleus staining were replaced immediately with fresh 
media. 
Deviations from encapsulation protocol 
B: Gelling solution with only Ca2+ was used to gel the capsules, as the capsules are 
made with alginate especially designed with many of MG and G blocks to form a 
stable gel without Ba2+ions present in the gelling solution (Morch et al., 2007). 
E: The gelatin/alginate-mixes were kept in an incubator with 37°C for approximately 1 
hour prior to encapsulation to prevent the gelatin to gel. 
F: The gelatin/alginate mixes and gelling solution were kept in heated water (approx. 
40°C) to prevent the gelatin to gel. The plastic tube was isolated with cotton and 
aluminium foil with the aim of preserving the elevated temperature for as long as 
possible. 
G: 0.9% alginate concentration. 
H (all): Gelling solution with only Ca2+ was used to gel the capsules. 
H1: The capsules became very small and had to be centrifuged for 2 minutes at 800 
RPM before washing, instead of filtered. 
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H2: As batch H1 consisted of very small capsules and the alginate used in H2 were 
the same as the alginate used in H1, but without RGD peptide, it was attempted to 
avoid such small capsules in batch H2. This was partially avoided by reducing flow 
time to 7,0 mL/hour and voltage to 5,8 kV. 
2.5. alamarBlue® 
Principle: alamarBlue® (produced by Invitrogen) is an assay for quantitative 
measurement of cell proliferation, viability and/or cytotoxicity. It is an oxidation-
reduction sensitive dye, which fluoresces and changes colour in response to growth 
and inhibition of growth. The active ingredient of alamarBlue® is resazurin, a non-
toxic, non-fluorescent and cell permeable compound. Live cells have a natural 
reductive power that converts resazurin into a fluorescent molecule called resorufin. 
Viable cells continue to do so over time, which enables a quantitative measurement 
of viability and cytotoxicity. The amount of fluorescence produced is thus proportional 
to the number of living cells (Page et al., 1993). 
Both fluorescence and absorbance measurement instrumentation can be used to 
collect data, however, fluorescence is considered to be the more sensitive. 
Absorbance is measured at 570 and 600 nm (Page et al., 1993). 
Experimental: Different protocols of alamarBlue® assay were tested during this 
study, as method 1 (described below) did not work adequately for all experiments. 
The different methods are described below.  
2.5.1. Method 1- OECs encapsulated in 1.8% UP-LVG alginate 
Five parallel samples of capsules and media estimated equal to 5000 cells were 
taken from each culture flask, and transferred to a clear-bottomed 96 well plate. 
Media from the corresponding culture flask were added up to a volume of 180μL in 
each well. 
Five parallels of 180μL media controls from each culture flask were transferred to the 
well plate. As a final control, five parallels of new unused OEC culture media were 
added to the well plate. 18μL of alamarBlue® reagent was added to each well and 
the plate was incubated in room temperature for four hours. 
The fluorescence intensity was measured by a multilabel microplate reader (Victor 
Wallac, Perkin Elmer) at 535/590 nm. 
2.5.2. Method 2 - OECs encapsulated in 1.0% Alg Epi RGD I 
Certain difficulties were experienced when applying method 1 to the cells 
encapsulated in 1.0% alginate gel. The fluorescence values turned out negative 
when subtracting the blank control sample values from the sample value. It was thus 
decided to increase the incubation time from 4 to 6 hours and check whether a 
prolonged incubation time would enable the cells to reduce the reagent sufficiently. 
After six hours of incubation the fluorescence values were negative for the lower cell 
concentrations (1.5 mil/mL). 
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2.5.3. Test round - OECs encapsulated in 1.0% UP-LVG alginate. 
The negative results obtained from the alamarBlue® assay using Method 2 spurred a 
test round where three different protocols were tried and their results compared. All 
three methods were performed on two concentrations of OECs encapsulated in 1.0% 
UP-LVG alginate; 1.0 mill/mL and 4.0 mil/mL. 
Method 3 – test round 
The third method was basically the same as method 2, except that the samples were 
incubated in 37°C and 7% CO2 for four and six hours. The fluorescence values were 
measured after four and six hours by a multilabel microplate reader (Victor Wallac, 
Perkin Elmer) at 535/590 nm. 
Method 4 – test round 
A volume of media and capsules corresponding to 50 000 cells were taken out from 
each culture flask and placed in transparent 6-well plate. Media from the 
corresponding culture flask was added to a total volume of 5,1 mL in each well. 0.51 
mL of alamarBlue® reagent were added to each well in the 6-well plate. 
Five parallels of control samples with a volume of 180 µl were withdrawn from each 
culture flask and placed in a 96 well plate. The control samples were each added 18 
µl alamarBlue® reagent.  
Both the 6-well plate containing capsules and media and the 96-well plate containing 
controls were incubated in 37°C and 7% CO2. 
Five samples of 180 µl from each batch in the 6-well plate were withdrawn and 
placed in a 96-well plate at three time points; 2, 4 and 6 hours after incubation. The 
fluorescence values of both samples and controls were measured by a multilabel 
microplate reader (Victor Wallac, Perkin Elmer) at 535/590 nm. 
Method 5 – test round 
Five parallels of 180 µl control samples were withdrawn from the media supernatant 
in each culture flask and placed in a 96-well plate. 18µl alamarBlue® reagent was 
added to each well sample. 
After withdrawal of control samples, 1 mL of alamarBlue® reagent were added 
directly to the culture flasks (total volume in flask: 10 mL). The control samples and 
the culture flasks were incubated in 37°C and 7% CO2. 
Five parallels of 180 µl were withdrawn from the flasks at three time points; 2, 4 and 
6 hours. The samples were placed in a 96-well plate and the fluorescence intensity 
was measured by a multilabel microplate reader (Victor Wallac, Perkin Elmer) at 
535/590 nm. The control samples were measured at the same time points. 
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2.6. MTT assay 
Principle: The MTT assay was developed by Tim Mossman in 1983 and is a versatile 
and quantitative method for measuring live cells quantitatively in homogenous cell 
cultures. The light yellow tetrazolium salt MTT (3-(4,5-dimethylthiazol-2-yl) 2,5-
diphenyl tetrazoliumbromide) contains a tetrazodium ring that is cleaved by various 
dehydrogenases in active mitochondrias, giving the insoluble dark blue crystal 
formazan. Adding DMSO will dissolve the formazan crystals and an absorbance 
measure device can measure the resulting colored solution.  As activated cells 
produce more formazan than dormant cells, the assay can be used to distinguish 
between active and dormant cells as well as live and dead cells (Mosmann, 1983). 
Experimental: In this project the MTT assay was performed to see if the results 
corresponded with the results obtained by the alamarBlue assay. Both assays were 
performed on OECs encapsulated in 1.0% UP-LVG with a concentration of 1.5 mil 
cells/mL alginate, on day 8, day 13 and day 21. 
Part I: Three parallels of 33μL capsules suspended in media were placed in three 
wells in a 24 well plate (PerkinElmer), EACH containing 40 capsules on average. 1 
mL media from the related culture flasks and 100μL of MTT solution (5 mg MTT/mL 
PBS, Invitrogen and Gibco®, respectively) was added to each well and the plate was 
incubated at 37°C and 7% CO2 for four hours. After incubation the capsules were 
washed three times with 1 mL 0.9% NaCl and sealed with tape and stored in 1 mL 
0.9% NaCl in a refrigerator. 
Part II: The liquid was pipetted off, and the number of remaining capsules were 
counted. 400μL of DMSO (Fischer Chemicals) were added to the wells before 
incubation in RT for 1 hour. After incubation 50μL of Sorensen’s solution (0,1 M 
glycine and 0,1 M NaCl adjusted to pH 10.5 by 1 M NaOH) was added to each well. 
Two parallels of 200μL from each well were transferred from the 24-well plate onto a 
96 well plate before measuring the absorbance at 570nm by an iMark Microplate 
Absorbance Reader (BioRad).  
2.7. Live/Dead 
Principle: The LIVE/DEAD Viability/Cytotoxicity Assay Kit (Molecular Probe) is an 
assay that simultaneously shows live and dead cells, utilizing two fluorescent probes.  
The polyanionic non-fluorescent dye calcein AM is enzymatically converted to the 
intensely fluorescent calcein in live cells due to their intracellular esterase activity. 
This enzyme is not active in dead cells. Calcein is well retained in live cells and 
fluoresces in an intense green color (ex/em 495nm/515nm). Ethidium homodimer-1 
(EthD-1) enters cells with damaged cell membranes and binds to the nucleic acids. 
This binding causes a 40-fold enhancement of bright red fluorescence (ex/em 
495/635). EthD-1 is excluded by the intact plasma membrane of live cells. There is 
virtually no background fluorescence because the dyes are not fluorescent before 
interacting with cells. Thus, both live and dead cells are dyed simultaneously and the 
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analysis is performed using a confocal microscope as shown in figure 2.1 (Invitrogen, 
2005). 
Experimental: A Live/Dead Viability Kit was purchased from Invitrogen. A working 
solution of 3 mL PBS (Gibco®), 0,8µL calcein AM and 1,3µL ethidium bromide was 
made and vortexed to ensure proper mixing. The work solution was stored in the 
refrigerator for no more than a week. 200 µL of pure PBS were added to capsules ( ≈ 
0.5 mL) in a cryotube (Nunc cryotubes™) followed by 200µL work solution. 
A volume of 200µL from each batch was transferred to a glass bottom microwell dish 
(MaTek Coropration) and examined with laser scanning confocal microscope (LSM 
510 by Carl Zeiss). Calcein was excited with an argon laser at 488 nm and EthD-1 
was excited with a helium-neon laser at 543 nm. A 10x water immersion objective 
was used during analysis. 
The same Live/Dead protocol was followed in all experiments, and the Live/Dead 
ratios were qualitatively estimated from the pictures taken with CLSM. 
 
Figure 2.1: The green cells are live cells, while the red cells are dead cells.  
Settings for the CLSM: 
Scan Mode; Plane, original data, multi track, 8 bit 
Objective; C-Apochromat 10x/0.45W 
Beamsplitters; MBS-1: HTF UV/488/543/633  
DBS1-1: Mirror 
DBS1-2: Mirror  
NDD MBS1-1: None  
MBS-2: HTF UV/488/543/633  
DBS1-2: Mirror  
DBS2-2: NFT 545  
NDD MBS1-2: None  
MBS-3: HTF UV/488/543/633  
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NDD MBS: None  
Lasers; Argon (488nm)  
HeNe (543nm)  
Filters; BP 505-530, LP 650  
Pinholes; 199µm 
2.8. Actin filament and nucleus staining using Phalloidin and DRAQ5 
Principle: Phalloidin is a probe that binds specifically to filamentous actin. It is 
isolated from the deadly Amanita phalloides mushroom and it is a bicyclic peptide. 
Phalloidin has virtually equal binding properties with F-actin from different species, 
both plants and animals with high selectivity and low non-specific binding. Invitrogen 
has conjugated the peptide to a photostable green fluorescent dye, Alexa Fluor 488® 
that enables both visualization and quantification of actin. Before staining, cells have 
to be both fixated and permeabilized. Alexa Fluor 488® is exitable at 495 nm and has 
emission at 518 nm (Wulf et al., 1979). 
Deep red fluorescent bisalkylaminoanthraquinone (DRAQ5) has a high affinity for 
DNA and is capable of entering both live and dead cells. The fluorescent dye is 100% 
synthetic and derived from intercalating cytostatika. It is exitable at 646nm and 
emissions at 681nm. Coloring of DNA takes place in a matter of seconds, and is 
enhanced by incubation at 37°C.  DRAQ5 is classified as cytotoxic, and not suitable 
for experiments where long term cell viability is a prerequisite Figure 2.2 depicts an 
example of an OEC that has been encapsulated in UP-LVG alginate an stained with 
phalloidin (green) and DRAG5 (red) (Smith et al., 2004). 
 
Figure 2.2: An olfactory ensheathing cell stained with phalloidin (green) and DRAG5 
(red). The green color represents F-actin, while red stains DNA. (Figure taken from this 
project).  
Experimental: Alexa Fluor 488® phalloidin was purchased from Invitrogen. DRAQ5™ 
was purchased from Biostatus Limited. 
50 µL of capsules in media suspension were pipetted into an Eppendorff tube and 
the capsules were allowed to sediment before the media was pipetted off. The 
capsules were washed with 100µL of 0.9% NaCl solution with 2 mM CaCl2, before 
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100µL of 0.9% NaCl solution with 2 mM CaCl2 with 3,7% FAH were added as fixation 
media. The Eppendorff tubes were incubated in 37°C with 7% CO2 for 15 minutes. 
Excess fixation media was removed by washing 3 times with 100µL 0.9% NaCl 
solution with 2 mM CaCl2, before 50µL 0,05% Saponin in 0.9% NaCl solution with 2 
mM CaCl2 was added. The samples were then incubated in RT for 10 minutes.  
The two dyes were added, Phalloidin (25 µL) and DRAQ5 (1 µL) and thoroughly 
mixed before the tubes were incubated for about 10 minutes in 37°C with 7% CO2. 
The capsules were washed with 100 µL 9% NaCl solution with 2 mM CaCl2 before 
imaging by a confocal microscope (LSM 510 by Carl Zeiss). The following settings 
were applied: 
Scan Mode: Plane, original data, multi track, 8 bit 
Objective: C-Apochromat 10x/0.45W, C-Apochromat 40x/1.2W, C-Apochromat 
63x/1.2 W 
Beamsplitters: MBS-1: HTF UV/488/543/633 DBS1-1: Mirror DBS1-2: NFT 
610 NDD MBS1-1: None MBS-2: HTF UV/488/543/633 DBS1-2: Mirror DBS2-2: 
NFT 610 NDD MBS1-2: None MBS-3: HTF UV/488/543/633 NDD MBS: None 
Lasers: Argon (488nm) HeNe (633nm) 
Filters: BP 505-530 LP 650 
Pinholes: 166µm, 212µm 
Some changes were applied to the original protocol, which states that 0,1.0% BSA in 
PBS should be used as washing solution and in the fixation media. This solution 
proved to dissolve the capsuled before imaging and it was therefore decided to 
replace it with 0.9% NaCl solution with 2 mM CaCl2, which worked satisfactorily. 
The amount of DRAQ5 was reduced from 1 µl to 0.5 µl in the last assay (Day 20 on 
batch H), as it was found to have much larger intensity than Alexa Fluor 488® 
phalloidin. 
2.9. Capsule stability 
The capsule stability was tested with different solutions with the aim of assessing the 
gel stability and to establish which method to use if it became necessary to extract 
cells from the capsules, that is, how to dissolve the alginate effectively without 
damaging the cells.  
Experimental: The capsule stability was tested with sterile water, 0.9% NaCl, MG 
lyase (Sigma-Aldrich®), 50 mM citrate (KeboLab AB) solved in sterile water, and 
50mM ethylenediaminetetraacetic acid (EDTA, Sigma) in 10mM HEPES (Sigma) 
buffer solved in PBS (Gibco®). 
20 µL of capsules (batch B1a, B1b, B2a and B2b, made with gelling solution 
containing only Ca2+ ions) suspended in OEC media were placed in 300 µL sterile 
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water in a 96 well plate in RT. The capsules were monitored with a light microscope 
at 10x magnification every 10 minutes for 30 minutes. 
20 µL of capsules (batch B1a, B1b, B2a and B2b, made with gelling solution 
containing only Ca2+ ions) suspended in OEC media were placed in 300 µL sterile 
0.9% NaCl in a 96 well plate in RT. The capsule stability was checked every 10 
minutes with a light microscope at 10x magnification. 
MG lyase enzyme  (8 units/mL) solved in 1 mL PBS was added to 0.5 mL capsules 
(batch C1a) suspended in 4 mL OEC growth media, and incubated in 37°C and 7% 
CO2 for three days.  
Citrate and EDTA solutions were sterile filtrated and pH adjusted to pH: 7,2-7,4 
before use. 
1 mL of citrate solution (50mM in 100 mL sterile water) was added to 100 μL 
suspension of capsules (batch C1a) in OEC media placed in a transparent 24 well 
plate. The capsules were monitored in a light microscope at 10x magnification every 
5 minutes for 25 minutes. For every 5 minutes without any dissolving capsules, 
another 1 mL of citrate solution was added to the capsules. When the volume 
became larger than the well could contain, the capsules were transferred to a 25 mL 
test tube. The capsules were checked again after 1.5 hours.  
600 μL EDTA solution (50 mM in 100 mL PBS with 10 mM HEPES) was added to 
100 μL capsules (batch C1a) suspended in OEC growth media placed in a 24 well 
plate. The capsules were monitored in a light microscope at 10x magnification after 
one minute. 
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3. Results 
3.1. Different concentrations of OECs encapsulated in 1.8% UP-LVG alginate 
Three different concentrations of OECs were encapsulated in 1.8% UP-LVG 
Ca2+/Ba2+  alginate; 1.5 mil/mL, 3.0 mil/mL and 5.0 mil/mL with the aim of observing 
differences in cell viability related to cell concentration in the capsules. They will be 
denoted A1a, A1b and A1c, respectively, in accordance with table 2.2 in section 2.1. 
The cells viability was measured by Live/Dead assay over a period of 14 days. 
The distribution of live and dead cells was visualized by 3D Z stack projections by 
CLSM. Figure 3.1 displays cross sections through the equator of capsules overlaid 
with transmitted light. 
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Figure 3.1: CLSM cross-sections through the equator of capsules made of 1.8% UP-
LVG alginate gelled with gelling solution containing Ca2+ and Ba2+ ions, containing 
OECs overlaid with transmitted light. Green fluorescence indicates live cells and red 
fluorescence indicate dead cells. A 10x objective was used for image acquisition. The 
size bar is 200µm. 
The capsules displayed a narrow size distribution with an approximate average 
diameter of 500µm. The structural integrity of the capsules remained intact 
throughout the experiment, with a few exceptions. These broken capsules were 
randomly distributed among the three different cell concentrations. The capsules 
retained their initial size throughout the experiment and showed no sign of swelling. 
The difference in cell concentration between the three batches can be clearly 
observed. 
CLSM Z stacks 3D projections from the Live/Dead assay can be observed in figure 
3.2. 
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Figure 3.2: Live/dead assay. CLSM Z stacks 3D projections of OECs encapsulated in 
1.8% UP-LVG alginate gelled with gelling solution containing Ca2+ and Ba2+ ions. 
Green fluorescence indicates live cells as opposed to red fluorescence, which 
indicates dead cells. Several capsules are shown in each picture. A 10x objective was 
used for image acquisition and the size bar is 200µm. 
At day 1 the cells in batch A1a displayed good viability with approximately 90% live 
cells. The A1b batch displayed lowest viability the day after encapsulation with 70% 
live cells, but the picture is overexposed, making the estimate inaccurate. Batch A1c 
had a viability of 80% at day 1. 
The picture of the 3.0 mil/mL capsules at day 1 introduces an artefact, as the 
capsules were moving during image acquisition. The picture is also somewhat 
overexposed. This causes the colonies to appear more numerous and more intensely 
coloured than they really were. 
It can be observed from figure 3.2 that the viability of the cells is declining rapidly for 
all cell concentrations over a period of 14 days. The estimated percentage of live 
cells is plotted in figure 3.3. 
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Figure 3.3: The estimated percentage of live cells in 1.8% UP-LVG capsules with 
different cell concentration, based on figure 3.2. 
The A1a batch display a higher viability than A1b and A1c up until day 10 where it 
declines from an estimated percentage of 85% live cells at day 7 to 30% live cells at 
day 10 (fig. 3.2 and 3.3). The A1b and A1c batches seemed to decline in viability 
earlier than A1a, at day 7 where A1b plunged from 80% live cells to 30% live cells at 
day 7 and A1c went from 80% live cells to 40%live cells. 
From day 7 to day 10 there was a slight increase from 40% to 50% in living cells in 
batch A1c, while batch A1b kept a constant percentage of 30% live cells. From day 
10 to 14 all batches displayed a declined in viability and the experiment was 
terminated. 
3.2. Encapsulation of OECS in 1.0% LG alginate grafted with 0.2% RGD 
peptide 
1.5 mil/mL and 5.0 mil/mL OECs were encapsulated in 1.0% LG Ca2+ alginate 
epimerised with mannuronan C5 epimerases AlgE4 and AlgE6 and grafted with 0.2% 
RGD peptide. As a control, both concentrations of OECs were encapsulated in non-
peptide grafted similar alginate. The purpose of this encapsulation was to see if the 
cells viability was affected by the RGD peptide grafted to alginate. Kristin Karstensen 
(Karstensen, 2010) observed attachment of OECs to RGD peptide in 0.2% RGD 
peptide grafted alginate gel 2D culture in her master project. However, no effect was 
observed of the RGD peptide upon OEC culture in 3D gels. She also observed a 
similar drop in viability upon 3D culture in 1.8% alginate concentration in these 
capsules. It was of great interest to see whether interaction would occur in a 3D 
environment in this experiment. 
The cells viability was measured by Live/Dead assay over a period of 22 days, at day 
1,3,7,10,14 and 22. The distribution of live and dead cells was visualized by 3D Z 
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stack projections by CLSM. Figure 3.4 displays cross sections through the equator of 
capsules overlaid with transmitted light. 
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Figure 3.4: CLSM cross-sections through the equator of 1.0% epimerised Ca2+ alginate 
capsules containing OECs overlaid with transmitted light.  A 10x objective was used 
for image acquisition. The size bar is 200µm. Due to technical problems the pictures 
from day 22 lack a size bar. 
The capsules displayed a larger variation in size than capsules made with 1.8% UP-
LVG alginate, and capsules with a tail were observed. The capsules in this 
experiment were generally smaller than the capsules observed in experiment 3.1, 
with a diameter of approximately 350µm on average. The capsules with 5.0 mil/mL 
cell concentration were perceived as larger than capsules with 1.5 mil/mL cell 
concentration on several occasions. 
All capsules appeared stable over 22 days in culture with no observed swelling. 
CLSM Z stack 3D projections are depicted in Figure 3.5. 
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Figure 3.5: Live/dead assay. CLSM Z stacks 3D projections of OECs encapsulated in 
1.0% epimerised Ca2+ alginate with and without RGD peptide graft. The pictures were 
taken at day 1, 3, 7, 10, 14 and 22 after encapsulation. Green fluorescence indicates 
live cells as opposed to red fluorescence, which indicates dead cells. Several 
capsules are shown in each picture. A 10x objective was used for image acquisition 
and the size bar is 200µm. 
The cells of all batches displayed very good viability at day 1 with live cell percentage 
> 90%. This indicated that the cells tolerated the encapsulation well. The pictures 
from day 1 and 2 for the B2a and B1b have low intensity, making the estimations 
insecure. 
The viability of the cells in all batches was high (>85%) up until day 10. From day 10 
to 14 many dead cells were observed in batch B2a and B1b. The dead cells were 
predominantly located inside the channel formations. A smaller fraction of dead cells 
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were observed at day 22, than day 14, especially in batch B2a and B2b. The live 
cells clusters seemed relatively constant in both batches in this time period. B1a 
displayed relatively high viability throughout the experiment, with an estimated 
decrease in live cell percentage from 95% to 70% after 22 days in culture as can be 
observed in figure 3.6.  The cells in batch B2b displayed an estimated viability 
percentage of 50% when the project was terminated but in contrast to batch B2a and 
B1b the viability seemed to decline gradually, without any sudden drops. 
The estimated live cell percentage is presented in Figure 3.6. 
 
Figure 3.6: The estimated percentage of live cells in 1.0% epimerised Ca2+ alginate 
with and without RGD peptide graft capsules with different cell concentration, based 
on Figure 3.5.  
No difference in viability between grafted (B2b and B2a) and non-grafted alginate 
(B1a and B1b) could be observed in this experiment. The two batches with relatively 
high viability were grafted and non-grafted, and consequently the two batches with 
low viability were also grafted and non-grafted alginate capsules. The lowest cell 
concentration (1.5 mil/mL) was represented on both ends of the viability scale, while 
the capsules with high cell concentration (5.0 mil/mL) both displayed low viability 
(<40%) after 22 days. 
No interaction of cells with RGD peptide could be observed as changes in 
morphology in this experiment. 
Figure 3.7 A clearly shows that most dead cells are located inside the channels, 
while live cells are situated in round, regular clusters. Figure 3.7 B and C may 
suggest that the round live clusters also are located inside channels. 
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Figure 3.7: A: CLSM Z stack 3D projection of a capsule from the B1a batch. The 
picture was obtained at day 14.  A 40x objective was used for image acquisition and 
the size bar is 9µm. B:CLSM cross-section through the equator of a capsule from the 
B2a batch overlaid with transmitted light. A 40x objective was used for image 
acquisition. The size bar is 49µm and the picture was obtained at day 14. C: CLSM 
cross-section through the equator of capsules from the B1b batch overlaid with 
transmitted light.  A 40x objective was used for image acquisition. The size bar is 
49µm and the picture was obtained at day 22. 
Star shaped channels were observed in all of the capsules regardless of RGD-graft 
or not. In the capsules with high cell concentration (B1b and B2b) these channels 
seemed to push the surface of the capsules outwards, causing the capsules to 
appear angular shaped. An example of such a capsule is depicted in figure 3.7 C. 
3.3. Encapsulation of OECs in 1.0% UP-LVG alginate I 
Two different concentrations of OECs were encapsulated in 1.0% UP-LVG Ca2+/Ba2+ 
alginate; 1.0 mil/mL and 4 mil/mL, denoted C1a and C1b. The purpose of this 
encapsulation was to check if the increased viability observed in experiment 3.2 was 
due to softer gel caused by lower alginate concentration (1.8% alginate versus 1.0% 
alginate) or due to differences in the alginate properties (UP-LVG alginate versus 
0.2% RGD peptide grafted alginate epimerized with mannuronan C-5 epimerases 
AlgE4 an AlgE6). 
The cell viability was measured by Live/Dead assay. Because of lower cell 
concentration than expected (1.0 mil/mL and 4 mil/mL versus 1.5 mil/mL and 5.0 
mil/mL), these batches were used to test different alamarBlue® protocols as 
described in the Materials and Methods section 2.5. It was decided not to use the 
alamarBlue® assay on these batches after the test round, as a new encapsulation 
(experiment 3.4) with cell concentration corresponding to the other experiments in 
this project. 
Batch C1a was kept in culture for 51 days while batch C1b was discarded after 22 
days, due to low cell viability. 
The distribution of live and dead cells was visualized by 3D Z stack projections by 
CLSM. Figure 3.8 displays cross sections through the equator of capsules overlaid 
with transmitted light.   
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Figure 3.8: CLSM cross-sections through the equator of 1.0% UP-LVG Ca2+/Ba2+- 
alginate capsules containing OECs overlaid with transmitted light.  A 10x objective 
was used for image acquisition and the size bar is 200µm. The 4 mil/mL cell 
concentration batch (C1b) was discarded at day 22 due to low cell viability. 
The capsules exhibited a narrow size distribution with circular capsules and a few 
broken capsules distributed randomly between the batches. Batch C1b displayed a 
larger capsule diameter than batch C1a. On average the diameter of C1a was 
approximately 350µm, while batch C1b displayed an approximate average diameter 
of 500µm. The capsules retained their initial size during the experiment. 
CLSM Z stack 3D projections are depicted in Figure 3.9. 
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Figure 3.9: Live/dead assay. CLSM Z stacks 3D projections of OECs encapsulated in 
1.0% UP-LVG Ca2+/Ba2+ alginate. Batch C1b was discarded at day 22 due to low cell 
viability. Green fluorescence indicates live cells as opposed to red fluorescence, 
which indicates dead cells. Several capsules are shown in each picture. A 10x 
objective was used for image acquisition and the size bar is 200µm. 
Both batches displayed high cell viability (estimated >75% live cells) up to day 17, 
with an exception of day 1 and 3 where the cell viability in both batches was roughly 
estimated to 50%. The dead cells are presumed to be washed out of the capsule, 
increasing the Live/Dead ratio in favour of live cells (figure 3.10). This may indicate 
that the cells in both batches did not tolerate the encapsulation process well. The 
viability of the cells in the C1b batch declined from day 17 to 22 from >75% live cells 
to approximately 50% live cells. These capsules were discarded at day 22. 
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Batch C1a displayed stable viability with an estimated live cell percentage over 75% 
up until day 36. From day 36 to 51 a slow decrease in viability was observed until the 
experiment was terminated at approximately 50% live cells in batch C1a. 
The estimated live cell percentage for both batches are presented in Figure 3.10. 
 
Figure 3.10: An estimate of live cell percentage of OECs encapsulated in 1.0% UP-LVG 
Ca2+/Ba2+ alginate, based on Figure 3.9. 
3.4. Encapsulation of OECs in 1.0% UP-LVG alginate II 
It was decided to repeat the encapsulation of two concentrations in 1.0% UP-LVG 
Ca2+/Ba2+ alginate because the cell concentrations became lower than expected in 
experiment 3.3. The two new batches denoted D1a and D1b obtained desired cell 
concentration 1.5 mil/mL and 5.0 mil/mL, respectively. 
The cell viability was measured with Live/Dead assay and alamarBlue® assay, and 
batch D1a was kept in culture for 36 days, while batch D1b was discarded after day 
14 due to low viability. 
Figure 3.11 displays cross sections through the equator of capsules overlaid with 
transmitted light obtained by CLSM. 
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Figure 3.11: CLSM cross-sections through the equator of 1.0% UP-LVG Ca2+/Ba2+ 
capsules containing OECs overlaid with transmitted light.  A 10x objective was used 
for image acquisition and the size bar is 200µm. The 5.0 mil/mL cell concentration 
batch (D1b) was discarded at day 14 due to low cell viability. 
Both batches displayed an average diameter of approximately 400µm, with no 
notable difference in capsule size between the two cell concentrations. The capsules 
retained their initial size throughout the experiment and only few broken capsules 
were observed.  
The distribution of live and dead cells was visualized by 3D Z stack projections by 
CLSM and is shown in figure 3.12. 
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Figure 3.12: Live/dead assay. CLSM Z stacks 3D projections of OECs encapsulated in 
1.0% UP-LVG Ca2+/Ba2+ alginate. Green fluorescence indicates live cells as opposed to 
red fluorescence, which indicates dead cells. Several capsules are shown in each 
picture. A 10x objective was used for image acquisition and the size bar is 200µm.  
Both batches displayed an estimated viability of 60% at day 2, but the picture for the 
D1b batch is overexposed, rendering the estimate for this batch uncertain. 
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The picture of the 5.0 mil/mL capsules at day 2 introduces an artefact, as the 
capsules were moving during image acquisition. This causes the cell clusters to 
appear larger and more intensely green coloured than they really were. The pictures 
of day 24, 27 and 36 (batch D1a) are somewhat overexposed, which made it difficult 
to assess Live/Dead ratio. This introduces uncertainties in the qualitative analysis, 
which must be taken into account when interpreting figure 3.13. 
As in experiment 3.3 the cells viability in batch D1a seems to increase from 
approximately 60% live cells to ca. 75% live cells after day 3 in the capsules. This 
does not apply for the cells in batch D1b, where the viability decreases rapidly from 
day 3 until termination of the batch due to low viability at day 14. It is probable that 
the cells that died during encapsulation in batch D1a were washed out of the 
capsules, and increased the Live/Dead ratio in favour of live cells. 
Batch D1a displayed high viability (>75% live cells) up until day 21, where the viability 
decreased gradually to an estimated value of 50% at day 36 when the experiment 
was terminated. An exception is day 16, where the viability was estimated to 40% live 
cells. 
The estimated live cell percentage for both batches are shown in figure 3.13. 
 
Figure 3.13: An estimated percentage of live cells encapsulated in 1.0% UP-LVG 
Ca2+/Ba2+ alginate , based on figure 3.12. 
3.5. OECs encapsulated in 1.0% UP-LVG alginate mixed with different 
concentrations of gelatin I 
OECs were encapsulated in 1.0% UP-LVG alginate mixed with gelatin to yield three 
different gelatin concentrations; 0.5 %, 1.0% and 2%, denoted E1, E2 and E3, 
respectively. All three batches had a cell concentration of 1.5 mil/mL and were gelled 
in gelling solution containing Ca2+/Ba2+ ions. 
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The purpose of this encapsulation was to make the alginate more similar to the ECM 
by mixing alginate with gelatin, and examine whether the gelatin influenced the cells, 
both in terms of viability and morphology. Gelatin may resemble collagen and 
collagen is the most abundant protein in the ECM. It was also of interest to monitor 
the capsule quality as well as the encapsulation process. 
Figure 3.14 displays cross sections through the equator of capsules overlaid with 
transmitted light obtained by CLSM. 
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Figure 3.14: CLSM cross-sections through the equator of capsules made of 1.0% UP-
LVG Ca2+/Ba2+ alginate mixed with gelatin containing 1.5 mil/mL OECs overlaid with 
transmitted light.  A 10x objective was used for image acquisition and the size bar is 
200µm. 
As can be observed in Figure 3.14, the irregular shape of the capsules increased 
proportionally with increasing gelatin concentration. The average capsule diameter 
was approximately 500µm, but it was sometimes difficult to assess due to the 
capsules irregular shape. The stability of the capsules was also affected by 
increasing gelatin concentration, with more broken capsules and escaped cells 
attached to the culture flask bottom in the E3 batch, less in the E2 batch and the 
stability of the E1 batch was comparable with the experience with 1.0% UP-LVG 
capsule stability. 
The cell colonies tended to be less dispersed and rather large compared to earlier 
experiments during this project. An example of two cell clusters can be observed in 
figure 3.15. The amount of cells in the capsules did also look smaller than in previous 
experiments. 
Some difficulties were experienced during encapsulation, as gelatin gels below ≈ 
35°C. It was a challenge to keep the temperature of the alginate-gelatin mix over this 
threshold before the ionic gelation with alginate took place and lack of experience 
and a proper protocol may have influenced the capsule result. It was decided to try 
another encapsulation with the same settings to improve the encapsulation process 
(described in section 3.6.), to see if the results obtained in this experience were 
reproducible. 
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Figure 3.15: Two cell clusters situated in a 1.0% UP-LVG alginate mixed with 1.0% 
gelatin capsule (E2). The picture was obtained by CLSM cross-sections through the 
equator of capsules overlaid with transmitted light.  A 40x objective was used for 
image acquisition and the size bar is 49µm. 
The distribution of live and dead cells was visualized by 3D Z stack projections by 
CLSM and is shown in figure 3.16. The alamarBlue® assay was also performed on 
these cells and the fluorescence values and calculations can be observed in 
appendix A9, while the graph is shown in appendix A10. 
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Figure 3.16: Live/dead assay. CLSM Z stacks 3D projections of OECs encapsulated in 
1.0% UP-LVG Ca2+/Ba2+ alginate mixed with gelatin. Green fluorescence indicates live 
cells as opposed to red fluorescence, which indicates dead cells. Several capsules are 
shown in each picture. A 10x objective was used for image acquisition and the size 
bar is 200µm. 
At day 1 the viable cell percentage was estimated to 60% for all three batches and it 
increased for all batches until day 3. It is probable that the cells that did not tolerate 
the encapsulation well and died as a result of it, were washed out of the capsule. 
The cells displayed overall high viability regardless of gelatin concentration, and it 
seemed like the viability of cells depended more on loss of capsules due to instability 
than on the material itself. As mentioned above, the cell clusters seem to be larger 
than experienced before, but the cell number appears lower than in the previous 
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experiments. Some background green fluorescence from the gel was experienced, 
which may have influenced image quality. 
The estimated live cell percentage for both batches are shown in figure 3.17. 
 
Figure 3.17: An estimated percentage of live cells encapsulated in 1.0% UP-LVG 
Ca2+/Ba2 alginate mixed with gelatin, based on figure 3.15. 
3.6. OECs encapsulated in 1.0% UP-LVG alginate mixed with different 
concentrations of gelatin II 
The experiment described in section 3.5 above was repeated with the same settings, 
with the aim of improving the encapsulation process and gain a narrower size 
distribution and more circular capsules. 
To improve the encapsulation it was decided to preheat both the gelling solution and 
alginate-gelatin mix to ≈ 40°C in a water bath before encapsulation, as well as 
insulating the plastic tube from the syringe to the needle to avoid gelling of the 
gelatin. 
Figure 3.18 displays cross sections through the equator of capsules overlaid with 
transmitted light obtained by CLSM. 
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Figure 3.18: CLSM cross-sections through the equator of capsules made of 1.0% UP-
LVG Ca2+/Ba2 alginate mixed with gelatin containing 1.5 mil/mL cells overlaid with 
transmitted light.  A 10x objective was used for image acquisition and the size bar is 
200µm. 
The capsule quality did improve, perhaps with most impact on the F2 batch. For both 
batch F2 and F3 the edges of the capsules became more defined compared to the 
capsules obtained in experiment 3.5. The shape of the capsules did also improve for 
batch F2 capsules, and F3 capsules, albeit to a lesser degree for the latter in terms 
of circular shape of the capsules. At day 14 of the experiment there were few F2 and 
F3 capsules left in the culture flask, suggesting that they had dissolved at this stage.  
The diameter of the capsules varied between 350-600µm in order F1>F3>>F2. 
The distribution of live and dead cells was visualized by 3D Z stack projections by 
CLSM and is shown in figure 3.19. 
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Figure 3.19: Live/dead assay. CLSM Z stacks 3D projections of 1.5 mil/mL OECs 
encapsulated in 1.0% UP-LVG Ca2+/Ba2 alginate mixed with gelatin. Green fluorescence 
indicates live cells as opposed to red fluorescence, which indicates dead cells. 
Several capsules are shown in each picture. A 10x objective was used for image 
acquisition and the size bar is 200µm. 
On day 1 batch E2 displayed a live cell percentage 60%, while E3 had 70% live cell 
percentage. As in the previous experiment (section 3.5) the cell viability was overall 
high throughout the experiment with no notable differences between the batches, 
with an exception of day 1 for batch F1. This picture was treated as an outlier and 
may be caused by unfortunate selection of capsules and was therefore excluded 
from figure 3.20. The capsules were only kept in culture for 16 days, because their 
main purpose was to improve the encapsulation process, and as can be observed in 
figure 3.20 the live cell percentage was > 70% when the experiment was terminated. 
The cell clusters may have been smaller and more dispersed than in the previous 
experiment (section 3.5). In the picture of F2 from day 1 green background 
fluorescence from the alginate-gelatin is clearly visible. 
An estimate of live cell percentage in all batches is presented in figure 3.20. 
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Figure 3.20: An estimated percentage of live cells encapsulated in 1.0% UP-LVG 
Ca2+/Ba2 alginate mixed with gelatin, based on figure 3.19. 
3.7. OECs encapsulated in 0.9% UP-LVG mixed with different ECM molecules 
and sulphated alginate 
0.9% UP-LVG Ca2+ /Ba2+ alginate was mixed with laminin, collagen, fibronectin and 
hyaluronic acid, creating four different batches with an ECM molecule concentration 
of 1.0 mg/mL. Sulphated MG-block alginate was mixed with 0.9% UP-LVG alginate to 
a concentration of 1.0 mg/mL. The purpose of the ECM molecule-alginate mixes 
were to mimic the environment in ECM, where all of these molecules may be  
present, and see if they affected the OECs in terms of viability or morphology. The 
sulphated alginate was included because of its likeness with the sulphated ECM 
molecule heparin and the same purpose in relation to OECs applied. 
Figure 3.21 displays cross sections through the equator of capsules overlaid with 
transmitted light obtained by CLSM. 
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Figure 3.21: CLSM cross-sections through the equator of capsules made of 1.0% UP-
LVG Ca2+/Ba2+ alginate mixed with 1.0 mg/mL different ECM molecules, and 1.0 mg/mL 
sulphated alginate containing 1.5 mil/mL OECs overlaid with transmitted light.  A 10x 
objective was used for image acquisition and the size bar is 200µm. 
At day 1 the capsule diameter varied between the different samples. Capsules 
containing laminin and hyaluronic acid displayed the largest relative diameter, 
capsules containing fibronectin and collagen were middle sized and sulphated 
alginate capsules were by far the smallest. The size distribution did also vary for all 
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batches of capsules. Capsules containing fibronectin were the only batch with 
relatively large fraction of tail formation. All capsules were stable and few broken 
capsules were observed during the experiment. 
The distribution of live and dead cells was visualized by 3D Z stack projections by 
CLSM and is shown in figure 3.22. 
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Figure 3.22: Live/dead assay. CLSM Z stacks 3D projections of 1.5 mil/mL OECs 
encapsulated in 1.0% UP-LVG Ca2+/Ba2+ alginate mixed with 1mg/mL different ECM 
molecules, and 1mg/mL sulphated alginate. Green fluorescence indicates live cells as 
opposed to red fluorescence, which indicates dead cells. Several capsules are shown 
in each picture. A 10x objective was used for image acquisition and the size bar is 
200µm.  
The settings of the CLSM were changed after day 7 to obtain higher resolution. This 
caused reduced intensity in pictures taken subsequently compared to the pictures 
taken before day 7 and may give a wrong impression of the Live/Dead ratio. G5 
capsules moved during image acquisition at day 3, which led to that the green live 
cell clusters seem larger than they were in reality. 
At day 1 all samples displayed viable cell percentage ≥ 75%. 
The cells residing in capsules containing collagen and hyaluronic acid displayed 
increased viability on day 3 and 7 after encapsulation, respectively. All the other 
batches displayed gradually decreasing viabilities after encapsulation, with the 
exception of cells encapsulated in sulphated alginate that showed improved viability 
on day 20 before it decreased again at day 28. 
The viability of all batches were estimated as lower than the viability of 1.5 mil/mL 
OECs encapsulated in 1.0% UP-LVG alginate, solely by comparing to previous 
experiments (3.3 and 3.4). 
Figure 3.23 shows that capsules containing hyaluronic acid and sulphated alginate 
displayed highest viability throughout the project, while collagen, fibronectin and 
laminin displayed approximately similar patterns of viability decline. 
An estimate of live cell percentage in all batches is presented in figure 3.23. 
 
Figure 3.23: An estimated percentage of live OECs encapsulated in 1.0% UP-LVG 
Ca2+/Ba2+ alginate mixed with 1mg/mL different ECM molecules, and 1mg/mL 
sulphated alginate, based on figure 3.22. 
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3.8. Encapsulation of OECS in 1.0% LG alginate grafted with 0,1-0.4% RGD 
peptide 
Experiment 3.2 was repeated with a different 1.0% epimerised Ca2+ alginate grafted 
with 0,1-0.4% RGD peptide, produced by Birgitte McDonagh during her master 
thesis. 1.5 mil/mL OECs were encapsulated in 1.0% peptide grafted epimerized 
alginate, 1.0% non-peptide grafted epimerized alginate and 1.0% UP-LVG alginate. 
Each batch was split in two and cultured in OECs growth media with, and without 
serum, giving a total of six batches. The cell culture in serum-free media was relevant 
for the collection of supernatant to protein analysis and was performed to see if the 
change in culture conditions was affecting cell viability. The purpose of this 
encapsulation was to see if an increased concentration of RGD peptide compared to 
the previous experiment (3.2) would elicit any response in the cells, in terms of cell 
viability and morphology. 
The cells viability was monitored by Live/Dead assay. 
Figure 3.24 displays cross sections through the equator of capsules overlaid with 
transmitted light obtained by CLSM. 
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Figure 3.24: CLSM cross-sections through the equator of 1.0% epimerised Ca2+ 
capsules grafted with 0,1-0.4% RGD peptide, non-peptide grafted and 1.0% UP-LVG 
alginate containing 1.5 mil/mL OECs overlaid with transmitted light.  A 10x objective 
was used for image acquisition and the size bar is 200µm. 
At day 1 he capsules made with RGD peptide grafted epimerized LG alginate 
displayed a very small diameter (< 250µm), compared to the other two batches and 
their shape was more irregular. 
The non-peptide grafted epimerized LG alginate capsules and the UP-LVG capsules 
displayed roughly the same diameter (< 400-500µm ) and they were almost circular 
with a narrow size distribution. 
Most capsules were stable throughout the experiment with a few randomly distributed 
broken capsules. Very few capsules of batch H2+ was observed during Live/Dead 
assay at day 20, which may have indicated that these capsules had dissolved and 
were less stable. 
The capsules made with alginate epimerized with AlgE4 and AlgE6 displayed the 
characteristic star shaped channels, which were also observed in experiment 3.2.  In 
addition, the RGD grafted alginate capsules developed an unidentified white 
precipitation on the capsule surface, which increased during the experiment until the 
capsules were perceived as opaque and white when examined without a microscope.  
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When inspected with cross sections through the equator of capsules overlaid with 
transmitted light by the CLSM, the surface appeared wrinkled and cracked. It looked 
like the capsules had shrivelled over time, but no apparent reduction of size was 
detected when the experiment was terminated at day 20. The wrinkled surface of an 
RGD peptide grafted alginate capsule can be observed in figure 3.25.A.  This effect 
was more pronounced in the RGD peptide grafted alginate capsules cultured in OEC 
growth media with serum, than those cultured in OEC growth media without serum. 
Some precipitation could be detected in the epimerized alginate without RGD graft as 
well, but this was not observed in approximately 1 out of 30 capsules, and the 
precipitation seemed to be located within the capsule. The surface of these capsules 
did not appear wrinkled and cracked when examined by cross sections through the 
equator of capsules overlaid with transmitted light, either. Epimerized alginate without 
RGD graft capsules can be observed in figure 3.25.B. The precipitate occurred 
independently of serum in the OEC growth medium or not. 
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A:  B:  
Figure 3.25: Section of CLSM pictures of: A: 0,1-0.4% RGD peptide grafted epimerized 
alginate with 1.5 mil/mL OEC concentration cultured in OEC growth media with serum, 
taken at day 20. B: epimerized LG alginate with 1.5 mil/mL OEC concentration cultured 
in OEC growth media without serum, taken at day 20. 
The distribution of live and dead cells was visualized by 3D Z stack projections by 
CLSM and is shown in figure 3.26. 
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Figure 3.26: Live/dead assay. CLSM Z stacks 3D projections of 1.5 mil/mL OECs 
encapsulated in 0,1-0.4% RGD peptide grafted epimerized 1.0% Ca2+ alginate, non-
peptide grafted epimerized 1.0% Ca2+ alginate and 1.0% UP-LVG Ca2+ alginate. Green 
fluorescence indicates live cells as opposed to red fluorescence, which indicates dead 
cells. Several capsules are shown in each picture. A 10x objective was used for image 
acquisition and the size bar is 200µm. In the picture of UP-LVG capsules with serum at 
day 28 the capsules are moving during picture acquisition, which caused the cell 
clusters to appear larger than they really were. 
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At day 1 batch H3+ and H3- (capsules made with 1.0% UP-LVG) displayed the 
lowest viability of 70% and 60% live cells respectively. The other batches with 
capsules made of epimerized alginate all displayed viabilities >70%. 
No apparent improvement in cell viability could be observed in the epimerized 
alginate capsules cultured in media containing serum, in fact, the lowest viability of all 
batches was displayed by the cells encapsulated in epimerized non-peptide grafted 
alginate cultured in OEC media with serum. 
There may have been a small difference in viability of the cells encapsulated in UP-
LVG alginate, with and without media as the estimated percentage of live cells were 
80% and 65% when the experiment was terminated, respectively. 
An estimate of live cell percentage in all batches is presented in figure 3.27. 
 
Figure 3.27: An estimated percentage of live OECs encapsulated in in 0,1-0.4% RGD 
peptide grafted 1.0% epimerized Ca2+ alginate, non-peptide grafted 1.0% epimerized 
Ca2+ alginate and 1.0% UP-LVG Ca2+ alginate, based on figure 3.26. The + and – 
designates whether the cells were cultured in serum with or without serum, 
respectively. 
3.9. Actin filament and nucleus staining 
Alexa Fluor 488® phalloidin and DRAQ5™ was used to stain F-actin and nuclear 
DNA, respectively. The fluorescent staining was examined by CLSM. The purpose of 
this staining was to detect eventual morphological changes in OECs due to 
encapsulation in RGD peptide grafted alginate (batch H1+ and H1-), and cells 
encapsulated in alginate mixed with ECM molecules and sulphated alginate (batch 
G1, G2, G3, G4 AND G5). No consistent morphological changes were observed in 
any sample. Most cells displayed a circular morphology and one example is given in 
figure 3.28. Some cells were of irregular shape, but these were not limited to any 
specific environment and were randomly distributed between the batches, both G 
and H. 
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Figure 3.28: Actin filament (Phalloidin, green) and nuclus staining (DRAQ5, red) of 
OEC in 1.0% UP-LVG alginate mixed with 1mg/mL laminin capsule at day 28. The 
picture was obtained by CLSM cross-sections through the equator of the capsule.  A 
40x objective was used for image acquisition and the size bar is 31µm. 
Most cells appeared in clusters, as can be seen in figure 3.30. In some cells DNA 
seemed to be located outside the actin perimeter, these were believed to be dead 
cells in various states of degradation. Overlap between green and red colour can be 
observed. 
 
Figure 3.30:  Actin filament (Phalloidin, green) and nuclus staining (DRAQ5, red) of 
OEC clusters encapsulated in 1.0% UP-LVG mixed with 1.0 mg/mL collagen (batch 
G4). The picture was obtained by CLSM cross-sections through the equator of the 
capsule at day 15.  A 40x objective was used for image acquisition and the size bar is 
31µm. 
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3.10. Bubble formation around cell clusters 
In several capsules a bubble shape around the encapsulated cells similar to that 
shown in figure 3.31 appeared. This could be caused by excretion of some 
substance from the cells that dissolve the alginate gel around them, creating a softer 
environment, or it may be caused by shrinking cells. 
 
Figure 3.31: Picture of OEC cultured in 1.0% UP-LVG capsule in media without serum, 
obtained at day 20. Around the cell a bubble shape can be observed. The picture was 
obtained by CLSM cross-sections through the equator of capsules overlaid with 
transmitted light.  A 40x objective was used for image acquisition and the size bar is 
35µm. 
3.11. alamarBlue® and MTT assay 
The alamar Blue assay® was performed on the cells encapsulated in the 
experiments described in section 3.1, 3.2, 3.3, 3.4 and 3.5 with the aim of 
quantitatively assess the cells viability and metabolic activity. It was decided to omit 
this assay in further encapsulations (3.6, 2.7 and 3.8) because the fluorescence 
values often turned out negative for samples from the lowest cell concentrations (1.5 
mil/mL) when the control sample of pure media from the corresponding culture flask 
were subtracted. Method 1 described in Materials and Methods section 2.51 was 
applied on the cells encapsulated in experiment 3.1 and 3.2, which are described 
below. The method is elaborated in appendix A1, and the fluorescence values an 
calculations are shown in A2. The graph is shown in appendix A3.  
In experiment 3.1 different concentrations of OECs were encapsulated in 1.8% UP-
LVG capsules, and their viability was tested with both Live/Dead assay and alamar 
Blue assay®. The protocol described as Method 1 was applied on these batches.   
It can be observed from figure 3.31 that the levels of fluorescence were rapidly 
declining during the period of 14 days, and higher signals in these samples 
compared to control resulted in positive values throughout the experiment. 
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Figure 3.31. Graph showing fluorescence values/1000 cells from alamarBlue® assay 
performed on cells from encapsulation A1a, A1b and A1c (different OEC concentration 
encapsulated in 1.8% UP-LVG alginate.) 
The results coincided with the results obtained in the Live/Dead assay, which was 
performed simultaneously in terms of reduced viability over time and the very rapid 
decline in viability of batch A1c, as can be observed in figure 3.2. The alamarBlue® 
assay might not illustrate the correct relationship between the cell concentration in 
the different batches as batch A1b were so close to A1a in fluorescence value, and 
should display values in the middle of A1a and A1c in terms of cell concentration. 
This may be due to low viability of the cells in batch A1b, and there were indications 
of low viability of cells in this batch in the Live/Dead assay. On day 7 in figure 3.2, 
batch A1b display low viability compared to the other two batches. 
In contrast to the alamarBlue® assays performed on later batches, all sample 
fluorescence values in this experiment were larger than the control sample, giving 
positive results when the control sample was subtracted. 
In the next experiments (3.2, 3.3, 3.4 and 3.5) problems with background values 
higher than the signals from cell containing samples were experienced, as well as 
low correlation with the results from the Live/Dead assay were experienced. The 
problems that were faced in experiment 3.2 is further elaborated in appendix A4. The 
calculations and fluorescence values are found in appendix A5, while a graph 
depicting the fluorescence values over time can be found in appendix A6. 
The difficulties that were experienced with the alamarBlue® assay during experiment 
3.2 spurred a test round, in which OECs encapsulated in 1.0% UP-LVG with a 
concentration of 1.5 mil/mL were utilized as a test subject. Four different protocols 
were tested, in addition to the regular protocol described as method 1 in section 2.51 
the Materials and Methods chapter. 
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Briefly explained, method 1 involved withdrawal of five parallels of media (180µl) with 
capsules from each culture flask, as well as control samples from the corresponding 
culture flask (180µL of only media). The samples were transferred to a 96 well plate 
and added 10% of alamarBlue® reagent (18µL) before incubation in RT for four 
hours. 
Method 2 was identical with method 1 in all but one detail, incubation in RT for six 
hours instead of four. This increased fluorescence values in both samples containing 
capsules and control samples, resulting in negative results still. 
Method 3 was also similar with method 1, except that the incubation was done in an 
incubator at 37°C and 7% CO2, which is the culture settings for OECs. 
Method 4 included a volume of media and capsules corresponding to 50 000 cells 
were taken out from each culture flask and placed in a 6-well plate. Media from the 
corresponding culture flask was added to a total volume of 5,1 mL in each well. 0.51 
mL of alamarBlue® reagent were added to each well in the 6-well plate. Five parallels 
of control samples with a volume of 180 µl were withdrawn from each culture flask 
and placed in a 96 well plate. The control samples were each added 18 µl 
alamarBlue® reagent and both the 6-well plate containing capsules and media and 
the 96-well plate containing controls were incubated in an incubator with 37°C and 
7% CO2. Five samples of 180 µl from each batch in the 6-well plate were withdrawn 
and placed in a 96-well plate at three time points; 2, 4 and 6 hours after incubation 
and their fluorescence was measured. 
Method 5 After withdrawal of control samples ( 5 x 180µL  with 5 x 18µL alamarBlue  
reagent added in a 96 well plate), 1 mL of alamarBlue® reagent were added directly 
to the culture flasks (total volume in flask: 10mL). The control samples and the 
culture flasks were incubated in an incubator with 37°C and 7% CO2. 
Five parallels of 180 µl were withdrawn from the flasks at three time points; 2, 4 and 
6 hours and the samples were placed in a 96-well plate and the fluorescence 
intensity was measured. 
The disadvantages and advantages with method 3, 4 and 5 are presented in table 9. 
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Table 9: Advantages and disadvantages of the three methods. 
 Method 3 Method 4 Method 5 
A
d
va
n
ta
g
e
s 
High sensitivity. 
Low contamination risk. 
No counting of capsules, 
less time-consuming than 
Method 3. 
No counting of capsules, 
less time-consuming than 
Method 3. 
Positive fluorescence 
values after two hours, 
because of the large cell 
number. 
D
is
a
d
va
n
ta
g
e
s 
Time-consuming. 
Occasionally background 
signals higher than signals 
from samples. 
Counting of capsules, 
difficult when the capsule 
number exceeds 100. 
 
Loss of many capsules 
every time the assay is 
performed.  
Lack of sensitivity, due to 
ten times higher cell 
number the recommended 
by Invitrogen. 
Low fluorescence per cell 
compared to Method 3. 
Potential contamination of 
the whole batch. 
Potential harmful effects of 
the alamarBlue® reagent 
on the cultured cells. 
Total media exchange 
every time the assay is 
performed, expensive and 
time-consuming. 
Lack of sensitivity, due to 
very high cell numbers 
compared to the number 
recommended by 
Invitrogen (5000 cells). 
Low fluorescence per cell 
compared to Method 3. 
Potential saturation of the 
reagent due to high cell 
numbers. 
 
It was decided to use method 3 when taking all considerations in account, and thus 
accept that some fluorescent values would become negative. In the next experiments 
(3.4 and 3.5) negative values were experienced to such a degree that the results of 
these alamarBlue® assays can be found in appendix A7, A8, A9 and A10 as they 
were discarded due lack of relevance. 
As one last test of the alamarBlue® assay, it was decided to compare it with another 
viability assay, the MTT assay. The fluorescence values and calculations that led to 
figure 3.32 can be found in appendix B3 and B4. Figure 3.32 clearly shows the 
negative fluorescence values for the alamarBlue® assay, while figure 3.33 displays 
positive absorbance values for the MTT assay, even though the numbers were low. 
The values are also increasing with time, which appears illogical as the viability of 
OECs have been shown to decrease over time when encapsulated. 
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Figure 3.32: alamarBlue® fluorescence values from 1.5 mil/mL OECs encapsulated in 
1.0% UP-LVG alginate obtained at day 8, 13 and 22.  
 
Figure 3.33: MTT absorbance values from on average 40 capsules. 1.5 mil/mL OECs 
encapsulated in 1.0% UP-LVG alginate obtained at day 8,13 and 22. 
The absorbance values and calculations that led to figure 3.33 can be viewed in 
appendix B1 and B2 shows the graph. Figure 3.34 shows the Live/Dead assay that 
was performed simultaneously with the alamarBlue assay and MTT assay. The 
Live/DEAD assay shows good viability on day 8, very few cell clusters, but few dead 
cells at day 13 and then again, good viability at day 22. The small amount of clusters 
at day 13 may be due to a smaller capsule number in the picture. The results support 
the MTT assay in that the viability is good, but shows no sign of increasing, which is 
not expected when culturing OECs in 3D capsules. 
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Figure 3.34: The Live/Dead assay performed on 1.5 mil/mL OECs encapsulated in 1.0% 
UP-LVG Ca2+/Ba2+ alginate, concurrent with the MTT and alamarBlue® assay. Green 
fluorescence indicates live cells as opposed to red fluorescence, which indicates dead 
cells. Several capsules are shown in each picture. A 10x objective was used for image 
acquisition and the size bar is 200µm. 
3.12. Capsule stability 
The stability of the capsules was tested in different solutions; pure water, 0,9 % NaCl, 
MG lyase, citrate and EDTA. The goal was to assess the gel strength and also to find 
a gentle capsule dissolver that did not harm the cells, in case the cells needed to be 
extracted from capsules.  
Pure water 
OECs encapsulated in 1.0% epimerised Ca2+ alginate capsules were placed in sterile 
water in room temperature for 1.5 hours, and checked in a light microscope every 10 
minutes. No changes in capsule stability was observed after 1.5 hours. 
0.9% NaCl 
OECs encapsulated in 1.0% epimerised Ca2+ alginate capsules were placed in sterile 
0.9% NaCl in room temperature and the capsule stability was checked in a light 
microscope at 10x magnification every 10 minutes. After 30 minutes, all capsules had 
dissolved. 
The capsules tested with sterile water and NaCl were both made with gelling solution 
containing only Ca2+ ions. 
MG lyase 
MG lyase enzyme  (8 units/mL) solved in 1 mL PBS was added to 0.5 mL batch C1a 
capsules (1.0 mil/mL OECs encapsulated in 1.0% UP-LVG Ca2+/Ba2+ alginate) 
suspended in 4 mL OEC growth media, and incubated in an incubator with 37°C and 
7% CO2 for three days. No effect on the capsules was observed on capsule stability 
in a light microscope at 10x magnification. 
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Citrate 
1 mL 50 mM citrate solution was added to 200 µL suspension of batch C1a (1.0 
mil/mL OECs encapsulated in 1.0% UP-LVG Ca2+/Ba2+ alginate) capsules in 1mL 
HBSS. The capsules were monitored in a light microscope at 10x magnification every 
5 minutes for 25 minutes. For every 5 minutes without any dissolving capsules, 
another 1 mL of citrate solution was added to the capsules. After 25 minutes and a 
total of 5 mL citrate solution, no effect on capsule stability could be observed.  
EDTA 
600 μL of 50 mM EDTA was added to 100 μL of batch C1a capsules suspended in 1 
mL OEC growth media, and were monitored in a light microscope at 10x 
magnification after 1 minute, because after 1 minute all capsules had dissolved. 
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4. Discussion 
4.1. Cell viability 
One of the major aims of the study was to investigate whether encapsulation of 
OECs in different types of alginate would improve cell viability over time. Viability of 
OECs up to 14 days in 1.8% UP-LVG Ca2+ alginate capsules have been reported by 
Kristin Karstensen (Karstensen, 2010), and similar results were achieved in this 
study. At day 14 very few cells inside the 1.8% UP-LVG Ca2+/Ba2+ alginate gel 
capsules were viable in any of the three batches with different cell concentration, 
although 1.5 mil/mL displayed better viability during the 14 days than 3.0 mil/mL and 
5.0 mil/mL (figure 3.2 and 3.3). 
Two concentrations of OECs (1.5 mil/mL and 5.0 mil/mL) were further encapsulated 
in 1.0% epimerized Ca2+ alginate gel  (figure 3.5 and 3.6), with (B2) and without (B1) 
0.2 % RGD peptide graft. The viability of the cells was extended with one week 
compared to cells encapsulated in 1.8% UP-LVG Ca2+ /Ba2+ alginate gel, and the 
experiment was terminated after 22 days. In this experiment the viability as a result of 
cell concentration was less pronounced as both 1.5 mil/mL batches displayed 70% 
and 30% viability after 22 days in culture, respectively. The two batches with 5.0 
mil/mL cell concentration displayed an average live cell percentage of 45%, after 22 
days in culture.  This experiment was therefore inconclusive in terms of improved 
viability connected to cell concentration, but indicated that a lower alginate 
concentration had a beneficial impact on cell viability. The experiment did not show a 
clear significance of the RGD peptide on cell viability. 
Star shaped channels were observed inside all capsules in this experiment, and a 
large fraction of dead cells were found to be located inside these channels. This was 
also found by Kristin Karstensen in her study (Karstensen, 2010).This experiment 
was later repeated in experiment 3.8 with another source of epimerized alginate 
grafted with ≈ 0.4% RGD peptide, which will be discussed below. 
It was thus decided to conduct an encapsulation of 1.5 mil/mL and 5.0 mil/mL OEC 
concentration in 1.0% UP-LVG alginate (figure 3.9 and 3.10), with the aim of 
examining whether it was the reduced alginate concentration that improved cell 
viability, or if viability depended on the composition of the epimerized alginate. As 
most of the dead cells observed in the experiment with OECS encapsulated in 1.0% 
epimerized Ca2+ alginate gel were located inside the aforementioned channels, it was 
also of interest to examine cell viability without the channel formation that was 
observed in the epimerized alginate, but with similar alginate concentration, as 
channel formation did not occur in the UP-LVG Ca2+/Ba2+ alginate capsules. The 
results were promising, with a stable live cell percentage of 60% in the C1a batch 
after 51 days. Batch C1b was discarded after 22 days with estimated 30% live cells. 
This result strengthened the hypothesis that lower cell concentration enhanced cell 
viability, and confirmed that lower alginate concentration improved cell viability 
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notably. Experiment 3.3 (figure 3.9 and 3.10), and 3.4  (figure 3.12 and 3.12) both 
supported this hypothesis. 
The viable cell percentage on day 1 provides an indication of how well the cells have 
tolerated the encapsulation process. A factor that can influence the cell viability 
during encapsulation is shear forces in the cell-alginate mix during mixing, as the 
shear forces may damage the plasma membrane. The shear forces will vary in terms 
of molecular weight of the alginate as well as the alginate concentration, as the shear 
forces increase proportionally with the solution’s viscosity (Lee and Mooney, 2012). 
Another factor may be the swiftness of execution of the encapsulation procedure; if 
the cells are kept in room temperature too long or stored in solutions other than OEC 
growth media for long periods, it may reduce cell viability.  
The live cell percentage varied from 70% to 90% in the 1.8% UP-LVG capsules, and 
from 50% to 60% in the 1.0% UP-LVG alginate capsules at day 1 post encapsulation. 
This did not coincide with theory in terms of lower shear rates expected with lower 
alginate concentration, but in the 1.0% UP-LVG alginate capsules the viability 
increased during the project. The cell viability only decreased over time for the cells 
in the 1.8% UP-LVG alginate capsules. 
The cells in the 1.0% epimerized alginate capsules (3.2 and 3.8) displayed overall 
high live cell percentages of ≥ 80%. The high cell viability in these two experiments 
may be caused by lower viscosity or be due to a more effective encapsulation 
process. The capsules mixed with gelatin (3.5 and 3.6) displayed 60% and on 
average 65% live cell percentage after encapsulation, respectively, and the relatively 
low cell viability might have been caused by the heating of the solutions, 
implemented to avoid gelling of the gelatin during the encapsulation process, at least 
in experiment 3.6 where both the gelling solution and gelatin alginate mix was kept at 
40°C for as long as possible. 
The cells in the 0.9% UP-LVG alginate capsules mixed with ECM molecules 
displayed an overall high viability, and the same held true for the 0.9% UP-LVG 
alginate mixed with sulphated alginate. These mixes displayed higher cell viabilities 
than pure 1.0% UP-LVG alginate capsules at day 1, and this might be explained by 
less viscosity in the solution before encapsulation, due to lower alginate 
concentration. 
The cell concentration appeared to be varying from experiment to experiment. This 
may be caused by insufficient centrifugation of cells before encapsulation. 
It must be noted that all analysis of viability data are rough qualitative estimates of 
Live/Dead ratios from CLSM pictures with varying numbers of capsules present. It 
could have been beneficial to utilize software for these estimates, but this was not 
implemented during this study. The estimate tables are given in appendix C. The 
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alamarBlue® assay meant to provide a quantitative measurement of metabolic 
activity did not work satisfactorily during this project, and this is discussed below. 
4.1.1. Alginate concentration  
The elastic moduli of a gel has been shown to increase proportionally with the square 
of the alginate concentration (Smidsrød, 1972), and thus also the gel stiffness 
(Martinsen et al., 1989a) and gel strength (personal communication from Dr. Ing. 
Berit Strand, 05.05.2012).  This is illustrated in figure 4.1. 
The UP-LVG alginate used in this study had an average G – block length of NG>1 = 
12 and a G monomer fraction of 0.67. The two epimerized alginates utilized in 
experiment B has an average G block length of NG>1 = 4,5 and a G monomer fraction 
of 0.54. Referring to figure 4.1 it is therefore likely that the stiffness of the gel 
increases more prominently for UP-LVG gel when increasing the alginate 
concentration, than for the epimerized alginate gel. This is explained by the fact that 
more junctions will be created between the alginate chains in the high G gel, creating 
a more rigid and open network structure with larger pores. The epimerized alginate is 
composed of MG and G blocks with a few M blocks interspersed, and will create a 
more elastic and compact gel (Morch et al., 2007, Morch et al., 2008). 
 
 
Figure 4.1: Graph showing the increase in rigidity (load (g) needed to compress the 
alginate gel with 1 mm), versus the square of the alginate concentration (directly 
reproduced from (Smidsrod and Skjak-Braek, 1990)). 
The elasticity of the epimerized alginate gel is described by experiments where the 
elastic moduli have been investigated. These experiments show that while the high G 
gel is stiff (e.g. has a high elastic moduli), it is also brittle and will rupture under 
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pressure. Gels containing MG-blocks will have lower elastic moduli, but higher 
rupture strength (Mitchell and Blanshard, 1976) (Mitchell, 1980). The rupture strength 
increases proportionally with the molecular weight of the polymer (Moe, 1995). 
It is therefore hypothesized that a gel made from 1.0% epimerized alginate is softer, 
more compact and elastic than a gel made of 1.0% UP-LVG alginate and the latter 
will possess a more rigid and open chain network with larger pores (Smidsrod and 
Skjak-Braek, 1990). 
The gel strength is also dependent on the molecular weight of the polymer, but only 
to a certain extent. When the Mw is large enough to produce an intrinsic viscosity of 
550-600 mL/g the gel strength becomes constant and independent of Mw (Martinsen 
et al., 1989a). This holds true as long as the gel is Ca2+ saturated (Draget et al., 
1993). All alginates used in this experiment are of high molecular weight, and were 
gelled in gelling solution containing an abundance of crosslinking ions. The gel 
strength, and thus, stiffness was therefore thought to be independent of molecular 
weight, and only related to alginate concentration and composition. 
The OECs displayed highest viability in capsules with low cell concentration made 
from 1.0% UP-LVG alginate. It is therefore assumed that OECs demonstrate a 
preference for gels with an open network structure, which is soft due to low alginate 
concentration, than in a more compact but elastic gel. This suggests that less rigid 
biopolymer network structures might be utilized for OEC encapsulation for 
transplantation in vivo  . 
4.1.2. Alginate gel porosity 
The cells displayed lower viability in the more compact epimerized alginate gel. This 
could in part perhaps be explained by lower diffusion rates due to less porosity and 
thus lower permeability of proteins required by the cells. 
High G alginates have been reported to have the highest porosity and therefore the 
highest permeability. This is due to their open and rigid network, caused by many 
junctions between the polymer chains. Small molecules such as glucose and ethanol 
have diffusion rates up to 90% of the rates observed in pure water. Larger molecules 
such as proteins will experience diffusional resistance, depending on their charge, 
radius of gyration (RG), molecular weight and shape (Smidsrod and Skjak-Braek, 
1990). Most proteins are negatively charged at physiological pH, and will be repelled 
by the polyanionic alginate chains and this will decrease their diffusion rate in and out 
of alginate capsules (Smidsrod and Skjak-Braek, 1990). However, proteins with Mw  > 
3  105 kDa have been shown to diffuse through high G gels, with a diffusion rate 
depending on their size, shape and pH of the solution (Martinsen et al., 1989b). 
Epimerized alginate has shown reduced permeability for immunoglobulin with 
molecular weight of 150 kDa (Morch et al., 2007). 
It could be argued that the capsules in this study were so small (diameter ranging 
from approximately 250µm to 600µm) that the diffusional pathway for solutes was 
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short enough to secure satisfactory waste disposal and nutrition delivery (Colton, 
1996). 
Cell concentration was also shown to influence viability of the OECs, especially in 
UP-LVG capsules. Westrin and Axelsson reported that encapsulation of cells in gels 
hinders diffusion and that the diffusion rate decreases with increasing cell load 
(Westrin and Axelsson, 1991). This might partly explain the decreasing viability of 
cells in capsules containing higher cell concentrations, as the access to nutrition, 
oxygen and disposal of waste products is hindered by the decreased diffusion rates 
and the increase in competitors. Also, dead cells may have a negative effect on live 
cells in the capsule, as increased amounts of cellular waste accumulates in the 
restricted microenvironment in the capsule. Thus, a vicious cycle of cell death in 
capsules with large cell concentration occurs due to lower diffusion rates of nutrition, 
oxygen and waste products. The remains of the dead cells may create a toxic 
environment for the live cells in the capsule and low diffusion rate hinders the 
clearance of the cell remains, causing more cells to die. 
Increased cell concentration did not affect cell viability as clearly in epimerized 
alginate capsules, and one explanation could be the elasticity of the material. The 
alginate chain network may give in for pressure created by larger amounts of cells 
and permit them to spread out and shape their environment, in a way the rigid UP-
LVG gel may not permit. In the rigid high G gel high cell concentration may have 
created a limited and crowded environment. In contrast, increasing the alginate 
concentration and/or the cell concentration in UP-LVG alginate capsules will both 
result in lower viability as shown in figure 3.12, as the outcome is the same; a 
crowded and rigid limited living space where the cells are trapped in the chain 
network. 
4.1.3. Structural differences between UP-LVG capsules and epimerized alginate 
capsules 
Certain structural differences between the capsules made of UP-LVG and epimerized 
alginate I and II was observed. The latter displayed channels arranged in a star-like 
formation around the center of the capsule. These channels were presumed to be 
hollow, as dead cells appeared to fill the channels progressively through experiment 
3.2 and to some extent, 3.8. An example can be viewed in figure 3.25.A. The 
channels appeared to push the surface of the capsule outwards, as can be observed 
in figure 3.22. This led to the hypothesis that the alginate gel forming the surface of 
channels was stiffer than the rest of the capsule. 
Whether the cells were randomly trapped inside these channels or migrated there is 
not known. Some indications to that most cell clusters are located inside such 
channels were noted, and an example is shown in figure 3.22. This led to the 
hypothesis that the channels appear filled with dead cells because the clusters have 
disintegrated and their remains are trapped inside the channels. As the interior 
environment inside the channels is unknown, the reasons for the cells presence there 
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cannot be determined. It might be that the interior were perceived as less compact 
than the rest of the capsule, causing the cells to migrate there (as they have been 
shown to prefer softer gels) but the diffusion rate of nutrition and waste into the 
channels might be lower due to the assumed stiff surface of the channel. This would 
also explain the build-up of dead cell debris inside the channels. 
It has been suggested that the channels are formed by a viscous drag that may have 
occurred during gelling, and the channels are assumed to contain lower gel 
concentration (personal communication from Dr.Ing. Berit Strand and unpublished 
results from Kristin Karstensens research). 
4.1.4. RGD peptide grafted alginate I and II 
In experiment 3.2, high and low cell concentrations (1.5 mil/mL and 5.0 mil/mL) were 
encapsulated in 1.0% epimerized Ca2+ alginate grafted with 0.2% RGD peptide and 
epimerised with AlgE4 and AlgE6, creating an alginate consisting of MG and G 
blocks interspersed with M-blocks. A similar alginate without RGD peptide was 
included as control samples. The experiment was repeated (experiment 3.8), with a 
similar alginate from a different source and with only 1.5 mil/mL cell concentration 
with an added control sample of 1.0% UP-LVG capsules and a probable RGD 
peptide graft percentage of 0.4%. 
All cells displayed high viability with live cell percentage > 80% up until day 10 in 
experiment 3.2, regardless of batch. After day 10 the viability of the cells in the 1.5 
mil/mL cells concentration encapsulated in epimerized alginate without RGD peptide 
and the 5.0 mil/ mL cell concentration encapsulated in epimerized alginate with RGD 
peptide decreased quite suddenly from ≈ 80% to 40% and 30% at day 14, 
respectively, compared to the other two batches in which the viability decreased 
more gradually (figure 3.5 and 3.6).  
In this experiment no evident differences in cell viability was observed, in terms of 
either RGD peptide or cell concentration. The reason for the sudden decrease in cell 
viability in two of the batches at day 10 is not known.  
The cells in experiment 3.2 displayed a more uniform high viability with a live cell 
percentage ≥ 80%, up until day 10 than the cells in experiment 3.8 (figure 3.6 and 
3.27). However, after day 10 the viability decreased to ≤ 50% at day 22 for all 
samples, except the epimerized 1.0% Ca2+ alginate gel capsules containing 1.5 
mil/mL, which displayed 70% viable cells at day 22. In experiment 3.8 the epimerised 
1.0% Ca2+ alginate gel capsules with ≈ 0.4% RGD peptide graft cultured in serum-
containing media displayed ≥ 70% viable cells throughout the 20 days of the 
experiment, with the exception of day 14 when the live cell percentage was estimated 
to 50%. The epimerised 1.0% Ca2+ alginate gel capsules without RGD peptide 
cultured in serum-containing media displayed 80% live cells at day 1, and gradually 
decreased to 50% live cells at day 14 and this percentage was constant until 
termination at day 20. The increased viability in the RGD peptide grafted alginate gel 
capsules may be due to higher concentration of RGD peptide in the alginate utilized 
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in experiment 3.8. It must however be noted that no such effect was observed in the 
corresponding batches cultured in media without serum. Also, only one capsule were 
shown in the picture of epimerized 1.0% Ca2+ alginate gel capsules without RGD 
peptide cultured in serum-containing media at day 20, giving a poor estimate of 
viability in these capsules. 
It has been reported that cell ligand density must exceed a cell specific density 
threshold before they are able to elicit any reaction from the cells (Lee and Mooney, 
2012). As the RGD peptide fraction of the alginate was 0.2%, and ≈ 0.4% the ligands 
may have been placed too far from each other on the alginate chain network to reach 
this threshold, and consequently unable to impact the viability of the cells. In addition, 
the length of the spacer arm between the RGD peptide and the alginate chain is a 
key parameter for integrin attachment and at least four glycine residues is regarded 
as an appropriate number to promote a proper binding between integrin receptors 
and RGD peptides in fibroblasts in both 2D and 3D culture (Lee and Mooney, 2012). 
In this project the number of glycine residues in the spacer arm was only one glycine, 
and the short spacer length may be a part of the explanation for not observing any 
interaction between the OEC integrins and RGD peptides, and no impact on viability 
of the OECs. 
Kristin Karstensen (Karstensen, 2010) observed OEC attachment to RGD peptide 
alginates in 2D culture in 2D culture in her master thesis, using the same alginate 
(1.8% epimerized Ca2+ alginate with RGD peptide) as in this experiment. The OECs 
displayed a round morphology with bipolar protrusions attached to the substrate. The 
attachment decreased after 72 hours. Karstensen encapsulated OECs in the same 
alginate with 1.8% alginate concentration and did not observe any improved cell 
viability as a result of OEC interaction with the RGD peptide coupled alginates. 
Viable cells were found in the capsules up to approximately day 16, which correlates 
to the viability of cells in 1.8% UP-LVG alginate observed in this experiment. This 
may indicate that the alginate concentration is more important than the alginate 
composition. 
The alginate concentration that was used in experiment 3.2 and 3.8 was lower than 
the concentration Karstensen utilized (1.0% versus 1.8%) and it is therefore plausible 
that the RGD peptide had even lower density in the gel in these experiments than 
they displayed in Karstensens experiment. 
The only difference between this study and Kristin Karstensens study was that the 
cells showed an increased viability over time and thus, resided longer in the 
capsules. As no interaction was detected, the extended stay did not seem to improve 
the chance of interaction. It is also believed that cell-matrix interactions happen quite 
quickly (personal communication, Dr. Ing. Berit Strand 07.05.12) and Karstensen 
observed attachment of cells to RGD peptide after 24 hours (Karstensen, 2010). 
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4.2. Alginate mixed with ECM molecules 
4.2.1. 1.0% UP-LVG alginate mixed with gelatin 
Two experiments (3.5 and 3.6) with three different concentrations of gelatin (0.5%, 
1.0% and 2.0%) mixed with 1.0% UP-LVG was conducted. It was hypothesized that 
gelatin would resemble collagen, which is the most abundant protein in the 
connective tissue. OECs were encapsulated with a concentration of 1.5 mil/mL 
alginate and kept in culture for 22 days in experiment 3.5. Experiment 3.6 focused 
mostly on improving the encapsulation process, and the cells were kept in culture for 
16 days. In both experiments the cells displayed high viability regardless of gelatin 
concentration, comparable to the viability of 1.5 mil/mL encapsulated in 1.0% UP-
LVG alginate gel. 
The cells were cultured at 37°C, which is above the melting point for gelatin. It was 
therefore hypothesized that the gelatin did not contribute to gel formation, but were 
found dispersed as α-chains in the alginate gel (Babel, 1996) unlike collagen that is 
comprised of three different polypeptide α-chains intertwined in a triple helix 
conformation (Bruce Alberts, 2002). It was also hypothesized that gelatin α-chains 
might retain some of the RGD peptide domains present in collagen that integrins bind 
to.  Integrin-mediated cell adhesion to these domains might have induced 
morphological change, but no morphological changes were observed in this 
experiment. As the gelatin was mixed with the alginate and not linked directly to it in 
any way, it might be proposed that if binding of integrins to RGD peptides occurred it 
would not lead to morphological changes as the gelatin chains were dispersed freely 
in the mixture. The cells might pull them along, instead of changing shape as they 
might have done if the gelatin had been fixed in the lattice. 
Gelatine is thought to have a net positive charge at physiological pH, and this would 
probably lead to interaction with the polyanionic alginate chains (personal 
communication, Magnus Hattrem, 10.05.2012), perhaps rendering the RGD domains 
sterically unavailable for the OECs. 
Assuming that less junctions between the alginate chains were formed, it would lead 
to an even softer gel than pure 1.0% UP-LVG alginate, and this may explain the 
relatively high cell viability observed in these experiments. In the alamarBlue® assay 
that was performed on these cells at the same time points as the Live/Dead assay 
the viability and metabolic activity seemed to be proportional with gelatin 
concentration as seen appendix A10. This could be explained by the auto-
fluorescence of gelatin observed in both experiment 3.5 and 3.6, as alamarBlue® 
also utilizes fluorescence, or it could reflect the viability of the cells. A drawback with 
this assay is background signals higher than signals from samples registered for the 
lowest gelatin concentration, which casts doubt on the assays accuracy. The high 
background signals are further discussed below. No obvious differences in viability 
between the batches could be observed in the Live/Dead assay (figures 3.54 and 
3.53). 
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The cell clusters in all samples in experiment 3.5 were larger than observed in any of 
the other experiments. This may be due to inadequate mixing of the cells with the 
alginate-gelatin solution before encapsulation, as the process had to be done rapidly 
to prevent the gelatin from gelling. This was taken into account when encapsulating 
in experiment 3.6, where mixing was done more thoroughly. This resulted in smaller 
cell clusters, but the cell clusters still appeared larger than the cell clusters observed 
in previous experiments. This might have been due to increased elasticity in the gel, 
enabling the clusters to spread out. 
4.2.2. 1.0% UP-LVG mixed with different ECM molecules, and sulphated MG 
alginate 
In experiment 3.7, four batches of 1.5 mil/mL OECs were encapsulated in 1.0% UP-
LVG alginate gel with one ECM molecule mixed with the gel per batch. Sulphated 
MG alginate with an average of 1.5 sulphate groups per monomer (personal 
communication, Øystein Arlov) was included in the experiment. The sulphated 
alginate resemble the ECM protein heparin and to a lesser degree, HSPGs. 
The experiment was terminated at day 28, with varying cell viabilities in the different 
samples. Common for all was an overall lower cell viability compared with the viability 
observed for cells with similar concentration encapsulated in pure 1.0% UP-LVG, but 
as no control sample with pure 1.0% UP-LVG alginate was cultured simultaneously, 
the samples cannot be directly compared. 
The reason for the reduced viability is not known. All of the proteins mixed with the 
alginate are quite large, as all of them have a molecular weight over 3  105 Da, while 
hyaluronic acid ranges from 5  103  - 2  106 Da (Deister et al., 2007). A hypothesis 
could be that the large molecules block the pores in the alginate and decrease the 
diffusion rate of solutes as mentioned above. The drawback of this theory is that the 
gelatin-alginate mix displayed rather good viabilities, despite the fact that gelatin has 
a molecular weight of 9,5  105. Perhaps gelatin interrupts junction formation, and 
thus creates a softer elastic gel or interacts with the alginate in a different way due to 
its net positive charge, while the ECM molecules do not interrupt junction formation 
and just block the pores. Also, the concentration of gelatin was much higher, 0.5-2 % 
per 1.0% alginate and is therefore not directly comparable. High concentrations of 
heparin has been shown to kill cancer cells (personal communication, Øystein Arlov, 
14.05.2012), but these concentrations are believed to be much higher than the 
sulphate concentrations utilized in this project.  
As most proteins have a net negative charge at neutral pH (Smidsrod and Skjak-
Braek, 1990) it is assumed that collagen, fibronectin and laminin will not interact with 
the polyanionic alginate chains. This might support that the proteins do not interfere 
with junction formation and merely clogs the pores, obstructing diffusion. As 
hyaluronic acid is highly negatively charged (Picart et al., 2001), the same hypothesis 
applies to hyaluronic acid. 
84 
 
Laminin has been reported to destabilize Ca2+ crosslinked alginate chains, as laminin 
has high affinity for calcium ions (Tisay and Key, 1999). This was not observed 
during the 28 days of the experiment, as the alginate beads stayed relatively intact 
compared to the other batches for the duration of the experiment. 
The cell clusters in the sulphated alginate capsules appear larger than in the 
capsules without sulphate. This may be due to insufficient mixing of cells and 
alginate before encapsulation. Another hypothesis is that the MG composition of the 
sulphated alginate creates a more elastic gel, allowing the cells to form their 
environment and spread out in a way that was not possible in the rigid pure UP-LVG 
alginate gel. The cells displayed good viability up until day 20, where the estimated 
percentage of live cells was 80%. At day 28 this had dropped to 50%. The reason for 
this is not known, but it can be hypothesized that the high sulphate content compared 
to heparin is decrease cell viability. 
4.3. Morphology 
It is of interest to acquire knowledge of which matrices that induces change from 
circular cell morphology to stellate- or spindle-like morphology. The different 
morphologies are associated with different protein expression and secretion, and 
therefore the type of morphology will indicate the type of benefits to be derived from 
OEC transplantation after encapsulation and transplantation into CNS. 
Several different approaches were attempted with the main aim of improving OEC 
viability. It was also attempted to observe cell-matrix interactions by CLSM. The cells 
were encapsulated in alginate with RGD peptide graft (experiment 3.2 and 3.8), 
alginate mixed with gelatin (experiment 3.5 and 3.6) and alginate mixed with one 
ECM molecule per batch, and sulphated MG alginate (experiment 3.7). None of 
these alginate compositions induced detectable changes in cell morphology. The 
cells were examined with CLSM with Live/Dead assay at both 10 x magnification and 
40 x magnification. The actin and nucleus of the cells in experiment 3.7 and 3.8 were 
stained and examined and most of the cells were found to either gather in clusters, 
making it difficult to assess their morphology, or to be spherical. Some cells with non-
circular shapes that were not associated with any known morphology were randomly 
distributed between the different experiments, but none was distinctly linked to one 
specific alginate variety. 
As mentioned before, all ligands require a certain ligand density to elicit a cell 
reaction, and this density may not have been reached in these experiments. The 
gelatin and ECM molecules that were only mixed with alginate may not have 
provided a firm enough anchorage even if the cell may have attached to them; the 
attachment could cause the cell to drag the ligand along with it instead of changing 
morphology. Another explanation may be that the conformation of the ligands is 
different in the negatively charged alginate gel, and this might make the binding 
domains less sterically available for the cells. 
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4.4. Capsule stability 
The capsules made from 1.8% UP-LVG Ca2+/Ba2+ alginate gel capsules were stable 
throughout the experiment (3.1) period of 14 days, with no observable swelling or 
syneresis. 1.0% UP-LVG capsules (3.3) were shown to be stable after 51 days in 
culture and no swelling or syneresis was observed. The diameter of 1.0% UP-LVG 
capsules proved to be smaller than the 1.8 % capsules, because of decreased 
viscosity in the alginate solution before gelling. The capsules with high cell 
concentration displayed a notably larger diameter than capsules with less cell 
concentration. This may be caused by reduced number of junctions between alginate 
chains due to high cell numbers (personal communication, Dr. Ing. Berit Strand, 
14.05.2012). 
High G gels have been shown to be stable over time, especially when crosslinked 
with Ba2+ions in addition to Ca2+ ions. G-blocks have high affinity for Ba2+ ions that 
counteracts the exchange of crosslinking ions with other non-crosslinking ions, such 
as Na+. This hinders swelling and dissolution of capsules. 
The epimerized Ca2+alginate gel capsules utilized in experiment 3.2 was stable in 
culture for 22 days, with no observed swelling. This alginate was engineered to be 
crosslinked with Ca+ without the need for Ba2+ ions to keep it stable. The alginate 
contains a large fraction of MG blocks (FMG = 0.35), compared with UP-LVG alginate, 
which contains a MG fraction of 0.12. The high MG content counteracts swelling 
without the need of Ba2+ in the gelling solution (Morch et al., 2006).The epimerized 
alginate produced smaller capsules than the capsules observed in experiment 3.1. 
This might be caused by the epimerized alginates tendency to create smaller and 
more compact gels. It was also observed that the capsules containing high cell 
concentration appeared larger than the low cell concentration capsules, but to a 
lesser degree than the diameter difference observed in experiment 3.3. The star 
shaped channels described earlier was observed in all batches, and the mechanisms 
leading to these formations are not known. This is discussed more thoroughly earlier 
in the discussion part (4.1.3.). The channels did not appear to affect the capsule 
stability. 
In experiment 3.5 and 3.6 different concentrations of gelatin (0.5%, 1.0% and 2.0%) 
was mixed with 1.0% UP-LVG alginate and gelled in the presence of Ca2+ and Ba2+ 
ions. The capsules from experiment 3.5 displayed increased instability and irregular 
shapes proportionally with increased gelatin concentration. However, in experiment 
3.6 the alginate mixed with the middle gelatin concentration displayed the most 
circular and stable capsules. This may be due to better encapsulation routines, as 
the gelatin-alginate mix and gelling solution was kept at ≈ 40°C as long as possible 
up until encapsulation. 
In the capsules containing ECM molecules it was observed that the capsule diameter 
varied between the different samples. Capsules containing laminin and hyaluronic 
acid displayed the largest relative diameter, capsules containing fibronectin and 
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collagen were middle sized and sulphated alginate capsules were by far the smallest. 
The capsules containing fibronectin were the only batch that displayed a tail 
formation (figure 3.21). The reason for the variation in capsule size in the samples is 
not known. 
White precipitation that increased over time was observed on the surface of the 
capsules made of 1.0% epimerized Ca2+ with ≈ 0.4% RGD peptide graft in 
experiment 3.8. The precipitation occurred on the capsules cultured in OEC media 
containing serum, and the surface of these capsules appeared dark, wrinkled and 
cracked when observed by transmitted light in the CLSM. As the cells in these 
capsules displayed the highest viability throughout the period of the experiment, it is 
not believed that the precipitation affected cell viability negatively. 
Precipitation was observed in the 1.0% epimerized Ca2+ capsules grown in media 
without serum as well, but to a much lesser degree. No surface precipitation was 
observed in capsules made of 1.0% epimerized Ca2 alginate. It is therefore 
hypothesized that the precipitation is linked to protein content in the media, and RGD 
peptide grafted alginate. As no precipitation was observed with 0.2% RGD peptide 
content, it is proposed that the ≈ 0.4% RGD peptide content led to precipitation when 
the capsules was cultured with protein-containing media. Some internal precipitation 
in roughly 1 out of 30 of the epimerized alginate capsules without RGD peptide was 
also observed (figure 3.25 B). This has been reported before and has been 
suggested to be linked with dead cells in the capsules (personal communication, Dr. 
Ing. Berit L. Strand). The internal precipitation was not observed until day 14 of the 
experiment and exclusively in capsules cultured in media without serum. The cells in 
both samples of epimerized alginate displayed decreasing viabilities from day 7 to 
day 10, independent of serum-containing media or not. 
It could be proposed that the wrinkled and cracked surface of the epimerized alginate 
capsuled with RGD graft was caused by syneresis. The alginate did have NG>1 = 3, 
which was lower than the corresponding alginate in experiment 3.2, but the MG-block 
content was roughly similar (table 2.1) and no unambiguous sign of shrinking was 
observed during experiment 3.8. A similar local collapse of the gel upon binding of 
protein has been observed in beads coated with poly-L-lysine(Strand et al., 2002b). 
It was attempted to dissolve 1.0% Ca2+/Ba2+ UP-LVG alginate capsules with MG 
lyase, citrate and EDTA. Only EDTA led to capsule dissolution, which is unfortunate 
in terms of cell extraction as EDTA is toxic for cells. 1.0% Ca2+ epimerized alginate 
capsules were attempted dissolved in pure water and 0.9% NaCl. The capsules did 
not dissolve in pure water, but did dissolve in 0.9% NaCl. The 1.0% Ca2+/Ba2+ UP-
LVG alginate capsules are not believed to dissolve in 0.9% NaCl as the capsules 
were stored in this solution for weeks during the MTT assay, with no sign of effect on 
the capsules. It is proposed that Ba2+ crosslinking prevents disintegration caused by 
NaCl, and this is supported by literature (Morch et al., 2006, Morch et al., 2007) 
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4.5. alamarBlue® 
The alamar Blue assay® was performed on the cells encapsulated in the 
experiments described in section 3.1. 3.2, 3.3, 3.4 and 3.5 with the aim of 
quantitatively assessing the cells metabolic activity. It was later decided to omit this 
assay in further encapsulations (3.6, 2.7 and 3.8) because the fluorescence values 
often turned out negative for samples from the lowest cell concentrations (1.5 mil/mL) 
when the control sample of pure media from the corresponding culture flask were 
subtracted from the fluorescence value of the sample. 
Several different alamarBlue® protocols were tested during the project, but the assay 
did only work satisfactorily in experiment 3.1. In all other experiments the lowest cell 
concentrations produced background signals higher than signals from samples 
containing cells. The reason for this is not known, but it is hypothesized that the cells 
have a very low metabolic activity and do not proliferate when encapsulated. Why the 
OEC media produced such high fluorescence signals it not known, but contamination 
cannot be ruled out. Another source of error may be the alginate itself, it may bind 
the reagent and hinder its conversion to a fluorescent molecule. 
The MTT assay showed increasing mitochondrial activity throughout the experiment, 
which implies that the cells either proliferated inside the capsules or increased their 
metabolomics activity. This is not expected when culturing OECs in 3D capsules, and 
has not been observed in previous experiments. The concurrent Live/Dead assay 
showed good overall viability of the cells, but it did not seem to increase. As the 
experience with MTT was limited to this test round it is not possible to assess its 
accuracy when assaying viability and metabolic activity of OECs, but the absorbance 
values were at least positive, however, the increasing viability and metabolic activity 
is not probable. It may be that the alginate displays some inherent absorbance, and 
one approach if this is the case is to include capsules without cells as a control 
sample. 
Rokstad et al encapsulated endo cells in 1.8% Ca2+ UP-LVG alginate and used the 
MTT assay to measure survival and proliferation of the encapsulated cells, with good 
results. These cells proliferate when cultured in capsules, and this may explain why 
the MTT assay provides reliable results, as the cells display higher mitochondrial 
activity (Rokstad et al., 2003). Karstensen used the MTT assay on myoblasts 
encapsulated in 1.8% epimerized alginate with 0.2% RGD graft. The cells were 
expected to divide 1-2 times during encapsulation. The MTT values obtained during 
the experiment correlated generally well with Live/Dead staining observed by CLSM 
(Karstensen, 2010). Again, these were proliferating cells, but not to the same extent 
as in Rokstad’s experiment. 
4.6. Future perspectives 
The percentage of RGD peptide graft coupled to the alginate chains should be 
increased, with the aim of gaining higher ligand density, and thus eliciting effects on 
the cell via integrin binding. It should also be attempted to increase the glycine 
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residue spacer length to at least four monomers in accordance to the findings of 
Mooney et al (Lee and Mooney, 2012). 
It would also be interesting to observe whether the surface precipitation experienced 
in this project will occur on capsules with higher RGD peptide graft percentage. If so, 
the mechanisms behind the formation of precipitate should be investigated. As the 
capsule surface might collapse from protein adhesion on the surface due to low FG 
fraction in the alginate, it could be beneficial to couple the RGD peptide to an alginate 
with higher NG>1 number. This may also be beneficial for the OEC viability as they 
displayed higher viability in UP-LVG alginate gel, which has NG>1 = 12, in contrast to 
the epimerised alginate with ≈ 0.4% RGD peptide that has NG>1  = 3. 
The channel formation inside epimerized alginate capsules should be avoided, as 
increasing amounts of dead cells are observed inside these channels over time. It 
would also be interesting to examine the structure of these channels by using 
fluorescent alginate, which would indicate alginate concentration gradients 
throughout the capsule and reveal if the channels are hollow, as it has been 
suggested. 
It would be interesting to observe whether the bubble formation described in section 
3.10  was present from the beginning of encapsulations or formed over time. It would 
also be interesting to investigate whether the bubble formation occurred in both RGD 
peptide coupled gels and non-coupled gels. 
The actin filament and nuclear DNA staining that was performed at day 20 and day 
28 in this project should have been done earlier to ensure that the cells in the 
pictures were live cells, as the concurrent Live/Dead assay displayed many dead 
cells at the time. In addition, many of the cells with stained actin filament and nuclear 
DNA displayed stained DNA outside the actin boundaries of the cells, and thus they 
were perceived as dead, disintegrating cells. 
As it is difficult to assess and quantify cell-matrix interaction in a 3D environment only 
with the aid of actin filament/nuclear DNA staining and Live/Dead assays perhaps 
another approach could be more effective. Mooney et al has proposed a FRET 
method where a fluorophore is be coupled to the cell adhesion peptides conjugated 
to the polymer chains and the cell membrane is be pre-stained with a another 
fluorophore. The cell receptor ligands can thus be quantified (Lee and Mooney, 
2012). 
The Live/Dead assay performed in this study aimed at a rough qualitative 
assessment of cell viabilities. It would be beneficial to utilize a software programme 
to assess the distribution of red and green cells in the CLSM 3D projections, as it 
would be more accurate and provide less variation in the assessment. The MTT and 
alamarBlue® assay should also be optimized for encapsulated OEC cells, to provide 
a quantitative measurement of the metabolic activity and cell viability. 
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The settings of the electrostatic bead generator should be optimized for lower 
alginate concentrations to ensure narrow size distribution of capsules and obtain 
capsules with a suitable diameter. 
If encapsulation of cells in gelatin-alginate mix is attempted it would be interesting to 
investigate the capsules with scanning electron microscope (SEM) to assess whether 
the gelatin resembles collagen triple helices in the capsule. 
If morphology changes of the OECs are observed, protein analysis should be 
performed to elucidate what proteins the cells are expressing. The different 
morphologies are associated with different protein expression and knowledge of the 
protein production of encapsulated OECs is important in terms of capsule design with 
the aim of cell-mediated repair of CNS lesions. 
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5. Conclusion 
Alginate concentration was found to be the key parameter for the OECs viability in 
this project, as viable cells were observed for as long as 51 days in capsules with 1.0 
mil/mL cell concentration in capsules made from 1.0% UP-LVG Ca2+/Ba2+ alginate.  
In 1.8% UP-LVG Ca2+/Ba2+ alginate capsules, viable cells were only observed for 14 
days. In all subsequent experiments the 1.0% alginate concentration was utilized, 
and the capsules displayed viable cells for longer periods than 14 days.  The 
beneficial effect of lower alginate concentration is assumed to be related to the 
resulting lower rigidity of the gel, and possible increased gel porosity and thus higher 
diffusion rates of nutrients, waste and oxygen. High cell concentration in the alginate 
capsules also proved to have an impact on cell viability, but this effect was most 
evident in the UP-LVG alginate gels. The negative effect on cell viability related to 
high cell concentration was not as profound in the epimerized Ca2+ alginate gels. 
RGD peptide grafted onto alginate did not show any unambiguous effect on cell 
viability, regardless of 0.2 % peptide graft or ≈ 0.4% peptide graft. The cell viability in 
capsules made of 1.0% UP-LVG Ca2+ /Ba2+ alginate mixed with gelatin was overall 
high, and the major reason for cell death in these samples was capsule instability 
and consequently capsule breakage. The samples of capsules made of 0.9% UP-
LVG alginate mixed with one ECM molecule, and 0.9% UP-LVG alginate mixed with 
sulphated alginate displayed overall lower cell viabilities than previous experiments 
performed with pure 1.0% UP-LVG alginate capsules. 
No changes of morphology induced by the different types of alginate matrices were 
detected during this project. The RGD peptide grafted alginate may have failed to 
induce morphological changes due to low ligand density, short spacer arm or sterical 
hindrance, preventing the OECs integrins to attach to the RGD peptide. The gelatin-
alginate mix also failed to induce morphology change in the OECs, and neither did 
any of the ECM molecule-alginate mixes or the sulphated alginate-alginate mix. This 
may have been due to sterical hindrance or unfortunate conformation of the gelatin. 
All capsule varieties displayed generally good stability in culture, with the exception 
of the gelatin-alginate mix capsules that progressively dissolved. Precipitation that 
increased over time in culture occurred on the surface ≈ 0.4% RGD peptide grafted 
epimerized alginate capsules. It is suggested that this precipitation is linked to the 
presence of protein in the culture media, and the increased RGD peptide content in 
relation the 0.2% RGD peptide grafted epimerized alginate capsules, where no such 
precipitation was observed. The binding of protein to the surface may have induced 
local collapse of the gel due to lower FG fraction in the ≈ 0.4% RGD peptide grafted 
epimerized alginate capsules compared to the 0.2% RGD peptide grafted epimerized 
alginate capsules, causing the observed wrinkled and cracked capsule surface. 
The Live/Dead assay was found to perform satisfactorily throughout the project, 
giving reliable, yet rough estimates of cell viability. To provide a quantitative 
measurement if viability and metabolic activity the alamarBlue® assay was included 
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in the project. The alamarBlue® assay did not work satisfactorily as it produced 
background signals higher than signals from samples containing cells, especially for 
lower cell concentrations. The MTT assay was performed simultaneously as the 
alamarBlue® assay with the aim of comparing their results, and the results turned out 
to be opposite of each other. None of the metabolic assays seemed to correspond to 
the results obtained by the Live/Dead assay. 
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Appendix A: alamarBlue® assay 
The procedure of the different alamarBlue® assays are elaborated below, as the 
assay did not work satisfactorily, and is therefore not included in the main part of the 
report.  
A1: Procedure of the alamarBlue assay performed in experiment 3.1 
Three different cell concentrations were encapsulated in 1.8% UP-LVG alginate in 
the experiment:  
A1a: 1.5 ∙ 10 cells/		 
A1b: 3 ∙ 10	 cells/		 
A1c: 5 ∙ 10 cells/		 
The alamarBlue® assay was performed at day 1, 3, 7, 10 and 14 during the 
experiment. The amount of media and capsules used in the assay was computed by 
the following calculations: 
 =


 =


	(0.250)  
V = 0,654/capsule = 0,0654		 
The following calculation gives the number of cells per capsule: 
A1: 1.5 ∙ 10 cells/		 ∙ 0,0654		 = 98,1 cells/capsule 
B1:	3 ∙ 10 cells/		 ∙ 0,0654		 = 196,2 cells/capsule 
C1: 5 ∙ 10 cells/		 ∙ 0,0654		 = 327 cells/capsule 
The appropriate number of cells per sample tested with alamarBlue® assay is 5000 
cells, according to the manual designed by the manufacturer, Invitrogen. The 
following calculation shows how many capsules that were required to meet this 
requisition. 
A1a: 
	
,	/ !"
= 51	#$%&'()& 
A1b:  
	
,*	/ !"
= 25	#$%&'()& 
A1c: 
	
*+	/ !"
= 15	#$%&'()& 
1 mL capsules/ 10 mL media gives: 
,-
,,-/ !"
  =15290 capsules in 10 mL media. 
Subsequently, this gives 1529 capsules/mL media, and the calculations that led to 
sample volume are shown below: 
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A1: 
	 !"
*	 !"/.-
= 0,033 = 33	 
B1: 
*	 !"
*	 !"/.-
= 0,016	 = 16	 
C1:	
	 !"
*	 !"/.-
= 0,0098	 ≈ 10	 
The setup protocol is shown in table 1. 
Batch Work solution Sample 
withdrawal 
Desired 
number of 
capsules 
Media from 
culture flask 
alamarBlue® 
reagent 
1.5mil/mL 1 mL  5 × 33μL 51 147 μL 18μL 
3.0 mil/mL 1 mL 5 × 16μL 25 164 μL 18μL 
5.0 mil/mL 1 mL 5 × 10 μL 15 170 μL 18μL 
Media from culture flask 
1.5mil/mL 1 mL   5 × 180μL 18μL 
3.0 mil/mL 1 mL   5 × 180μL 18μL 
5.0 mil/mL 
Clean media 
1 
900μL 
  5 × 180μL 
5 × 180μL 
18μL 
18μL 
Table A1: The protocol for the alamarBlue® assay used in experiment 1 
The amount of media used in the assay was replaced after every alamarBlue® 
assay. 
The sample was left in room temperature with an incubation time of 4 hours with the 
96 well plate with opaque walls and see-through bottom covered by aluminium foil, 
and fluorescence was measured at 535nm and 590nm on a Victor platelet reader. At 
day three the incubation time were only 3 hours. 
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A2: Fluorescence values and calculations from experiment 3.1  
    Fluorescence for parallels 1-5 Fluorescence for control parallels 1-5 
Batch Day 1 2 3 4 5 1 2 3 4 5 
A1c 1 469 221   367 829 63 87 63 87 63 
  3 295 269 262 257 238 196 188 203 190 190 
  7 327 344 316 380 338 252 226 274 221 226 
  10 244 262 228   284 194 207 205   205 
  14 207 255 212 208 256 186 192 180 210 192 
A1b 1 225 237 130 146 373 76 76 89 76 89 
  3 200 233 295 231   191 194 191 206   
  7 275 286 247 278 255 223 230 196 237 223 
  10 206 182 246   226 172 165 165 172 165 
  14 180 202 226 196   166 164 166 173 166 
A1a 1 179 181 244 191 252 97 97 94 94 94 
  3 189 167 193 226 190 140 146 148 148 140 
  7 236 289 230 252 216 165 162 192 187 187 
  10 192 173 211 217 274 146 166 164 159 159 
  14 186 192 180 210 278 161 193 186 177 177 
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Average Fluorescence per well-average blank Number of capsules in each well 
control 1 2 3 4 5 1 2 3 4 5 
72,6 396,4 148,4 
 
294,4 756,4 11 4 
 
11 25 
193,4 101,6 75,6 68,6 63,6 44,6 3 1 4 8 7 
239,8 87,2 104,2 76,2 140.2 98,2 5 21 7 27 16 
202,75 41,25 59,25 25,25 -202,75 81,25 5 5 4 
 
31 
192 15 63 20 16 64 18 17 6 10 55 
81,2 143,8 155,8 48,8 64,8 291.8 5 17 10 7 21 
195,5 4,5 37,5 99,5 35,5 
 
6 8 29 10 
 
221.8 53,2 64,2 25,2 56,2 33,2 17 6 6 30 10 
168 38,2 14,2 78,2 
 
58,2 20 6 34 
 
44 
167 13 35 59 29 
 
18 54 38 39 
 
95,2 83,8 85,8 148,8 95,8 156,8 45 53 70 65 63 
144,4 44,6 22,6 48,6 81,6 45,6 42 35 37 83 47 
178,6 57,4 110.4 51,4 73,4 37,4 30 42 38 37 21 
159 33,2 14,2 52,2 58,2 115,2 12 15 32 35 102 
179 7,2 13,2 1,2 31,2 99,2 14 10 35 11 77 
 
Standard 
deviation: 
A1c 148,0422051 868,7411434 161,6012336 116,6654413 39,59007484 
A1b 94,38516454 18,42182967 31,68668209 4,355777003 3,872335399 
A1a 12,29832179 7,24557439 8,570218225 21,48413641 32,24450915 
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Average 
Standard 
deviation 
fluor/cell *1000 *1000 
986,030 148,042 
854,170 868,741 
270.410 161,601 
219,951 116,665 
64,462 39,590 
129,074 94,385 
27,235 18,422 
42,223 31,687 
17,953 4,356 
8,333 3,872 
57,997 12,298 
30,148 7,246 
53,263 8,570 
49,314 21,484 
36,323 32,245 
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A3: Graph of fluorescence/1000 cells from experiment 3.1 
 
Figure A3: Graph showing fluorescence values from alamarBlue assay performed on 
batch A1a, A1b and A1c. 
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A4: Second experiment: The alamarBlue procedure for experiment 3.2 
Two different cell concentrations were used: 1.5 mil/mL and 5.0 mil/mL and both 
were encapsulated in 1.0% LG alginate with and without RGD peptide grafted onto it. 
In total this setup included four batches. 
It was assumed that the size of the capsules was the same as in the previous 
experiment, and hence the same setup as described above was applied in this 
assay. However, it was discovered during day 1 Live/Dead assay that the average 
diameter was noticeably smaller, thus giving the capsules only 1/3 of the assumed 
volume. This difference could have been caused by less viscosity of the alginate and 
led to a new calculation of sample amount: 
Average radius: 0,174μm 
 =


 =


	(0,174)  
V = 0,654/capsule = 0,022		 
A2: 1.5 ∙ 10 cells/		 ∙ 0,022		 = 33 cells/capsule 
B2:	5 ∙ 10 cells/		 ∙ 0,022		 = 110 cells/capsule 
Number of capsules required to obtain 5000 cells/well: 
B1: 
	
	/ !"
= 152	#$%&'()& 
B2:  
	
	/ !"
= 45	#$%&'()& 
1 mL capsules/ 10 mL media gives:  
,-
,**,-/ !"
  =45454,5 capsules in 10 mL media. 
Subsequently, this gives 4545,5 capsules/mL media, and the calculations that led to 
sample volume are shown below:  
B1: 
*	 !"
,	 !"/.-
= 0,033	 = 33	 
B2: 
	 !"
,	 !"/.-
= 0,009,8	 = 9,8	≈10	 
The capsules with 5.0 mil/mL cell concentration were slightly larger than the capsules 
containing 1.5 miL/mL cell concentration. This may have caused the cell number in 
the higher cell concentration sample to be larger than intended (5000 cells/well).  
On day 1 the same setup was used as in the previous experiment, but after 
encountering the same problem with contaminating of the controls by capsules, it 
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was decided to increase work solution of media from the culture flask from 1 mL to 
1.5 mL. 
This improved the quality of the controls considerably and combined with the new 
calculations it led to the revised protocol setup shown in table 2. 
Batch Work 
solution 
Sample 
withdrawal 
Desired 
number of 
capsules 
Media from 
culture flask 
alamarBlue® 
reagent 
1.5mil/mL Alg 1 mL  5 × 33μL 152 147 μL 18μL 
5.0 mil/mL Alg 1 mL 5 × 10 μL 45 170 μL 18μL 
1.5mil/mL Alg+RGD 1 mL  5 × 33μL 152 147 μL 18μL 
5.0 mil/mL Alg+RGD 1 mL 5 × 10 μL 45 170 μL 18μL 
Media from culture flask 
1.5mil/mL 1.5 mL   5 × 180μL 18μL 
5mil/mL Alg 1.5 mL   5 × 180μL 18μL 
1.5mil/mL Alg+RGD 1.5 mL   5 × 180μL 18μL 
5mil/mL Alg+RGD 1.5 mL   5 × 180μL 18μL 
Clean media 900 μL   5 × 180μL 18μL 
Table A4: The revised alamarBlue® protocol for the second experiment 
A 96 well plate with opaque walls and see-through bottom was used as in experiment 
A1. 
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A5: Fluorescence values and calculations from experiment 3.2 
    Fluorescence for samples 1-5 Fluorescence for control samples 1-5 
Batch Day 1 2 3 4 5 1 2 3 4 5 
B1a 3 102 102   113 103 182 180   161 153 
  7 133 143 148 138 147 187 187 204 201 182 
  10 128 138 144 135 140 181 170 183 203 173 
  14 103 99 107 153 154 153 153 154 167   
  22 228 170 204 213 203   192 158 143 165 
B1b 3 223 187 195 261 314 226 243 235 203 227 
  7 324 420 353 430 358 274 222 282 259 265 
  10 190 194 215 185 205 187 203 198 184 190 
  14 157 183 142 148 154 152 143 165   153 
  22 172 152 135 165 155 161 132 148 133 167 
B2a 3 193 194 180 188 231 179 164 187 187 161 
  7 226 284 294 245   221 212 226 214 213 
  10 247 360 248 244 209 163 162 184 184 212 
  14 208 180 187 182 154 143 135 157 151 157 
  22 204 177 168 204 217 154 149 156 164 151 
B2b 3 268 306 334 253 341 183 227 219 202 198 
  7 313 563 337 385 367 248 245 262 305 246 
  10 266 218 244 246 206 216 186 230 205 209 
  14 151 177 154 132 156 149   165   175 
  22 131 152 175 152 136 130 147 140 149 134 
 
Standard B1a 10,04341055 3,666255497 2,71729441 11,42586666 12,30036243 
deviation B1b 8,471598628 2,139323012 4,119897508 2,556270847 4,329189768 
*1000 B2a 6,471612501 36,38200568 5,860664808 7,955146768 6,086870158 
B2b 6,516363884 6,850913585 7,796310555 24,8159889 5,219767535 
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    Average  Fluorescens per well - average control 
Number of 
capsules 
per well         
Batch Day control 1 2 3 4 5 1 2 3 4 5 
B1a 3 169 -67 -67 -169 -56 -66 68 161 134 91 95 
  7 192,2 -59,2 -49,2 -44,2 -54,2 -45,2 84 70 93 74 57 
  10 182 -54 -44 -38 -47 -42 78 75 61 63 52 
  14 157 -54 -58 -50 -4 -3 66 82 84 129 87 
  22 165 64 6 40 49 39 86 56 58 45 35 
B1b 3 226,8 -3,8 -39,8 -31,8 34,2 87,2 62   23 80 120 
  7 260,4 63,6 159,6 92,6 169,6 97,6 65 129   132 125 
  10 192,4 -2,4 1,6 22,6 -7,4 12,6 21 13 27 21 40 
  14 153 4 30 -11 -5 1 59 62 40 54 31 
  22 148 24 4 -13 17 7 71 25 36 19 11 
B2a 3 175,6 17,4 18,4 4,4 12,4 55,4 61 49 54 45 83 
  7 217,2 8,8 66,8 76,8 27,8 -217,2 35 74 102 36 111 
  10 181 66 179 67 63 28 90   75 75 61 
  14 149 59,4 31,4 38,4 33,4 5,4 104 42 48 72 38 
  22 155 49,2 22,2 13,2 49,2 62,2 76 112 51 157 9 
B2b 3 205,8 62,2 100,2 128,2 47,2 135,2 20 48 79 37 55 
  7 261,2 51,8 301,8 75,8 123,8 105,8   99 21 52 56 
  10 209,2 56,8 8,8 34,8 36,8 -3,2 36 16 20 23 14 
  14 163 -12 14 -9 -31 -7 11 24 50 5 25 
  22 140 -9 12 35 12 -4 30 56 29 36 66 
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    Fluorescene per capsule Cells per 
Batch Day 1 2 3 4 5 capsule 
B1a 3 -0,985 -0,416 -1,261 -0,615 -0,695 33 
  7 -0,705 -0,703 -0,475 -0,732 -0,793 33 
  10 -0,692 -0,587 -0,623 -0,746 -0,808 33 
  14 -0,814 -0,704 -0,592 -0,029 -0,032 33 
  22 0,738 0,098 0,681 1,078 1,100 33 
B1b 3 -0,061   -1,383 0,428 0,727 110 
  7 0,978 1,237   1,285 0,781 110 
  10 -0,114 0,123 0,837 -0,352 0,315 110 
  14 0,064 0,480 -0,281 -0,097 0,024 110 
  22 0,335 0,152 -0,367 0,884 0,618 110 
B2a 3 0,285 0,376 0,081 0,276 0,667 33 
  7 0,251 0,903 0,753 0,772 -1,957 33 
  10 0,733   0,893 0,840 0,459 33 
  14 0,571 0,748 0,800 0,464 0,142 33 
  22 0,647 0,198 0,259 0,313 6,911 33 
B2b 3 3,110 2,088 1,623 1,276 2,458 110 
  7   3,048 3,610 2,381 1,889 110 
  10 1,578 0,550 1,740 1,600 -0,229 110 
  14 -1,091 0,583 -0,180 -6,200 -0,280 110 
  22 -0,300 0,214 1,207 0,333 -0,061 110 
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    Fluorescence per cell Average St.dev. 
Batch Day           fluor/cell   
B1a 3 -0,030 -0,013 -0,038 -0,019 -0,021 -24,077 10,043 
  7 -0,021 -0,021 -0,014 -0,022 -0,024 -20,656 3,666 
  10 -0,021 -0,018 -0,019 -0,023 -0,024 -20,943 2,717 
  14 -0,025 -0,021 -0,018 -0,001 -0,001 -13,161 11,426 
  22 0,022 0,003 0,021 0,033 0,033 22,396 12,300 
B1b 3 -0,001   -0,013 0,004 0,007 -0,658 8,472 
  7 0,009 0,011   0,012 0,007 9,730 2,139 
  10 -0,001 0,001 0,008 -0,003 0,003 1,470 4,120 
  14 0,001 0,004 -0,003 -0,001 0,000 0,344 2,556 
  22 0,003 0,001 -0,003 0,008 0,006 2,951 4,329 
B2a 3 0,009 0,011 0,002 0,008 0,020 10,214 6,472 
  7 0,008 0,027 0,023 0,023 -0,059 4,379 36,382 
  10 0,022   0,027 0,025 0,014 22,164 5,861 
  14 0,017 0,023 0,024 0,014 0,004 16,514 7,955 
  22 0,020 0,006 0,008 0,009   10,741 6,087 
B2b 3 0,028 0,019 0,015 0,012 0,022 19,189 6,516 
  7   0,028 0,033 0,022 0,017 24,837 6,851 
  10 0,014 0,005 0,016 0,015 -0,002 9,526 7,796 
  14 -0,010 0,005 -0,002 -0,056 -0,003 -13,032 24,816 
  22 -0,003 0,002 0,011 0,003 -0,001 2,534 5,220 
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A6: Graph of fluorescence value/1000 cells from experiment 3.2 
 
Figure A6: Graph showing fluorescence values/1000 cells from alamarBlue® assay performed on cells from encapsulation B1a, B1b, 
B2a and B2b (encapsulation of high and low cell concentration in alginate with and without RGD-grafted onto it) 
 
In experiment 3.2 two different OEC concentrations (1.5 mil/mL and 5.0 mil/mL) were encapsulated in LG 0.2% RGD grafted 
alginate and a similar alginate without RGD graft, resulting in four different batches (B1a, B1b, B2a and B2b) as seen in figure 1 
below. Batch B2a displayed fluorescence values above zero throughout the experiment, whilst the B2b batch had positive 
fluorescence values up until day 12 approximately. At day 14 the fluorescence values from batch B2b were negative, but the cells in 
the batch appeared to redeem themselves from day 14 to day 22, when the values turned positive again. The B1a batch displayed 
negative fluorescence values up until the last day of the experiment. The cells may have adjusted to the environment inside the 
capsules, but the results from the concurrent Live/Dead assay did not support this theory. Batch B1b displayed low viability 
throughout the experiment with fluorescence values slightly larger than zero, according to the alamarBlue® assay. These results 
can be observed in figure 1. The concurrent Live/Dead assay did not correlate well with this result as the viability of cells in all 
batches in the experiment were estimated as almost similar up until day 10 (Figure 3.6.) 
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A7: Fluorescence values and calculations for experiment 3.4 
    Fluorescence for samples, parallels 1-5 Fluorescence for control samples, parallels 1-5 
Batch Day 1 2 3 4 5 1 2 3 4 5 
D1a 2 944 939 1140 982 1041 358 327 326 347   
  3 623 517 563 557 605 650 619 650 613 654 
  7 1208 1491 1298 722 926 688 939 1072 1121 1074 
  10 363 345 362 404 389 558 542 569 526 532 
  14 226 202 214 182 232 191 198 218 215 221 
  16 184 255 167 188 224 210 206 216 206 232 
  20 184 180 162 177 190 280 250 254 242 246 
  24 119 149 138 151 144 191 198 222 196   
  27 146 199 213 233 193 256 252 277 255 289 
  29 132 119 130 143 129 238 206 229 210 214 
D1b 2 1144 1650 1598 1274 1828 834 873 798     
  3 1870 1626 1389 1482 1661 1374 1290 1450 1329   
  7 1143 1471 1833 1900 1700 1511 1319 1308 1465 1439 
  10 805 1164 814 795 766 729 780 759 749 799 
  14 252 423 434 456 357 198 211 207 224 262 
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    Average  Fluorescence/well - average control Number of capsules in each well 
Batch Day controls 1 2 3 4 5 1 2 3 4 5 
D1a 2 339,5 605 600 801 643 702 85 54 120 92 119 
  3 637,2 -14,2 -120,2 -74,2 -80,2 -32,2 96 51 47 63 45 
  7 978,8 229,2 512,2 319,2 -256,8 -52,8 28 55 51 106 53 
  10 545,4 -182 -200,4 -183,4 -141,4 -156,4 74 42 39 59 33 
  14 209 17 -7 5 -27 23 92 27 62 29 77 
  16 214 -30 41 -47 -26 10 150 27 33 88   
  20 254 -70 -74 -92 -77 -64 86 59 40 16 72 
  24 202 -83 -53 -64 -51 -58 33 45 49 79 58 
  27 266 -120 -67 -53 -33 -73 43 95 44 30 30 
  29 219 -87 -100 -89 -76 -90 200 54 6 17 12 
D1b 2 835 309 815 763 439 993 7 41 35 20 42 
  3 1360,75 509,25 265,25 28,25 121,25 300,25 52 32 22 25 46 
  7 1408,4 -265,4 62,6 424,6 491,6 291,6 15 28 32 18 8 
  10 763,2 41,8 400,8 50,8 31,8 2,8 37 112 45 14 28 
  14 220 32 203 214 236 137 16 50 63 55 31 
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    Fluorescence per capsule No. of cells 
Batch Day 1 2 3 4 5 per capsule 
D1a 2 7,111764706 11,10185185 6,670833333 6,983695652 5,894957983 33 
  3 -0,147916667 -2,356862745 -1,578723404 -1,273015873 -0,715555556 33 
  7 8,185714286 9,312727273 6,258823529 -2,422641509 -0,996226415 33 
  10 -2,464864865 -4,771428571 -4,702564103 -2,396610169 -4,739393939 33 
  14 0,189130435 -0,244444444 0,087096774 -0,917241379 0,303896104 33 
  16 -0,2 1,518518519 -1,424242424 -0,295454545   33 
  20 -0,818604651 -1,261016949 -2,31 -4,8375 -0,894444444 33 
  24 -2,507575758 -1,172222222 -1,301020408 -0,642405063 -0,995689655 33 
  27 -2,786046512 -0,703157895 -1,2 -1,093333333 -2,426666667 33 
  29 -0,437 -1,859259259 -14,9 -4,494117647 -7,533333333 33 
D1b 2 44,14285714 19,87804878 21,8 21,95 23,64285714 110 
  3 9,793269231 8,2890625 1,284090909 4,85 6,527173913 110 
  7 -17,69333333 2,235714286 13,26875 27,31111111 36,45 110 
  10 1,12972973 3,578571429 1,128888889 2,271428571 0,1 110 
  14 1,975 4,052 3,39047619 4,283636364 4,406451613 110 
 
Standard deviation 
D1a 61,807 25,478 163,915 38,306 14,916 36,79 50,952 21,41 27,53 174 
D1b 91,570 29,930 193,403 12,069 9,096           
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    Fluorescence per cell Average St. dev. 
Batch Day 1 2 3 4 5 fluor./1000 cells *1000 
D1a 2 0,215508021 0,336419753 0,202146465 0,211627141 0,17863509 228,8672941 61,80716281 
  3 -0,004482323 -0,071420083 -0,047840103 -0,038576239 -0,021683502 -36,80044997 25,4780779 
  7 0,248051948 0,282203857 0,189661319 -0,073413379 -0,030188679 123,2630131 163,9147875 
  10 -0,074692875 -0,144588745 -0,142501943 -0,072624551 -0,143617998 -115,6052221 38,30584832 
  14 0,005731225 -0,007407407 0,002639296 -0,027795193 0,009208973 -3,524621278 14,91597875 
  16 -0,006060606 0,046015713 -0,043158861 -0,008953168   -3,039230691 36,78802159 
  20 -0,024806202 -0,038212635 -0,07 -0,146590909 -0,027104377 -61,34282451 50,95189983 
  24 -0,075987144 -0,035521886 -0,039424861 -0,01946682 -0,030172414 -40,11462489 21,41019659 
  27 -0,084425652 -0,021307815 -0,036363636 -0,033131313 -0,073535354 -49,75275398 27,53396634 
  29 -0,013242424 -0,05634119 -0,451515152 -0,136185383 -0,228282828 -177,1133954 173,9463694 
D1b 2 0,401298701 0,180709534 0,198181818 0,199545455 0,214935065 238,9341147 91,57037095 
  3 0,08902972 0,075355114 0,011673554 0,044090909 0,059337945 55,89744828 29,93047119 
  7 -0,160848485 0,020324675 0,120625 0,248282828 0,331363636 111,949531 193,4027229 
  10 0,01027027 0,032532468 0,010262626 0,020649351 0,000909091 14,92476112 12,06897933 
  14 0,017954545 0,036836364 0,030822511 0,038942149 0,040058651 32,92284394 9,095723837 
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A8: Graph of fluorescence values per 1000 cells  for experiment 3.4 
 
Figure A8: Graph showing fluorescence values/1000 cells from alamarBlue® assay performed on cells from encapsulation D1a and 
D1b 
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A9: Fluorescence values and calculations for experiment 3.5 
    Fluorescence for samples, parallels 1-5 Fluorescence for control samples, parallels 1-5 
Batch Day 1 2 3 4 5 1 2 3 4 5 
E1 1 199 211 188 242 210 160 150 164 178 172 
  3 64 77 101 90 141 163 139 187 138 155 
  6 141 145 173 180 175 156 190 152 151 147 
  9 113 128 163 144 168 166 172 176 155 131 
  13 147 150 182 164 145 180 151 159 186   
  15 134 120 118 140 112 163 163 163 192 188 
E2 1 201 514 227 212 236 171 164 170 150 169 
  3 149 169 157 154 139 162 169 155 165 175 
  6 142 274 154 185 182 149 150 159 161 151 
  9 131 154 192 180 163 133 186 176 166 157 
  13 133 177 205 205 204 146 174 168 180 137 
  15 211 170 142 177 156 173 206 145 151 159 
E2 1 545 398 330 298 338 159 180 160 164 185 
  3 216 208 268 209 178 165 135 160 168 159 
  6 174 305 257 221 263 125 152 163 166 139 
  9 208 244 273 172 162 143 156 160 172   
  13 194 317 235 196 207 155 160 166 191 184 
  15 311 186 161 143 164 164 153 137 149 136 
Blank media 
controls 
Day Fluorescence values of blank media 
  1 2 3 4 5 
1 168 161 173 169 177 
3 144 154 154 144 157 
6 125 152 163 166 139 
9 173 144 169 142   
13 155 214 158     
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    Average Fluorescence per well- average control Number of capsules in each well 
Batch Day control 1 2 3 4 5 1 2 3 4 5 
E1 1 164,8 34,2 46,2 23,2 77,2 45,2 40 46 45 52 63 
  3 156,4 -92,4 -79,4 -55,4 -66,4 -15,4 11 45 34 20 75 
  6 159,2 -18,2 -14,2 13,8 20,8 15,8 79 35 62 73 53 
  9 160 -47,0 -32,0 3,0 -16,0 8,0 13 20 33 41 36 
  13 169 -22,0 -19,0 13,0 -5,0 -24,0 26 71 43 52 45 
  15 173,8 -39,8 -53,8 -55,8 -33,8 -61,8 65 35 29 35 46 
E2 1 164,8000 36,2 349,2 62,2 47,2 71,2 6 38 29 26 15 
  3 165,2 -16,2 3,8 -8,2 -11,2 -26,2 18 48 17 14 8 
  6 154 -12,0 120,0 0,0 31,0 28,0   52   20 8 
  9 163,6 -32,6 -9,6 28,4 16,4 -0,6     13 10 11 
  13 161 -28,0 16,0 44,0 44,0 43,0 7 16 33 13 29 
  15 166,8 44,2 3,2 -24,8 10,2 -10,8 33 36 16     
E2 1 169,6 375,4 228,4 160,4 128,4 168,4 45 54 51 18 32 
  3 157,4 58,6 50,6 110,6 51,6 20,6 18 27 36 33 35 
  6 149 25,0 156,0 108,0 72,0 114,0   36 38 24 30 
  9 157,75 50,3 86,3 115,3 14,3 4,3 31 27 49 13 6 
  13 171,2 22,8 145,8 63,8 24,8 35,8 16 41 14 8 10 
  15 147,8 163,2 38,2 13,2 -4,8 16,2 108 28 7     
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    Fluorescence per capsule No. of cells 
Batch Day 1 2 3 4 5 per capsule 
E1 1 0,855 1,004347826 0,515555556 1,484615385 0,717460317 33 
  3 -8,4 -1,764444444 -1,629411765 -3,32 -0,205333333 33 
  6 -0,230379747 -0,405714286 0,222580645 0,284931507 0,298113208 33 
  9 -3,615384615 -1,6 0,090909091 -0,390243902 0,222222222 33 
  13 -0,846153846 -0,267605634 0,302325581 -0,096153846 -0,533333333 33 
  15 -0,612307692 -1,537142857 -1,924137931 -0,965714286 -1,343478261 33 
E2 1 6,033333333 9,189473684 2,144827586 1,815384615 4,746666667 33 
  3 -0,9 0,079166667 -0,482352941 -0,8 -3,275 33 
  6   2,307692308   1,55 3,5 33 
  9     2,184615385 1,64 -0,054545455 33 
  13 -4 1 1,333333333 3,384615385 1,482758621 33 
  15 1,339393939 0,088888889 -1,55     33 
E2 1 8,342222222 4,22962963 3,145098039 7,133333333 5,2625 33 
  3 3,255555556 1,874074074 3,072222222 1,563636364 0,588571429 33 
  6   4,333333333 2,842105263 3 3,8 33 
  9 1,620967742 3,194444444 2,352040816 1,096153846 0,708333333 33 
  13 1,425 3,556097561 4,557142857 3,1 3,58 33 
  15 1,511111111 1,364285714 1,885714286     33 
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    Fluorescence/cell         Average St. Dev*1000 
Batch Day           fluor/1000cells   
E1 1 0,025909091 0,030434783 0,015622896 0,044988345 0,021741222 27,73926717 11,07845931 
  3 -0,254545455 -0,053468013 -0,049376114 -0,100606061 -0,006222222 -92,84357298 96,37280191 
  6 -0,006981204 -0,012294372 0,006744868 0,008634288 0,009033734 1,027462588 9,953176961 
  9 -0,10955711 -0,048484848 0,002754821 -0,011825573 0,006734007 -32,07574063 48,48209762 
  13 -0,025641026 -0,008109262 0,009161381 -0,002913753 -0,016161616 -8,732855018 13,18642518 
  15 -0,018554779 -0,046580087 -0,05830721 -0,029264069 -0,040711462 -38,68352138 15,37408379 
E2 1 0,182828283 0,2784689 0,064994775 0,055011655 0,143838384 145,0283993 91,84907409 
  3 -0,027272727 0,00239899 -0,014616756 -0,024242424 -0,099242424 -32,59506833 39,01207461 
  6   0,06993007 0 0,046969697 0,106060606 55,74009324 44,41241303 
  9   0 0,066200466 0,04969697 -0,001652893 28,56113583 34,60283541 
  13 -0,121212121 0,03030303 0,04040404 0,102564103 0,044932079 19,39822629 83,51641969 
  15 0,040587695 0,002693603 -0,046969697     -1,229466381 43,91033001 
E2 1 0,252794613 0,128170595 0,095306001 0,216161616 0,159469697 170,3805044 64,07983043 
  3 0,098653199 0,056790123 0,093097643 0,04738292 0,017835498 62,75187663 33,53728848 
  6   0,131313131 0,086124402 0,090909091 0,115151515 105,8745348 21,1913254 
  9 0,049120235 0,096801347 0,071273964 0,033216783 0,021464646 54,37539504 30,18254445 
  13 0,043181818 0,107760532 0,138095238 0,093939394 0,108484848 98,29236617 34,76320736 
  15 0,045791246 0,041341991 0,057142857     48,09203143 8,147824919 
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A10: Fluorescence values/1000 cells from experiment 3.5 
 
Figure A10: Graph showing fluorescence values/1000 cells from alamarBlue® assay performed on cells from encapsulation E1,E2 and 
E3 
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Appendix B: MTT assay performed in comparison with the alamarBlue® assay 
As the alamarBlue® assay did not work satisfactorily during the project, it was decided to compare its results with the MTT assay to 
see if both assays showed similar results. The Live/Dead assay was utilized as control on both assays. The assays were performed 
on 1.5 mil/mL OECs encapsulated in 1.0% UP-LVG alginate, at day 8, 13 and 22.  
B1: Absorbance values and calculations from the MTT assay. 
Raw Data 
Wavelength:570.0                 
Day 1 2 3 4 5 6 Average absorbance St.dev 
8 0,055 0,052 0,058 0,052 0,049 0,054 0,053333333 0,003076795 
                  
13 0,049 0,062 0,061 0,049 0,059 0,063 0,057166667 0,006462714 
                  
22 0,056 0,066 0,065 0,056 0,069   0,0624 0,006024948 
                  
              
Average absorbance blank 
samples   
Blank samples (DMSO)  0,052 0,046 0,048 0,045 0,048 0,045 0,047333333   
 
Day 
Average absobance - average absorbance blank 
samples 
8 0,006 
13 0,009833333 
22 0,015066667 
 
Standard deviation 0,003077 0,006463 0,006025 
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B2: Graph showing the MTT absorbance values for 1.5 mil/mL encapsulated in 1.0% UP-LVG 
 
Figure B1: Graph showing absorbance values, shown as an average value of two parallels of 40 capsules. MTT assay performed cell 
concentration 1.5 mil/mL 
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B3: Fluorescence values from the alamarBlue® assay performed on comparison with the MTT assay 
  Fluorescence values for samples, parallels 1-5 
Day 1 2 3 4 5 
8 574 616 749 532 546 
13 103 121 143 132 151 
22 119 135 123 122 147 
  Blank samples , media without capsules  Average 
Day 1 2 3 4 5 controls 
8 579 624 567 615 620 601 
13 130 143 144 158 247 164 
22 141 140 154 177 165 155 
  Fluorescence per well - mean, blank. 
Day 1 2 3 4 5 
8 -27 15 148 -69 -55 
13 -61 -43 -21 -32 -13 
22 -36 -20 -32 -33 -8 
  Number of capsules in each well 
Day 1 2 3 4 5 
8 227 250 250 92 46 
13 120 63 100 75 85 
22 98 120 85 27 83 
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  Fluorescence per capsule 
Day 1 2 3 4 5 
8 -0,118942731 0,06 0,592 -0,75 
-
1,195652174 
13 -0,511666667 
-
0,688888889 -0,214 -0,432 
-
0,157647059 
22 -0,371428571 -0,17 
-
0,381176471 
-
1,237037037 
-
0,101204819 
  Cells (Fluorescence/capsule)/(Cells/capsule) 
Day per capsule.           
8 33 
-
0,003604325 0,001818182 0,017939394 
-
0,022727273 
-
0,036231884 
13 33 
-
0,015505051 
-
0,020875421 
-
0,006484848 
-
0,013090909 
-
0,004777184 
22 33 
-
0,011255411 
-
0,005151515 
-
0,011550802 
-
0,037485971 
-
0,003066813 
  Average Normalised Standard  
Day 
 fluor/1000 
cells   deviation 
8 -0,008561181 1 0,021218671 
13 -0,012146683 1,418809177 0,006609216 
22 -0,013702102 1,600492038 0,01380678 
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    1 2 3 4 5 Average 
Blank Day 8 149 147 164 179 138 155 
samples: Day 13 153 168 162 165 160 162 
            Average  159 
Standard 
deviation:   0,021218671 0,006609216 0,01380678 
 
 
B4: Graph showing fluorescence per cell from alamarBlue® assay performed in comparison with MTT assay 
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Appendix C: Excel tables for the estimated live cell percentages in chapter 3 
The Live/Dead assay that was performed on all experiments during the project was 
analyzed with estimated live cell percentage based on 3D projections obtained by 
CLSM. The estimated live cells percentages from all experiments are shown below.  
Experiment 3.1  Day   
Cell conc. 1 3 7 10 14 
1.5 mil/mL 
(A1a) 90 90 85 30 10 
3.0 mil/mL 
(A1b) 70 80 30 30 30 
5.0 mil/mL 
(A1c) 80 80 40 50 15 
  Day 
Experiment 3.2 1 3 7 10 14 22 
Cell conc.             
1.5 mil/mL 
(B1a) 95 95 95 95 80 70 
1.5 mil/mL 
(B2a) 90 90 90 90 30 30 
5.0 mil/ML 
(B1b) 90 90 90 85 40 40 
5.0 mil/ML 
(B2b) 95 95 95 80 60 50 
 
  Cell conc. 
Experiment 3.3 1.0 mil/mL (C1a) 4.0 mil/mL (C1b) 
Day     
1 50 50 
2 70 80 
9 80 80 
10 80 50 
14 80 40 
17 80   
22 75   
24 75   
29 75   
32 75   
36 70   
44 60   
51 50   
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  Cell conc. 
Experiment 3.4 1.5 mil/mL 5.0 mil/mL 
Day     
2 60 60 
3 75 50 
7 75 50 
10 75 60 
14 80 30 
16 40   
21 75   
24 60   
27 60   
36 60   
 
  Percentage of gelatin 
Experiment 3.5 0.5% 1.0% 2.0% 
Day       
1 60 60 60 
3 70 70 80 
6 80 80 70 
9 70 80 75 
13 70 70 80 
22 60 80 70 
 
Experiment 3.6 Percentage of gelatin 
Day 0.5% 1.0% 2.0% 
1   70 60 
9 80 85 85 
16 75 75 75 
 
Experiment 3.7 Day 
Additive 1 3 7 14 20 28 
Sulphated Alg 75 80 65 65 80 50 
Hyalruronan 75 80 95 70 70 50 
Fibronectin 80 70 60 50 40 20 
Laminin 80 60 60 50 40 40 
Collagen 75 95 50 40 40 40 
Experiment 3.8 Alginate type 
Day RGD + RGD- Epi+ Epi- UP-LVG+ UP-LVG- 
1 75 75 80 80 70 60 
7 80 70 70 75 60 70 
14 80 40 50 50 70 65 
20 75 70 50 70 80 65 
 
